Analogs of xanomeline, analogs of trospium, and methods of use thereof

Abstract

Disclosed herein are xanomeline and trospium prodrugs and analogs, as well as methods for making and using the prodrugs and analogs to treat, for example, neuropsychiatric disorders.

Description

CROSS-REFERENCE TO RELATED APPLICATIONSThis application is a PCT International Patent Application claiming the benefit of and priority to U.S. Non-Provisional Application No. 18 / 444,450, filed February 16, 2024, PCT International Application No. PCT / US2024 / 026115, filed on April 24, 2024, and U.S. Provisional Application No. 63 / 699,063, filed on September 25, 2024, which are incorporated herein by reference in their entireties.FIELDThe present disclosure relates to analogs of xanomeline and analogs of trospium including analogs intended to act as prodrugs and methods for using such analogs to treat neuropsychiatric disorders.BACKGROUNDSchizophrenia and related neuropsychiatric diseases are among the leading causes of disability worldwide. Despite recent advances, there remains a need for new therapeutics to support treatment of debilitating neuropsychiatric diseases, such as schizophrenia.Recently, xanomeline and trospium have received renewed interest for the treatment of schizophrenia and other disorders.BRIEF SUMMARYIn one aspect, the present disclosure is directed to analogs and prodrugs of xanomeline, such as a compound of Formula (X-I), Formula (X-I):wherein PG is an optional progroup that forms an N-oxide, or has the formula -(CR1R2)-OR3; LG is an optional leaving group, provided that only one LG is present in Formula (X-I). AlsoIn one aspect, the present disclosure is directed to analogs and prodrugs of trospium, such as a compound of Formula (T-I),wherein R1is hydrogen, halo, -OR2;R2is selected from C1-30 alkyl, Rx, -C(O)OR3, -C(O)R4, -CH(R5)OR6, -Si(R5)3, -Si(OR5)3, -S(O)2R5, -C(R5)2OR5, -C(R5)2SR5, -C(R5)2S(O)R5, -C(R5)2S(O)2R5, -C(R5)2O-Si(R5)3, - C(R5)2O-Si(OR5)3, -C(R5)2S-Si(R5)3, -C(R5)2S-Si(OR5)3, -C(R5)2S(O)Si(R5)3, -C(R5)2S(O)Si(OR5)3, -C(R5)2S(O)2Si(R5)3, -C(R5)2S(O)2Si(OR5)3, -CH(R5)NRaC(O)Rd, -CH(R5)NRCRC, -CH(R5)NRaC(O)ORd, -CH(R5)OC(O)NReRe; -C(R5)2OC(O)OR3, -C(R5)2OC(O)R4, and -P(O)OR9(OR10);R3is selected from alkyl, alkenyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl, and -(CH2)m-Rb, -(CHRa)m-Rb, wherein alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl is unsubstituted or substituted with one or more group selected from halogen, Ra, -ORa, -NRCRC, -C(O)ORaand -N(Ra)C(O)ORa, -C(R5)2-OC(O)C(R5)2NRCRC, - C(R5)2-OC(O)C(R5)3, -CH(R5)Ry, -CH(R5)OCH(R5)Ry, -(CH2)m- Rb, -(CHRa)m-Rb, -(CRaRa)m-Rb;R4is selected from -Si(Rd)3, -C(R5)2-NRCRC, -C(R5)2-C(R5)2-RZ; alkyl, alkenyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl, and -(CH2)m-Rb, -(CHRa)m-Rb, wherein alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl is unsubstituted or substituted with one or more group selected from halogen, Ra, -ORa, -NRCRC, -C(O)ORaand - N(Ra)C(O)ORa, -C(R5)2-OC(O)C(R5)2NRCRC, -C(R5)2-OC(O)C(R5)3, -CH(R5)Ry, - CH(R5)OCH(R5)Ry, -(CH2)m-Rb, -(CHRa)m-Rb, -(CRaRa)m-Rb; each R5is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, or heterocyclylalkyl wherein alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl is unsubstituted or substituted with one or more group selected from halogen, Ra, -ORa, -NRCRC, -C(O)ORaand -N(Ra)C(O)ORa; each of R9and R10is independently hydrogen, C1-4 alkyl, -(CH2)„-Rf, -(CHRa)„-Rf, -(CRaRa)„-Rf; n is independently for each occurrence 2 or 3; f is independently -OH, -NH2, -N(Rn)C(O)R7, -N(Rn)C(O)OR12, -OC(O)R13, - OC(O)NRCRC, andRais, for each occurrence, independently selected from the group consisting of hydrogen, (C1-6) alkyl and (C3-8) cycloalkyl; each Rbis independently selected from the group consisting of -S-S-(CHRa)m-NRcRc, -OSi(Rd)3, -C(O)ORa, -OC(O)Rd, -OC(O)R7; each Rcis independently hydrogen, Ra, or, alternatively, two Rcare taken together with the nitrogen atom to which they are bonded to form a 4 to 8-membered cycloheteroalkyl, which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different groups selected from oxo, -CH20Ra, -C(O)Raand Rdgroups; each Rdis independently selected from (C1-6) alkyl, 5-membered heteroaryl, 6- membered heteroaryl and 6-membered aryl, each optionally substituted with each optionally substituted with 1, 2 or 3 groups selected from halogen, C1-4 alkyl, and -ORa; m is independently for each occurrence 2 or 3; each Reis Ra, wherein at least one of the Ragroups is substituted with at least one group selected from -OC1-6alkyl, -OC(O)C1-6alkyl, -OH, -SC1-6alkyl, and -SH;Rxis selected from the group consisting ofRyisY is N or CH;RzisX' is a pharmaceutically acceptable counterion, provided that when R1is hydrogen, the compound is enriched in deuterium.Also disclosed are methods for using the disclosed trospium analogs, such as in a method for treating a neuropsychiatric disorder.In one aspect, the present disclosure is directed to a compound of Formula (1’):Formula (!’) wherein:X' is absent or is an anion;R1is:(i) -o-;wherein: each R5and R6independently are hydrogen, deuterium, C1-24 alkyl, -C1-24 cyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -(C2-24 alkenylene)-Si(Ruj)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Ruj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)-Ci-24 alkyl, -(C1-24 alkylene)- S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i- 5O-0-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -Ci- 6 alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(O)-(Ce- 10 aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2-24 alkenyl;R4is:(ii-a) -C(O)-Ci-24 alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -C(O)-(Ci-24 alkylene)-Ce-i4 aryl, -C(O)-(C2-24 alkenylene)-Ce-i4 aryl, - C(O)-(C2-24 alkynylene)-Ce-io aryl, -C(O)-(Ci-24 alkylene)-C(O)-O-Ci-24 alkyl, - C(O)-(Ci-24 alkylene)-C(O)-O-C2-24 alkenylene, -C(O)-(C2-24 alkenylene)-C(O)-O- C1-24 alkyl, -C(O)-C(O)-O-C 1-24 alkyl, -C(O)-C(O)-OH, -C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-O- C1-24 alkyl, -C(O)-(C2-24 alkynylene)-C(O)-OH, -C(O)-(Ci-24alkylene)-C(O)- (cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-C(O)-(bile acid), - C(O)-(C2-24 alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkenylene)-C(O)-(bile acid), -C(O)-(Ci-24 alkylene)-O-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkynylene)- C(O)-(bile acid), -C(O)-(Ci-24alkylene)-C(O)OH, -C(O)-O-(Ci.24alkylene)- C(O)-O-(Ci-4alkyl), -C(0)-0-(CH2CH20)O-2O-(CI-4alkyl), C(O)-(C2-24 alkenylene)-C(O)OH, -C(O)-Ce-i4 aryl, -C(O)-C3-is cycloalkyl, -C(O)-(3- to 10- membered heterocycle), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24(5- to 10-membered heteroaryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(C6-i4 aryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci- 24 alkylene)-(bile acid), -C(O)-(Ci-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkylene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkyl ene)-0-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-O-(bile acid), -C(O)- (cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i -5o-0-Rlia, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted,Rliais H, deuterium, C1-24 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24 alkyl, -C(O)-O-Ci-24haloalkyl, -C(O)-O-C2-30 alkenyl, - C(O)-O-C2-24 alkynyl, -C(O)-O-(Ci.24alkylene)-C6-i4 aryl, -C(O)-O-(C2-24 alkenylene)-C6-i4 aryl, -C(O)-O-(Ci-24alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2- 24alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci-24alkylene)-C(O)OH, -C(O)-O- (C2-24 alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, -C(O)-O-C3-i5cycloalkyl, -C(O)- O-(3- to 10-membered heterocycle), -C(O)-O-(5- to 10-membered heteroaryl), - C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(Ce-i4 aryl) -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered heterocycle) - C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(C2-24 alkenylene)-(Ce-i4 aryl) -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(0)-0-(C2- 24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-O-(Ci-24 alkylene)- (cholesterol or dihydrocholesterol), -C(O)-O-(C2-24 alkylene)-(bile acid), -C(O)- (C1-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkyl ene)-0-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)- (C1-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O- (bile acid), C(O)-(Ci-24 alkylene)-C(O)-(cholesterol or dihydrocholesterol), - C(O)-(C1 -24 alkylene)-C(O)-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(0)-0-(Ci.24 alkylene)-(0-CH2CH2)i-5o-0- Rllb, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene,Rllbis H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-c) -Si(Rsi)3, wherein each RS1independently is C1-24 alkyl, C2-30 alkenyl, Ce-io aryl, -O-C1-24 alkyl, -O-C2-30 alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;(ii-d) -C(O)-CH(Riid)2, -C(O)-(Ci-24alkylene)-C(O)-O-CH(Riid)2or -C(O)-(Ci-24alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlld)2, wherein the alkylene is unsubstituted or is optionally substituted, wherein each Rlldindependently is -CH2-O-C(O)-Ci-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or -CH2-O-P(O)2-O-(CI-6alkylene)-N+(Riid’)3wherein each Rlldindependently is C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-e) -C(O)-O-CH(Riie)2, -C(O)-O-(Ci-24alkylene)-C(O)-O-CH(Riie)2or -C(O)- O-(Ci-24 alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlie)2, wherein the alkylene is unsubstituted or is optionally substituted; wherein each Rlieindependently is -CH2-O-C(O)-Ci-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, -CH2-O-P(O)2-O-(CI.24 alkylene)-N(Riie’)2or - CH2-O-P(O)2-O-(CI-24 alkylene)-N+(Rlie)3, wherein the alkyl, alkenyl, or alkylene is unsubstituted or is optionally substituted; wherein each Rlieis independently H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-f) -C(O)O-C(O)-CHRiif-N(Riif)2, -C(O)O-(Ci-i2alkylene)-C(O)-CHRiif-N(Riif)2, -C(O)O-(Ci-i2alkylene)-O-C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-NRiif-C(O)-O-Ci-24alkyl, -C(O)-(Ci-24alkylene)-NRiif-C(O)- CHRiif-N(Riif)2, or -C(O)-(Ci-24alkylene)-NR "r-C(O)-CHR"l-N(R "r)-C(O)-O- Ci-24 alkyl, or salts thereof, wherein the alkyl and alkylene are unsubstituted or optionally substituted, wherein each Rllfindependently is H or C1-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1-6alkyl, -C(O)-NH2, -S-C1-6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4-each Rllfindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4- to 10- membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted;(ii-g) -P(O)(ORiig)2, -P(O)2(ORiig), -P(O)(ORiig)-O-(Ci-20alkylene)-O-Ci-20alkyl, -P(O)(O-(Ci-20alkylene)-O-C(O)-Riig))2, -P(O)(O-(Ci-20alkylene)-O-C(O)-O- Riig))2, -P(O)2(O-(Ci-20alkylene)-O-C(O)-O-Riig)), -P(O)2(O-(Ci-20alkylene)- C(O)-O-Riig)),-P(O)(N(Riig)2)2, or -P(O)2(O-(Ci-20alkylene)-O-C(O)-Riig)), wherein the alkyl or alkylene is unsubstituted or is optionally substituted, wherein each Rllgindependently is H, C1-20 alkyl, or Ce-io aryl, or two Rllg, together with the atoms to which they are attached, combine to form 5- to 10-membered heterocyclyl wherein alkyl and heterocyclyl are unsubstituted or is optionally substituted;(ii-h) -S(O)2-N(Rllh)2, wherein each Rllhindependently is H or C1-20 alkyl;(ii-i) -C(0)-(Ci-2o alkylene)-(Ce-io aryl) or -C(0)-(Ci-2o alkylene)-0-(Ce-io aryl), wherein the alkylene is unsubstituted or is optionally further substituted, the Ce-io aryl is substituted by one or more R111, and the aryl is optionally further optionally substituted, wherein R111is -O-C(O)-C1-6alkyl, -O-C(O)-C3-8 cycloalkyl, -O-C(0)-Ce-io aryl or C1-6alkyl, wherein the alkyl, cycloalkyl, and aryl is unsubstituted or is optionally further substituted; or(ii-j) -(Ci-24 alkylene)-Si(R11-i)2-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)-Ci-24 alkyl, - (Ci-24alkylene)-S(O)2-Ci-24alkyl, -O-(Ci-24alkylene)-Si(Riij)2-Ci-24alkyl, -O- (Ci-24 alkylene)-Si(O)-Ci-24 alkyl, or -O-(Ci-24 alkylene)-Si(O)2-Ci-24 alkyl,, wherein the alkylene and alkyl are unsubstituted or are optionally further substituted, wherein each R"1independently is C1-6alkyl or two R"1, together with the atom to which they are attached, combine to form a C3-8 cycloalkyl, wherein the alkyl and cycloalkyl are unsubstituted or are optionally substituted;(n-m) ' ' j-- each R5, R6, R5, and R6independently are hydrogen, deuterium, C1-24 alkyl, -Ci-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)- C2-24 alkynyl, -(C1-24 alkylene)-Si(Riij)2-Ci-24 alkyl, -Si(Riij)2-Ci-24 alkyl, -(C2-3o alkenylene)-Si(R11-i)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Rllj)2-C2-24 alkenyl, - Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)- S(O)-Ci-24 alkyl, -(C1-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(O-CH2CH2)i- 5o-0-Riv, -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i-50-O-Riv, C6-io aryl, 5- to 10- membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;R7is C1-20 alkyl, C3-io cycloalkyl, Ce-io aryl, bile acid, cholesterol, dihydrocholesterol, -(C1-20 alkyl ene)-O-(C 1-6 alkyl), -(C1-20 alkylene)-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-(Ci-6alkyl), 3- to 10-membered heterocyclyl; 5- to 10-membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)- C(O)-O-(3- to 10-membered heterocyclyl); -(C1-20 alkyl ene)-C(0)-0-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10- membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl); - (C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), -CHRAA-NRN2, - (C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHRAA-NRN2, -alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(Ci- 6 alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(Ci- 6 alkylene)-C(O)- cholesterol, or -(C1-6alkylene)-NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6alkylene)-NRN- dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, or -NRN- dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; wherein RAAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-Ci.6alkyl, -C(O)- NH2, -S-CI-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; andRA 2is H, Ci-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)- NH2, -S-CI-6 alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl.;(ii-o) -(C1-6alkylene)-(optionally substituted Ce-io aryl)-R110wherein:Rii0is -O-C(O)H, -0-C(0)-Ci-2o alkyl, -O-C1-20 alkyl, -O-C(O)-O- C1-20 alkyl, -O-C(O)-N(Rn'llo)2, -O-C(O)-(3- to 10-membered cycloalkyl), -O- C(O)-C3-8 cycloalkyl, -O-C(O)-O-C3.8cycloalkyl, -O-C(O)-N(Rn iio)-C3.8cycloalkyl, wherein each Rn'110independently is H or C1-20 alkyl; n is 0 or 1; andR"'° is H, C1-6alkyl, -O-C(O)-(ii-p) -C(O)-(O)m-(Ci-6alkylene)-N(Rii-p’)-Rii-p, wherein: m is 0 or 1;R"'pis cholesterol, dihydrocholesterol, or a bile acid; andR"'pis H or C1-6alkylalkynylene)-(optionally substituted 5- to 10-membered heteroaryl), -C(O)-NRliq- (optionally substituted Ce-io aryl), -C(O)-NRliq-(optionally substituted 5- to 10- membered heteroaryl), -C(0)-NRiiq’-(Ci-2o alkylene)-O-C(O)-Riiq’, -C(O)-N(Riiq’)2or - C(0)-NRiik’-(Ci-2o alkylene)-C(O)-O-Riiqwherein each Rliqindependently is H or C1-20 alkyl;(iii) -(Ci -24 alkylene)-(5- to 10-membered heteroaryl), wherein the alkylene and heteroaryl are unsubstituted or are optionally substituted; or(iv) -(Ci-24 alkylene)-(O-CH2CH2)i-50-O-Rlv, and R1Vis H, C1-24 alkyl, or C2-24 alkenyl, wherein the alkylene, alkyl, and alkenyl are unsubstituted or are optionally substituted;R2is CH3, CH2D, CHD2, or CD3; andR3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium;(v) -O-C(O)-N(Rala)Ra2aor -NRXA-C(O)-ORa2a; wherein RXAis H or C1-12 alkyl, wherein the C1-12 alkyl is optionally substituted or unsubstituted;Ralais H, Ce-io aryl, or Ci-3o alkyl, wherein each Ce-io aryl or Ci-3o alkyl is optionally substituted or unsubstituted;Ra2ais:(i-a) -Ci-30alkyl, -(Ci-30alkylene)-O-C(O)Rla, -(Ci-30alkylene)-C(O)-ORla, -(Ci-3o alkylene)-(Ce-io arylene)-O-C(O)-Rla; wherein Rlais optionally substituted or unsubstituted C1-12 alkyl or optionally substituted or unsubstituted 5-to 10-membered heteroaryl; or(ii-a) Ce-io aryl, -(Ce-io arylene)-(Ci-i2 alkylene)-O-C(O)-R2a, or -(5- to 10- membered heteroarylene)-(Ci-i2 alkylene)-O-C(O)-R2a; wherein R2ais optionally substituted or unsubstituted C1-12 alkyl or -(C1-12 alkylene)-NR2aR2a, wherein the C1-12 alkylene is optionally substituted or unsubstituted; and each R2aand R2aindependently is H or optionally substituted or unsubstituted C1-12 alkyl.(vi) -(C1-6alkylene)-(5- to 10-membered heteroaryl optionally substituted by one or more oxo or C1-6alkyl) or -(C1-6alkylene)-Ce-io aryl;wherein:aryl optionally substituted with C1-6alkoxy, or R5and R6combine to form oxo; or R5and R6can be taken together to form a C3-8 cycloalkyl or 3- to 10-membered heterocyclyl;R1Vis C1-20 alkyl; andR1Vis H or C1-6alkyl;wherein:R5, R6, R5, and R6each independently are hydrogen, C1-20 alkyl optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl optionally substituted with C1-6alkoxy, or (i) R5and R6combine to form oxo or (ii) R5and R6combine to form oxo, or (i) R5and R6can be taken together to form a C3-8 cycloalkyl or 3- to 10-membered heterocyclyl, or (ii) R5and R6, together with the atom to which they are attached, combine to form C3-8 cycloalkyl or 3- to 10-membered heterocyclyl; andRvis C1-20 alkyl, C3-8 cycloalkyl, mono or dialkyl amino, or 3- to 10-membered heterocyclyl; orwherein: each R5and R6independently are as defined for Formula (1’);R4Tis Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the Ce-io aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;RNis H, Ci-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted; andRNis H, Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;wherein: R5and R6are each independently H, C1-6alkyl, or Ce-io aryl.M;M is -0-R4, -NR’-(CI-20 alkylene)-R4, -0-(Ci-2o alkylene)-R4, -0-(Ci-2o alkylene)-O-R4or -(Ci -20 alkylene)-R4, wherein the C1-6alkylene is optionally substituted with hydroxyl;R’ is H or C1-6alkyl;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; each Rcindependently is C1-6alkyl; and each X independently is a pharmaceutically acceptable anion.R5R6., wherein R5and R6independently are as defined for Formula (1 ’); andRing A is:(i) Ce-i4 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl;(iv) 5- to 10-membered heteroaryl;(v) cholesterol, dihydrocholesterol, or a bile acid; wherein the aryl, heterocycle, cycloalkyl, heteroaryl, cholesterol, dihydrocholesterol, or bile acid are unsubstituted or are optionally substituted.(xii)each R5, R6, R5, and R6independently are hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, - C(O)-Ci-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(Ci-24alkylene)-Si(Riij)2-Ci-24 alkyl, -Si(Rllj)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Ruj)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Rllj)2- " " ’ -Si(R“ )2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)- yl, -(Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(Ci-heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;R7is C1-20 alkyl, C3-10 cycloalkyl, Ce-io aryl, bile acid, cholesterol, dihydrocholesterol, - (C1-20 alkyl ene)-O-(C 1-6 alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)-O-C(O)- O-(C1-6alkyl), -(C1-20 alkyl ene)-O-C(O)-(C 1-6 alkyl), 3- to 10-membered heterocyclyl; 5- to 10- membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), -(C1-20 alkyl ene)-C(0)-0-(3- to 10-membered heterocyclyl); -(C1-20 alkylene)-C(O)-O-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -O- C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10- membered heterocyclyl); -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), - CHRAA-NRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHR^-NR^, -(C1-20 alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)O- C(0)-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(C1-6alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)- cholesterol, or -(C1-6alkylene)-NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)-NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN- dihydrocholesterol, or -NRN-dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; wherein RAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH- C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; andsubstituted by -OH, or 5- to 10-membered heteroaryl;(xiii)Y1, and Y4each independently are O, NRN, or CH2;Y2and Y3each independently are O, NRN, or a bond; each RNindependently is H or C1-6alkyl;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are each hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl,C2-30 alkenyl, -O-C(O)-Ci-24alkyl, -O-C(O)-C2-30 alkenyl, -C(O)-Ci-24alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(R11-i)2-Ci-24 alkyl, - Si(Riij)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Riij)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Riij)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)- C1-24 alkyl, -(Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24 alkylene)- (O-CH2CH2)I -50-O-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -(C1-6alkylene)-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2-24 alkenyl;L is a bond, C1-24 alkylene, C2-24 alkenylene, Ce-io arylene, -(C1-6alkyl)-(Ce-io arylene)- or C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is optionally substituted;R4is H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-10 alkylene)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-memberedCi-io alkylene)-(cholesterol), -(Ci-io alkylene)-(dihydrocholesterol), -(Ci-ioalkylene)-C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-O-(C1-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkyl ene)-O-C(O)-O-(C 1-6 alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkyl ene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(O)-O-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkyl ene)-C(O)-O-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - (C1-6alkylene)-C(O)NRN-(Ci-6alkylene)-C(O)-OH, -(Ci-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, alkenylene, or alkyl is unsubstituted or is optionally substituted; n is 1 to 20;RAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RA 2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl;substituted; and each Rlldindependently is optionally substituted C1-6alkyl.In one aspect, the present disclosure is directed to a compound of Formula (1),Formula (1) wherein: X' is absent or is an anion;R1is:wherein: each R5and R6independently are hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(Riij)2-Ci-24 alkyl, -Si(Riij)2-Ci-24 alkyl, -(C2-3o alkenylene)-Si(Riij)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Rllj)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)-Ci-24 alkyl, -(C1-24 alkylene)- S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i- 50-O-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -Ci- 6 alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(O)-(Ce- 10 aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;each R1Vis independently H, deuterium, C1-22 alkyl or C2.24alkenyl;R4is:(ii-a) -C(O)-Ci-24 alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2.24alkynyl, -C(O)-(Ci-24alkylene)-Ce-i4aryl, -C(O)-(C2.24alkenylene)-Ce-i4aryl, - C(O)-(C2.24alkynylene)-Ce-io aryl, -C(O)-(Ci-24alkylene)-C(O)-O-Ci-24alkyl, - C(O)-(Ci-24alkylene)-C(O)-O-C2.24alkenylene, -C(O)-(C2.24alkenylene)-C(O)-O- Ci-24alkyl, -C(O)-C(O)-O-Ci-24alkyl, -C(O)-C(O)-OH, -C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)-(C2.24alkynylene)-C(O)-O- Ci-24alkyl, -C(O)-(C2.24alkynylene)-C(O)-OH, -C(O)-(Ci-24alkylene)-C(O)- (cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-C(O)-(bile acid), - C(O)-(C2.24alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2.24alkenylene)-C(O)-(bile acid), -C(O)-(Ci-24alkylene)-O-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-O-C(O)-(bile acid), -C(O)-(C2.24alkynylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2.24alkynylene)- C(O)-(bile acid), -C(O)-(Ci-24alkylene)-C(O)OH, -C(O)-(C2.24alkenylene)- C(O)OH, -C(O)-Ce-i4aryl, -C(O)-C3-is cycloalkyl, -C(O)-(3- to 10-membered heterocycle), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24alkylene)-(C6-i4aryl), -C(O)-(Ci-22alkylene)-(3- to 10-membered heterocycle), -C(O)-(Ci-24alkylene)-(5- to 10- membered heteroaryl), -C(O)-(C2.24alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2.24alkenylene)-(Ce-i4aryl), -C(O)-(C2.24alkenylene)-(3- to 10- membered heterocycle), -C(O)-(C2.24alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-(bile acid), -C(O)-(Ci-24alkylene)-O-(Ce-i4aryl), -C(O)-(Ci-24alkylene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24alkylene)-O-(5- to 10-membered heteroaryl), -C(O)-(Ci-24alkylene)-O-(bile acid), -C(O)- (cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24alkylene)-(O-CH2CH2)i -5o-0-Rlia, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted,Rliais H, deuterium, Ci-24alkyl or C2.24alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;alkenylene)-C6-i4 aryl, -C(O)-O-(Ci-24alkylene)-C(O)-O-Ci-24alkyl, -C(O)-O-(C2. 24alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci-24alkylene)-C(O)OH, -C(0)-0- (C2-24alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, -C(O)-O-C3-i5 cycloalkyl, -C(O)- O-(3- to 10-membered heterocycle), -C(O)-O-(5- to 10-membered heteroaryl), - C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(Ce-i4 aryl) -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered heterocycle) - C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2.24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(C2.24 alkenylene)-(C6-i4 aryl) -C(O)-O-(C2.24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-O-(C2. 24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-O-(Ci-24 alkylene)- (cholesterol or dihydrocholesterol), -C(O)-O-(C2.24 alkylene)-(bile acid), -C(O)- (Ci-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkyl ene)-0-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)- (Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O- (bile acid), C(O)-(Ci-24 alkylene)-C(O)-(cholesterol or dihydrocholesterol), - C(O)-(C1 -24alkylene)-C(O)-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-O-(Ci-24alkylene)-(O-CH2CH2)i.50-O- Rllb, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRllbis H, deuterium, Ci-22alkyl or C2.24alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-c) -Si(Rsi)3, wherein each RS1independently is Ci-24alkyl, C2.3o alkenyl, Ce-io aryl, -O-Ci-24alkyl, -O-C2-3o alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;R2is CH3, CH2D, CHD2, or CD3; andR3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium.In one aspect, the present disclosure is directed to a compound of Formula (1-F),whereinX' is absent or is an anion; each R1and R2independently are as defined for Formula (1); and each R1 Fa, R1Fb, Ra. R2Fa, R2Fb, R3Fa, R3Fb, R4Fa, R4Fb, R5Fa, R5Fb, R6Fa, R6Fb, R7F, R8FaR8Fb, R9Fa, and R9Fbare independently H, D, or F.In one aspect, the present disclosure is directed to a compound of Formula (2’),Formula (2’) whereinX' is absent or is an anion; andR1Tis:(i) halogen, -O-C1-6alkyl, -O-(C1-6alkylene)-Ce-io aryl, -O-C1-6haloalkyl, -O- S(O)2-Ci-6alkyl, -O-S(O)2-Ci-6haloalkyl, -0-S(0)2-C6-io aryl, -O-S(O)2-O-Ci-6alkyl, -O- S(O)2-O-C1-6haloalkyl, or -0-S(0)2-0-Ce-io aryl, wherein the alkyl, alkylene, aryl, or haloalkyl is optionally substituted; orwherein: n is 0 or 1;haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2.24alkynyl, -(Ci-24alkylene)-Si(Riij)2-Ci.24alkyl, -Si(Riij)2-Ci-24alkyl, -(C2.30alkenylene)-Si(Riij)2-Ci-24alkyl, — (C2.24alkenylene)-Si(R11-i)2-C2-24alkenyl, -Si(R11-’)2-C2.24alkenyl, -(Ci-C24alkylene)-Si(Riij)2-C2.24alkenyl, -S(O)2-O-Ci-6alkyl, S(O)2-O-Ci-6haloalkyl, -S(O)2-O- Ce-io aryl, -(Ci-24alkylene)-S(O)-Ci-24alkyl, -(Ci-24alkylene)-S(O)2-Ci-24alkyl, -(Ci-24alkylene)-S(O)-Ci-24alkylene, -(Ci-24alkylene)-S(O)2-Ci-24alkylene, -(Ci-24alkylene)- (0-CH2CH2)i-5o-0-Riv, -C(O)-(Ci-24alkylene)-(0-CH2CH2)i-5o-0-Riv, C6-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(0)-(Ce-io aryl), -C(O)- (5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR2Tand R3Tcombine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the heterocyclyl, or cycloalkyl is unsubstituted or is optionally substituted; each R1Vis independently H, deuterium, Ci-24alkyl or Ci-24alkenyl; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring;R4Tis:(ii-a) -C(O)-Ci-24alkyl, -(CH2CH20)o-2o-(Ci-4alkyl), -C(0)-0-(CH2CH20)o-2o- (Ci-4alkyl), -C(O)-Ci-24haloalkyl, -C(0)-C2.3o alkenyl, -C(O)-C2.24alkynyl, - C(O)-(Ci-24alkylene)-Ce-io aryl, -C(O)-(C2.24alkenylene)-Ce-io aryl, -C(O)-(C2.24alkynylene)-Ce-io aryl, -C(O)-(Ci-24alkylene)-C(O)-O-Ci-24alkyl, -C(O)-(C2.24alkenylene)-C(O)-O-Ci-24alkyl, -C(O)-C(O)-O-Ci-24alkyl, -C(O)-C(O)-OH, - C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)- (C2.24alkynylene)-C(O)-O-Ci-24alkyl, -C(O)-(C2.24alkynylene)-C(O)-OH, -C(O)- (Ci-24alkylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkyl ene)- C(O)-(bile acid), -C(O)-(C2.24alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2.24alkenylene)-C(O)-(bile acid), -C(O)-(C2.24alkynylene)-C(O)-O-(cholesterol or dihydrocholesterol), -C(O)-(C2.24alkynylene)-C(O)-(bile acid), -C(O)-(Ci-24alkylene)-C(O)-NH-Ci-24alkyl, -C(O)-NH-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-NH-C 1-24 alkyl, -C(O)-(C2-24 alkynylene)-C(0)-NH2, -C(O)-(Ci-24 alkylene)-C(O)-NH(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-C(O)-NH(bile acid), -C(O)-(C2-24 alkenylene)-C(O)-NH(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkenylene)-C(O)-NH(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-NH-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkynylene)-C(O)-NH(bile acid), -C(0)-(C2- 24 alkynylene)-O-C(O)-O-C i-24 alkyl, -C(O)-(Ci-24alkylene)-C(O)OH, -C(O)-(C2- 24 alkenylene)-C(O)OH, -C(O)-Ce-i4 aryl, -C(O)-C3-i5 cycloalkyl, -C(O)-(3- to 10- membered heterocycle), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24 alkylene)-(Ce-i4 aryl), - C(O)-(C1 -24 alkylene)-(3- to 10-membered heterocycle), -C(O)-(C 1-24 alkyl ene)- (5- to 10-membered heteroaryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(C6-i4 aryl), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(C2-24 alkenylene)-(C3-i5 cycloalkyl), -C(0)-(C2- 24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkenylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkenylene)-(bile acid), -C(O)-(Ci-24 alkylene)- (cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-(bile acid), -C(O)-(Ci- 24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkyl ene)-0-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)- (C1-24 alkylene)-O-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), -C(O)- (bile acid), -(bile acid), or -C(O)-(Ci-24alkylene)-(0-CH2CH2)i-5o-0-Riia', -C(O)- OH, or Ce-io aryl, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, Rliais H, C1-24 alkyl or C1-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24 alkyl, -C(O)-O-Ci-24haloalkyl, -C(O)-O-C2-30 alkenyl, - C(O)-O-C2-24 alkynyl, -C(O)-O-(Ci.24alkylene)-C6-io aryl, -C(O)-O-(C2-24 alkenylene)-C6-io aryl, -C(O)-O-C(O)-O-Ci-24alkyl, -C(O)-O-C(O)-OH, -C(O)- O-(Ci-24 alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2-24 alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2-24 alkenylene)-O-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci.24alkylene)-C(O)OH, -C(O)-O-(C2-24 alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, - C(O)-O-C3-i5 cycloalkyl, -C(O)-O-(3- to 10-membered heterocycle), -C(O)-O-(5-10-membered heterocycle) -C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)- O-(C2-24 alkenylene)-(C6-i4 aryl), -C(O)-O-(C2-24 alkenyl ene) -(3- to 10-membered heterocycle), -C(O)-O-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)- O-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-O-(Ci-24 alkylene)- (bile acid), -C(O)-O-(C2-24 alkenylene)-(cholesterol or dihydrocholesterol), - C(O)-O-(C2-24 alkenylene)-(bile acid), -C(O)-O-(cholesterol or dihydrocholesterol), -C(O)-O-(bile acid), or -C(O)-O-(Ci-24 alkylene)-(O- CH2CH2)i-50-O-Riib', -C(O)-(Ci-24 alkylene)-C(O)NRN-(Ci-24 alkylene)-C(O)- ORN, -C(O)-O-(CI-24 alkylene)-C(O)OH, -C(O)-O-(Ci-24alkylene)-C(O)NRN2, - C(O)-O-C3-8 cycloalkyl, -C(O)-O-(Ci-24alkylene)-OH, -C(O)-O-(C2-30 alkenylene)-OH, -C(O)-O-(C2-24 alkynylene)-OH, -C(O)-O-(cholesterol or dihydrocholesterol), or -C(O)-O-(bile acid), wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRllbis H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted, wherein each RNindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-c) -O-Si(Riic)3, or -O-Liic-Si(Riic)2-Liic, wherein each R11Cindependently is C1-24 alkyl, C2-24 alkenyl, Ce-io aryl, -O-Ci -24 alkyl, -O-C2-24 alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;Liicis Ci -24 alkylene; andLiic’ is Ci -24 alkyl, wherein the alkylene and alkyl is unsubstituted or is optionally substituted;(ii-d) -C(O)-Liid-((C(O))n-iid-Riid, wherein Llldis a C1-24 alkylene, C2-24 alkenylene, C2-24 alkynylene, C3-8 cycloalkylene, or a bond, n-iid is 0 or 1; andwherein each R5and R6independently are as defined for R5and R6of Formula (1), respectively;R2is CH3, CH2D, CHD2, or CD3;X' is absent or is an anion; andR3is a C1-6alkyl optionally substituted with at least one deuterium or halogen; orwherein X' is absent or is an anion;(ii-e) -C(O)-(Ci-24 alkylene)-(Ce-io aryl), wherein the Ce-io aryl is optionally substituted by one or more Rlie, wherein Rlieis -O-C(O)-C1-6alkyl, -O-C(O)-C3-8 cycloalkyl, -O- C(0)-Ce-io aryl or C1-6alkyl;(ii-f) — C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-NRiif-C(O)-O-Ci-24alkyl, -C(O)- (Ci-24alkylene)-NRiif-C(O)-CHRiif-N(Riif)2, or -C(O)-(Ci-24alkylene)-NRiif- C(O)-CHRllf-N(Rllf)-C(O)-O-Ci-24- alkyl, or salts thereof, wherein the alkyl and alkylene are unsubstituted or optionally substituted, wherein each Rllfindependently is H or C1-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1-6alkyl, -C(O)-NH2, -S-CI-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl, or salts thereof; and each Rllfindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted, or two Rllf, together with the atom to which they are attached, combine to form a 3- to 10- membered heterocyclyl; or Rllfand one Rllf, together with the atom to which they are attached, combine to form a 3- to 10- membered heterocyclyl;unsubstituted or is optionally substituted, wherein each Rllgindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or -CH2-O-P(O)2-O-(C1-6alkylene)-N(Riig’)3wherein each Rllgindependently is C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-h) -C(O)-O-CH(Riih)2, -C(O)-O-C(O)-O-CH(Riih)2, -C(O)-O-(Ci-24alkylene)- C(O)-O-C(O)-O-CH(Riih)2, -C(O)-O-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Riih)2, -C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Riih)2, or -C(O)-O-(Ci-24alkylene)-C(O)-O- (Ci-24 alkylene)-C(O)-O-CH(Rllh)2, wherein the alkylene is unsubstituted or is optionally substituted; wherein each Rllhindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, -CH2-O-P(O)2-O-(CI-24alkylene)-N(Riih’)2or - CH2-O-P(O)2-O-(CI-24 alkylene)-N(Rllh)3, wherein the alkyl, alkenyl, alkylene is unsubstituted or is optionally substituted; wherein each Rllhis independently H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-i) -P(O)(ORiii)2, -P(O)2(ORiii), -P(O)(ORiii)-O-(Ci-24 alkylene)-O-Ci-24alkyl, - P(O)(O-(Ci-24 alkylene)-C(O)-Riii))2, -P(O)(O-(Ci-24alkylene)-O-C(O)-Riii))2, - P(O)(O-(Ci-24 alkylene)-O-C(O)-O-Riii))2, -P(O)2(O-(Ci-24alkylene)-O-C(O)- R )), -P(O)2(O-(Ci-24 alkylene^O-CCO^O-R”)), -P(O)2(O-(Ci-24alkylene)-C(O)- O-R111)) or -P(O)(N(R1U)2)2, wherein the alkyl or alkylene is unsubstituted or is optionally substituted, wherein each R111independently is H, deuterium, or C1-20 alkyl, wherein alkyl is unsubstituted or is optionally substituted;(ii-j) C1-6alkyl;(ii-k) -C(O)-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-O-(Ci-i2 alkylene)-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-C(O)-O-(C 1-12 alkylene)-(optionally substituted pyrimidine)-(C1-6alkylene)- (optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 ie)-O-C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionallypyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), or -C(O)-(Ci-i2 alkylene)-NR1-C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), wherein the alkylene is unsubstituted or is optionally substituted, and wherein each R1independently is H or unsubstituted or optionally substituted C1-6alkyl;(ii-1) -C(O)-RAA, -C(O)-(Ci-i2 alkylene)^, -C(0)-NH-(Cni2 alkylene)^, - C(O)-O-(Ci-i2 alkylene)-RAA-C(0)-(0)m-(Ci-2o alkylene)-O-C(O)CHRii l-N(Rii- p)2, -C(0)-(0)m-(Ci-2o alkylene)-N(Rii'1)-C(O)CHRii'1-N(Rii'1)2, -C(O)-(O)m-(Cn 20 alkylene)-O-C(O)CHRii l-N(Rii l)-C(O)CHRii l-N(Rii l)2, or -C(0)-(0)m-(Ci-2o alkylene)-N(Rii-1)-C(O)CHRii'1-N(Rii'1)-C(O)CHRii'1-N(Rii'1)2wherein: m is 0 or 1; each R11’1independently is H or C1-6alkyl; and each R11’1independently is H, Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(O)-NH2, - S-Ci-6 alkyl, -NH-C(=NH)NH2, C6.10 aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;R is:(i)-O-C(O)-C(Riif)N(Riif)(Riif), -C(Riif)N(Riif)(Riif), - C(O)N(Riif)-(Ci-i2 alkyl), -N(Riif)C(O)-(Ci-i2 alkyl), or -C(O)OH;(ii) Ce-io aryl, -0-(Ce-io arylene)-(Ci-i2 alkyl), -(Ce-io arylene)-(Ci- 12 alkyl), -(Ce-io arylene)-C(O)N(Rllf)-(Ci-i2 alkyl), -NH-(Ce-io arylene)- C(O)N(Riif)-(Ci-i2 alkyl), -(C6-io arylene)-N(Riif)C(O)-(Ci-i2 alkyl); or(iii) -(C3-8 cycloalkylene)-C(O)N(Rllf)-(Ci-i2 alkyl), -(C3-8 cycloalkylene)-(Ci-i2 alkylene)-N(Rllf)-C(O)-(Ci-i2 alkyl); wherein: each Rllfindependently is H or C1-12 alkyl; each Rllfindependently is H or C 1-6 alkyl; and each C1-6alkyl, C1-12 alkyl, Ce-io aryl, Ce-io arylene, C3-8 cycloalkylene, or C1-12 alkylene is optionally substituted or unsubstituted.(ii-q) -C(O)-N(RNlb)RN2b, wherein RNlbis H or optionally substituted or unsubstituted vl; andRN2bis:Ci-12 alkyl is optionally substituted or unsubstituted;(ii-b) -(5- to 10-membered heteroarylene)-(Ci-i2 alkylene)-O-C(O)-(Ci-i2 alkylene), wherein each 5- to 10-membered heteroarylene, or C1-12 alkylene is optionally substituted or unsubstituted;(iii-b) -(C1-12 alkylene)-C(O)-NRiiibRiiib, -(C1-12 alkylene)-NRiiibRiiib’-C(O)-(Ci-i2alkyl), -(Ce-io arylene)-C(O)-NRlllbRlllb, or -(C1-12 alkylene)-(C3-8 cycloalkylene)-C(O)- NRiubRiub’, wherein each C 1-12 alkylene, C1-12 alkyl, Ce-io arylene, or C3-8 cycloalkene is optionally substituted or unsubstituted;Rlllbis H or optionally substituted or unsubstituted C1-12 alkyl; andRlllbis H, optionally substituted or unsubstituted C1-12 alkyl, or -(C1-12 alkylene)- (Ce-io aryl), wherein each C1-12 alkylene or Ce-io aryl is optionally substituted or unsubstituted;(iv-b) -(C1-12 alkylene)-C(O)-O-(bile acid), -(C1-12 alkylene)-C(O)-O- (cholesterol), or -(C1-12 alkylene)-C(O)-O-(dehydrocholesterol), wherein each C1-12 alkylene is optionally substituted or unsubstituted; or(v-b) -(Ci -12 alkylene)-C(O)-O-(Ci-i2 alkylene)-(3- to 10-membered heterocyclyl), -(C1-12 alkylene)-(C3-8 cycloalkylene)-C(O)-O-(C 1-12 alkylene)-(3- to 10-membered heterocyclyl), or - (Ce-io arylene)-C(O)-O-(Ci-i2 alkylene)-(3- to 10-membered heterocyclyl), wherein each C1-12 alkylene, C3-8 cycloalkylene, Ce-io arylene, or 3- to 10-membered heterocyclyl is optionallysubstituted or unsub stituted;(iii) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl; wherein the alkyl or aryl are unsubstituted or optionally substituted;R2is C1-20 alkyl, C3-10 cycloalkyl, Ce-io aryl, -(C1-20 alkylene)-O-(C1-6alkyl), -(Ci- 20 alkylene)-O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), 3- to 10-membered heterocyclyl; 5- to 10-membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), - (Ci-10 alkyl ene)-C(O)-O-(C 1-6 alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)-O-(3- to 10-membered heterocyclyl); -(C1-10 alkylene)-C(O)-O-(5- to 10- membered heteroaryl), -(C1-20 alkyl ene)-(3- to 10-membered heterocyclyl); -(C1-20 ie)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered0-(5- to 10-membered heteroaryl), -CHR^-NR^, -(C1-20 alkylene)-CHRAA-NRN2, -(Ci- 20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)- C(0)-0-(Ci-2o alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)-N+(Ci- 6 alkyl)3, -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(C1-6alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)- cholesterol, or -(C1-6alkylene)- NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)-NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, or - NRN-dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; or(ii-k) -C(O)-NRiik-(Ci -20 alkylene, C 1-20 alkenylene, or C1-20 alkynylene)- (optionally substituted Ce-io aryl), -C(O)-NRiik’-(Ci -20 alkylene, C 1-20 alkenylene, or C1-20 alkynylene)-(optionally substituted 5- to 10-membered heteroaryl), - C(O)-NRllk-(optionally substituted Ce-io aryl), -C(O)-NRllk-(optionally substituted 5- to 10-membered heteroaryl), -C(O)-NRllk’-(C1-20 alkylene)-O- C(O)-Riik’, -C(O)-N(Riik)2or -C(0)-NRiik’-(Ci-2o alkylene)-C(O)-O-Riik” wherein each Rllkindependently is H or C1-20 alkyl;(ii-1) -(C(0))n-(0)m-(Ci-2o alkylene)-O-C(O)CHR11-f-N(R11-f)2, -(C(O))n- (0)m-(Ci-2o alkylene)-N(R11-f)-C(0)CHR11-f-N(R11-f)2, -(C(0))n-(0)m-(Ci.2o alkylene)-O-C(O)CHRii f-N(Rii f)-C(O)CHRii f-N(Rii f)2, or -(C(0))n-(0)m-(Ci-2o alkylene)-N(Rii'f)-C(O)CHRii'f-N(Rii'f)-C(O)CHRii'f-N(Rii'f)2wherein: n is 0 or 1; m is 0 or 1; each R11-findependently is H or C 1-6 alkyl; and each R11-findependently is H, Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(O)-NH2, - S-C1-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl.(ii-n) -(C(0))n-(C1-6alkylene)-N(Rii-n)-R“'n, wherein:(iv) .wherein:each independently are H, C1-20 alkyl optionally substituted by one or more Ce-io aryl, Ce-io aryl optionally substituted with one or more -O-C1-6alkyl, 5- to 10-membered heterocyclyl, C3-8 cycloalkyl, or -C(O)-4- to 10-membered heterocycle, or (i) R2T* and R3T* or (ii) R2'1** and R '1** combine to form oxo, or (i) R2T* and R3T* or (ii) R2'1** and R3'1**, together with the atom to which they are attached, combine to form a C3-8 cycloalkyl; and10-membered heterocyclyl, or 5- to 10- membered heteroaryl; wherein the alkyl, aryl, heterocyclyl, and heteroaryl are each unsubstituted or are optionally substituted;wherein: each R2Tand R3Tindependently are as defined for Formula (2);R4Tis Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the Ce-io aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;RNis H, Ci-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted; andRNis H, Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;wherein:L1is -C(R2T)(R3T)- or -P(O)(OH)-;R2Tand R3Teach independently are H, C1-6alkyl, or Ce-io aryl, or R2Tand R3Tcombine to form oxo;T 2" bond, -(C1-8 alkylene)-C(O)-*, -O-C(O)-(Ci-8alkylene)-C(O)-*, -C(O)-(Ci-81)-*, -O-C(O)-*, -O-(Ci-8 alkylene)-O-C(O)-(Ci-8 alkylene)-C(O)-*, -O-P(O)(OH)-M is -0-R4, -NR’-(CI-20 alkylene)-R4, -0-(Ci-2o alkylene)-R4, -0-(Ci-2o alkylene)-OR4, - (Ci-20 alkylene)-OR4, -(C1-20 alkylene)-C(O)-O-R4or -(C1-20 alkylene)-R4, wherein the C1-20 alkylene is optionally substituted with hydroxyl;R’ is H or C1-6alkyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.(vii), whereinY1, and Y4each independently are CH2, NRN, or O;Y2, and Y3each independently are a bond, NRN, or O; each RNindependently is H or C1-6alkyl;R2Tand R3Tare each independently hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)- C1-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(Riij)2-Ci- 24 alkyl, -Si(Rllj)2-Ci-24 alkyl, -(62-30 alkenylene)-Si(R11-i)2-Ci-24 alkyl, -(C2-24 alkenylene)- Si(Riij)2-C2-24 alkenyl, -Si(Riij)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Riij)2-C2-24 alkenyl, - S(O)2-O-Ci-6alkyl, S(O)2-O-Ci-6haloalkyl, -S(0)2-0-C6-io aryl, -(C1-24 alkylene)-S(O)- C1-24 alkyl, -(Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, - (Ci-24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci-24alkylene)-(0-CH2CH2)i-5o-0-Riv, -C(O)- (Ci -24 alkylene)-(O-CH2CH2)i-50-O-Rlv, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-s cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-s cycloalkyl), -C1-6alkylene-(4- to 10- membered heterocyclyl), -C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), - C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orsubstituted; each R1Vis independently H, deuterium, C1-24 alkyl or C1-24 alkenyl; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring;L is a bond, C1-24 alkylene, C2-24 alkenylene, or C2-24 alkynylene; andR4Tis H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-10 alkylene)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-(cholesterol), -(C1-10 alkylene)-(dihydrocholesterol), -(C1-10 alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(C1-6alkyl), -(C1-20 alkyl ene)-O-(C 1-6 alkyl), -(C1-20 alkylene)-O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O- C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O-C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(3- to 10- membered heterocyclyl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl), -O- (3- to 10-membered heterocyclyl), -(C1-20 alkyl ene)-C(0)-0-(3- to 10-membered heterocyclyl), - (C1-20 alkyl ene)-O-C(O)-(C 1-6 alkylene)-(3- to 10-membered heterocyclyl), -CHRAA-NRN2, -(Cn 20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - " ” ’ )-C(O)NRN-(CI-6alkylene)-C(O)-OH, -(Ci-6alkylene)-C(O)-OH, -C(O)-(Ci-22(C3-15 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-memberedalkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, or alkyl is unsubstituted or is optionally substituted;R is H, -C(O)-NRN-CHRAA2-C(O)-OH; CI.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-CI.6 alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;R2is H, Ci-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Rlld)s, wherein the alkyl, alkenyl, and alkylene are unsubstituted or optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl;(viii), wherein Y4is CH2, NRN, or O;Y2and Y3each independently are a bond, NRN, or O;L is a bond, C1-24 alkylene, C2-24 alkenylene, or C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is unsubstituted or optionally substituted; each RNindependently is H or C1-6alkyl;R4Tis H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-10 alkylene)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(O)-O-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-(cholesterol), -(C1-10 alkylene)-(dihydrocholesterol), -(C1-10 alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)- -,’,-y(jroc]loiesteroij-NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, lium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, -O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(0)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkyl ene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkyl ene)-C(0)-0-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-0-C(0)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - (C1-6alkylene)-C(O)NRN-(Ci-6alkylene)-C(O)-OH, -(Ci-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkenylene, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, or alkyl is unsubstituted or is optionally substituted;RAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RAA2 is H or C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-Ci-6 alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, -CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Rlld)3, wherein the alkyl, alkenyl, and alkylene are unsubstituted or optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl.Formula (2) wherein:(i) halogen, -O-C1-6alkyl, -O-(C1-6alkylene)-Ce-io aryl, -O-C1-6haloalkyl, -O- S(O)2-Ci-6alkyl, -O-S(O)2-Ci-6haloalkyl, -0-S(0)2-C6-io aryl, -O-S(O)2-O-Ci-6alkyl, -O- S(O)2-O-C1-6haloalkyl, or -0-S(0)2-0-Ce-io aryl, wherein the alkyl, alkylene, aryl, or haloalkyl is optionally substituted; orwherein: n is 0 or 1;Y is -O-, -S-, -S(O)-, or -S(O)2-; each R2Tand R3Tindependently are hydrogen, deuterium, Ci-24 alkyl, -Ci-24 haloalkyl, C2.3o alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-C30alkenyl, -C(O)-C2.24alkynyl, -(Ci-24alkylene)-Si(Riij)2-Ci.24alkyl, -Si(Riij)2-Ci-24alkyl, -(C2.30alkenylene)-Si(Riij)2-Ci-24alkyl, -(C2.24 alkenylene)-Si(R11-i)2-C2-24 alkenyl, -Si(R11-’)2-C2.24 alkenyl, -(C1-C24 alkylene)-Si(Riij)2-C2.24alkenyl, -S(O)2-O-Ci-6alkyl, S(O)2-O-Ci-6haloalkyl, -S(O)2-O- Ce-io aryl, -(Ci-24 alkylene)-S(O)-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)-Ci-24 alkylene, -(Ci-24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci-24 alkylene)- (0-CH2CH2)i-5o-0-Riv, -C(O)-(Ci-24alkylene)-(0-CH2CH2)i-5o-0-Riv, C6-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-s cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-s cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(0)-(Ce-io aryl), -C(O)- (5- to 10-membered heteroaryl), -C(O)-(C3-s cycloalkyl), or -C(O)-(4- to 10-memberedR2Tand R3Tcombine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the heterocyclyl, or cycloalkyl is unsubstituted or is optionally substituted; each R1Vis independently H, deuterium, C1-24 alkyl or C1-24 alkenyl; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring; andR4Tis:(ii-a) -C(O)-Ci-24 alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -C(O)-(Ci-24 alkylene)-Ce-io aryl, -C(O)-(C2-24 alkenylene)-Ce-io aryl, - C(O)-(C2-24 alkynylene)-Ce-io aryl, -C(O)-(Ci-24 alkylene)-C(O)-O-Ci-24 alkyl, - C(O)-(C2-24 alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-C(O)-O-Ci-24alkyl, -C(O)- C(O)-OH, -C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-O-Ci-24 alkyl, -C(O)-(C2-24 alkynylene)- C(O)-OH, -C(O)-(Ci-24 alkylene)-C(O)-(cholesterol or dihydrocholesterol), - C(O)-(Ci-24 alkylene)-C(O)-(bile acid), -C(O)-(C2-24 alkenylene)-C(O)- (cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkenylene)-C(O)-(bile acid), - C(O)-(C2-24 alkynylene)-C(O)-O-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkynylene)-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-O-C(O)-O-Ci-24 alkyl, - C(O)-(Ci-24 alkylene)-C(O)OH, -C(O)-(C2-24 alkenylene)-C(O)OH, -C(O)-C6-i4 aryl, -C(O)-C3-i5 cycloalkyl, -C(O)-(3- to 10-membered heterocycle), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24 alkylene)-(C6-i4 aryl), -C(O)-(Ci-24 alkylene)-(3- to 10- membered heterocycle), -C(O)-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), - C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(Ce-i4 aryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)- (C1-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-(bile acid), -C(O)-(Ci-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkyl ene)-0-(3- to 10- membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-O-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24 alkylene)-(O- CH2CH2)i-5o-0-Rlia', -C(O)-OH, or Ce-io aryl, wherein the alkyl, alkenyl, alkynyl,Rliais H, Ci-24 alkyl or C1-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24 alkyl, -C(O)-O-Ci-24haloalkyl, -C(O)-O-C2-30 alkenyl, - C(O)-O-C2-24 alkynyl, -C(O)-O-(Ci.24alkylene)-C6-io aryl, -C(O)-O-(C2-24 alkenylene)-C6-io aryl, -C(O)-O-C(O)-O-Ci-24alkyl, -C(O)-O-C(O)-OH, -C(O)- O-(Ci-24 alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2-24 alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2-24 alkenylene)-O-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci.24alkylene)-C(O)OH, -C(O)-O-(C2-24 alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, - C(O)-O-C3-i5 cycloalkyl, -C(O)-O-(3- to 10-membered heterocycle), -C(O)-O-(5- to 10-membered heteroaryl), -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(Ce-i4 aryl), -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered heterocycle) -C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)- O-(C2-24 alkenylene)-(Ce-i4 aryl), -C(O)-O-(C2-24 alkenyl ene) -(3- to 10-membered heterocycle), -C(O)-O-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)- O-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-O-(Ci-24 alkylene)- (bile acid), -C(O)-O-(C2-24 alkenylene)-(cholesterol or dihydrocholesterol), - C(O)-O-(C2-24 alkenylene)-(bile acid), -C(O)-O-(cholesterol or dihydrocholesterol), -C(O)-O-(bile acid), or -C(O)-O-(Ci-24 alkylene)-(O- CH2CH2)i-50-O-Riib', -C(O)-(Ci-24 alkylene)-C(O)NRN-(Ci-24 alkylene)-C(O)- ORN, -C(O)-O-(CI-24 alkylene)-C(O)OH, -C(O)-O-(Ci-24alkylene)-C(O)NRN2, - C(O)-O-C3-8 cycloalkyl, -C(O)-O-(Ci-24alkylene)-OH, -C(O)-O-(C2-30 alkenylene)-OH, -C(O)-O-(C2-24 alkynylene)-OH, -C(O)-O-(cholesterol or dihydrocholesterol), or -C(O)-O-(bile acid), wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRllbis H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted, wherein each RNindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-c) -O-Si(Riic)3, or -O-Liic-Si(Riic)2-Liicor aryl is unsubstituted or is optionally substituted;Liicis Ci -24 alkylene; andLiic’ is Ci -24 alkyl, wherein the alkylene and alkyl is unsubstituted or is optionally substituted; or(ii-d) -C(O)-Liid-((C(O))n-iid-Riidwherein Llldis a C1-24 alkylene, C2-24 alkenylene, C2-24 alkynylene,C3-8 cycloalkylene, or a bond, n-iid is 0 or 1; andwherein each R5and R6independently are as defined for R5and R6of Formula (1), respectively;R2is CH3, CH2D, CHD2, or CD3;X' is absent or is an anion; andR3is a C1-6alkyl optionally substituted with at least one deuterium and / or halogen; orwherein X' is absent or is an anion.In one aspect, the present disclosure is directed to a pharmaceutical composition comprising a compound according to any one of the formulae or embodiments herein and a pharmaceutically acceptable excipient.In one aspect, the present disclosure is directed to a pharmaceutical composition comprising a compound of Formula (1), a compound of Formula (2), and a pharmaceutically acceptable excipient.In one aspect, the present disclosure is directed to a pharmaceutical composition comprising a compound of Formula (F), a compound of Formula (2’), and a pharmaceutically acceptable excipient.In one aspect, the present disclosure is directed to a method for treating a neuropsychiatric disease, comprising administering an effective amount of a compound of Table 1 or Table 2.In one aspect, the present disclosure is directed to a method of treating a neuropsychiatric disease in a subject in need thereof, comprising:(i) administering a compound of Formula (1) to the subject, and(ii) administering a compound of Formula (2) to the subject.In one aspect, the present disclosure is directed to a method of treating a neuropsychiatric disease in a subject in need thereof, comprising:(i) administering a compound of Formula (F) to the subject, and(ii) administering a compound of Formula (2’) to the subject.In one aspect, the present disclosure is directed to a method of treating a neuropsychiatric disease in a subject in need thereof, comprising:(i) administering a compound of Table 1 to the subject, and(ii) administering a compound of Table 2 to the subject.In one aspect, the present disclosure is directed to the use of the compound of any one of the formulae or embodiments herein for the preparation of a medicament for the treatment of a neuropsychiatric disease in a subject in need thereof.In one aspect, the present disclosure is directed to the use of the compound of any one of the formulae or embodiments herein in a method for the treatment of a neuropsychiatric disease in a subject in need thereof.In one aspect, the present disclosure is directed to a compound of any one of the formulae or embodiments herein in a method of treating a neuropsychiatric disease in a subject in need thereof.The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, which proceeds with reference to the accompanying figures.The foregoing and other objects, features, and advantages of the invention will become more apparent from the following detailed description, with reference to the accompanying figures.BRIEF DESCRIPTION OF THE FIGURESdescription, serve to explain the principles of the present disclosure. The drawings are only for the purpose of illustrating an embodiment of the disclosure and are not to be construed as limiting the invention. Further objects, features and advantages of the invention will become apparent from the following detailed description taken in conjunction with the accompanying figures showing illustrative embodiments of the disclosure.Figure 1 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline (1 mg / kg of xanomeline) to male Sprague Dawley (SD) rats.Figure 2 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl acetate iodide prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 3 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl heptanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 4 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl undecanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 5 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl hexadecanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 6 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxy ethyl pivalate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 7 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl propionate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 8 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl pentanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 9 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl hexanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 10 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl octanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 11 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl nonanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 12 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl decanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 13 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl dodecanoate iodide prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 14 shows mean concentration-time profiles of xanomeline following SC dosing of ethyl decatriaoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 16 shows mean concentration -time profiles of xanom eline following SC dosing of xanomeline methyl pentadecanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 17 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl isobutyrate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 18 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl neopentanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 19 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl "tert-butanoate" iodide prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 20 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl ethyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 21 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl propyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 22 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl butyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 23 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl pentylcarbonate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 24 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl hexyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 25 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl heptyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 26 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl octyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 27 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl nonyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 28 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl decyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 29 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl undecylcarbonate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 30 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl dodecylcarbonate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 31 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl decatriyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.32 shows mean concentration-time profiles of xanomeline following SC dosing ofFigure 33 shows mean concentration -time profiles of xanom eline following SC dosing of xanom eline methyl pentadecylcarbonate chloride prodrug (1 mg / kg of xanom eline) to male SD rats.Figure 34 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline methyl isopropyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 35 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl isobutyl carb onate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 36 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl tert-butylcarbonate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 37 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl tri-isopropylsilyl ether chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 38 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline N-oxide prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 39 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline methyl butanoate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 40 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline (5 mg / kg of xanomeline) to male Sprague Dawley (SD) rats.Figure 41 shows mean concentration -time profiles of xanomeline following SC dosing of xanomeline oxyisobutyl propanoate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 42 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxyethyl propanoate iodide prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 43 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxy ethyl pivalate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 44 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxybenzyl propanoate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 45 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxypropyl pivalate chloride prodrug (3.5 mg / kg of xanomeline) to male SD rats.Figure 46 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxypropyl propanoate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 47 shows mean concentration-time profiles of xanomeline following SC dosing of xanomeline oxybenzyl pivalate chloride prodrug (3.5 mg / kg of xanomeline) to male SD rats.48 shows mean concentration-time profiles of xanomeline following SC dosing ofxanomeline hemi-pamoate (5 mg / kg of xanomeline) to male SD rats.Figure 50 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxy ethyl pivalate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 51 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxypropyl pivalate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 52 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxypropyl pivalate iodide prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 53 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxyethyl pivalate pamoate prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 54 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxyethyl pivalate hemi-pamoate prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 55 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxypropyl pivalate pamoate prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 56 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline oxypropyl pivalate hemi-pamoate prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 57 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline (5 mg / kg of xanomeline) to male SD rats.Figure 58 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline mono-pamoate (5 mg / kg of xanomeline) to male SD rats.Figure 59 shows mean concentration-time profiles of xanomeline following IM dosing of xanomeline hemi-pamoate (5 mg / kg of xanomeline) to male SD rats.Figure 60 shows mean concentration-time profiles of prodrug following IM dosing of xanomeline oxy ethyl pivalate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 61 shows mean concentration-time profiles of prodrug following IM dosing of xanomeline oxypropyl pivalate chloride prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 62 shows mean concentration-time profiles of prodrug following IM dosing of xanomeline oxypropyl pivalate iodide prodrug (5 mg / kg of xanomeline) to male SD rats.Figure 63 shows mean concentration-time profiles of xanomeline following IV dosing of xanomeline (1 mg / kg of xanomeline) to male SD rats.Figure 64 shows mean concentration-time profiles of xanomeline following IV dosing of xanomeline oxy ethyl pivalate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 65 shows mean concentration-time profiles of prodrug following IV dosing of <ypropyl pivalate chloride prodrug (1 mg / kg of xanomeline) to male SD rats.Figure 67 shows mean concentration-time profiles of xanomeline following PO dosing of xanom eline (10 mg / kg of xanomeline) to male SD rats.Figure 68 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline oxypropyl pivalate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 69 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline oxy ethyl pivalate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 70 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl hexadecanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 71 shows mean concentration -time profiles of xanomeline following PO dosing of xanomeline methyl decatriaoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 72 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl nonanoate prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 73 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl octyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 74 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl dodecylcarbonate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 75 shows mean concentration -time profiles of xanomeline following PO dosing of xanomeline methyl pentadecylcarbonate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 76 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl octanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 77 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl decanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 78 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl undecanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 79 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl dodecanoate iodide prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 80 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl decatettaraoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 81 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl hexyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 82 shows mean concentration-time profiles of xanomeline following PO dosing of ethyl heptyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 84 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl pentanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 85 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl hexanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 86 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl pentadecanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 87 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl neopentanoate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 88 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl "tert-butanoate" iodide prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 89 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl propyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 90 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl butyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 91 shows mean concentration -time profiles of xanomeline following PO dosing of xanomeline methyl hexyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 92 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl decatettaryl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 93 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl isopropyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 94 shows mean concentration-time profiles of xanomeline following PO dosing of xanomeline methyl isobutyl carb onate chloride prodrug (10 mg / kg of xanomeline) to male SD rats.Figure 95 shows an XRPD of xanomeline oxypropyl pivalate chloride prodrug in the 2theta range of 5-70 °.Figure 96 shows an XRPD of xanomeline oxypropyl pivalate chloride prodrug in the 2theta range of 5-35 °.Figure 97 shows an XRPD of xanomeline oxy ethyl pivalate chloride prodrug in the 2theta range of 5-70 °.Figure 98 shows an XRPD of xanomeline oxy ethyl pivalate chloride prodrug in the 2theta ranee of 5-35 °methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 100 shows mean concentration -time profiles of xanomeline following PO dosing of l-((((Tert-butoxycarbonyl)-L-phenylalanyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3- yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 101 shows mean concentration -time profiles of xanomeline following PO dosing of l-(((5-(tert-butoxy)-5-oxopentanoyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 102 shows mean concentration-time profiles of xanomeline following PO dosing of 5-(4-(Hexyloxy)-l,2,5-thiadiazol-3-yl)-l (((hydroxy(((isopropoxycarbonyl)oxy)methoxy)phosphoryl)oxy)methyl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 103 shows mean concentration-time profiles of xanomeline following PO dosing of 5-(4-(Hexyloxy)-l,2,5-thiadiazol-3-yl)-l- (((hydroxy((pivaloyloxy)methoxy)phosphoryl)oxy)methyl)- 1 -methyl- 1 ,2,3,6-tetrahydropyridin- 1-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 104 shows mean concentration-time profiles of xanomeline following PO dosing of 5-(4-(Hexyloxy)- 1 ,2,5 -thiadiazol-3 -yl)- 1 -methyl- 1 -(((tetrahydro-2H-pyran-4- carbonyl)oxy)methyl)-l,2,3,6-tetrahydropyridin-l-ium chloride (10 mg / kg of xanomeline) to male SD rats.Figure 105 shows mean concentration -time profiles of xanomeline following PO dosing of l-((((Tert-butoxycarbonyl)-L-alanyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 106 shows mean concentration -time profiles of xanomeline following PO dosing of l-((((Tert-butoxycarbonyl)-L-leucyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 107 shows mean concentration-time profiles of xanomeline following PO dosing of l-((((Tert-butoxycarbonyl)-L-prolyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 108 shows mean concentration -time profiles of xanomeline following PO dosing of l-((((S)-4-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoyl)oxy)methyl)-5-(4- (hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 110 shows mean concentration -time profiles of xanomeline following PO dosing of l-(((6-(Tert-butoxy)-6-oxohexanoyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 111 shows mean concentration-time profiles of xanomeline following PO dosing of (5-(4-(Hexyloxy)- 1,2, 5-thiadiazol-3-yl)-l -methyl- 1,2,3, 6-tetrahydropyri din- 1-ium-l- yl)methyl hydrogen phosphate (10 mg / kg of xanomeline) to male SD rats.Figure 112 shows mean concentration-time profiles of xanomeline following PO dosing of 5-(4-(Hexyloxy)-l, 2, 5-thiadiazol-3-yl)- 1 -methyl- l-((5-methyl-2-oxo-l, 3-dioxol -4-yl)methyl)- 1,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 113 shows mean concentration -time profiles of xanomeline following PO dosing of 5-(4-(Hexyloxy)- 1 ,2,5-thiadiazol-3 -yl)- 1 -methyl- 1 -(((piperidine- 1 -carbonyl)oxy)methyl)- 1,2,3,6-tetrahydropyridin-l-ium chloride (10 mg / kg of xanomeline) to male SD rats.Figure 114 shows mean concentration-time profiles of xanomeline following PO dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-((octanoyloxy)methyl)-l,2,3,6- tetrahydropyridin-l-ium acetate (Xanomeline oxymethyl octanoate acetate) (10 mg / kg of xanomeline) to male SD rats.Figure 115 shows mean concentration-time profiles of xanomeline following PO dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-((tridecanoyloxy)methyl)-l,2,3,6- tetrahydropyridin-l-ium acetate (xanomeline oxymethyl tridecanoate acetate) (10 mg / kg of xanomeline) to male SD rats.Figure 116 shows mean concentration -time profiles of xanomeline following PO dosing of l-(((4-((l,3-Bis(((Z)-octadec-9-enoyl)oxy)propan-2-yl)oxy)-4-oxobutanoyl)oxy)methyl)-5- (4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 117 shows mean concentration -time profiles of xanomeline following PO dosing of l-(((8-((l,3-Bis(((Z)-octadec-9-enoyl)oxy)propan-2-yl)oxy)-8-oxooctanoyl)oxy)methyl)-5-(4- (hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.Figure 118 shows mean concentration-time profiles of xanomeline following PO dosing of l-('('('('Tert-butoxycarbonyl)glycyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- 5-tetrahydropyridin-l-ium iodide (10 mg / kg of xanomeline) to male SD rats.tetrahydropyridin-l-ium acetate (10 mg / kg of xanomeline) to male SD rats.Figure 120 shows mean concentration -time profiles of xanomeline following PO dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-(octanoyloxy)propyl)-l,2,3,6- tetrahydropyridin-l-ium acetate (10 mg / kg of xanomeline) to male SD rats.Figure 121 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(Hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(phenyl(propionyloxy)methyl)-l,2,3,6- tetrahydropyridin-l-ium chloride (5 mg / kg of xanomeline) to male SD rats.Figure 122 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-((octanoyloxy)methyl)-l,2,3,6- tetrahydropyridin-l-ium acetate (Xanomeline oxymethyl octanoate acetate) (5 mg / kg of xanomeline) to male SD rats.Figure 123 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-((tridecanoyloxy)methyl)-l,2,3,6- tetrahydropyridin-l-ium acetate (xanomeline oxymethyl tridecanoate acetate) (5 mg / kg of xanomeline) to male SD rats.Figure 124 shows mean concentration-time profiles of xanomeline following IM dosing of (5-(4-(Hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium-l- yl)methyl hydrogen phosphate (1 mg / kg of xanomeline) to male SD rats.Figure 125 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(Hexyloxy)-l, 2, 5-thiadiazol-3-yl)- 1 -methyl- l-((5-methyl-2-oxo-l, 3-dioxol -4-yl)methyl)- 1,2,3,6-tetrahydropyridin-l-ium iodide (2 mg / kg of xanomeline) to male SD rats.Figure 126 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(Hexyloxy)-l ,2,5-thiadiazol-3-yl)- 1 -methyl- 1 -(((tetrahydro-2H-pyran-4- carbonyl)oxy)methyl)-l,2,3,6-tetrahydropyridin-l-ium chloride (5 mg / kg of xanomeline) to male SD rats.Figure 127 shows mean concentration-time profiles of xanomeline following IM dosing of l-(((8-((l,3-Bis(((Z)-octadec-9-enoyl)oxy)propan-2-yl)oxy)-8-oxooctanoyl)oxy)methyl)-5-(4- (hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (2 mg / kg of xanomeline) to male SD rats.Figure 128 shows mean concentration-time profiles of xanomeline following IM dosing of l-(((4-((l,3-Bis(((Z)-octadec-9-enoyl)oxy)propan-2-yl)oxy)-4-oxobutanoyl)oxy)methyl)-5- I4-Ihexvloxv)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg ;) to male SD rats.methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 130 shows mean concentration-time profiles of xanomeline following IM dosing of l-((((Tert-butoxycarbonyl)-L-valyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats. Figure 131 shows mean concentration-time profiles of xanomeline following IM dosing of ^((((Tertbutoxy carbonyl)-L-phenylalanyl)oxy)methyl)-5-(4-(hexyloxy)- 1,2, 5-thiadiazol-3-yl)-l -methyl- 1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 132 shows mean concentration-time profiles of xanomeline following IM dosing of l-(((6-(Tert-butoxy)-6-oxohexanoyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 133 shows mean concentration-time profiles of xanomeline following IM dosing of l-(((5-(tert-butoxy)-5-oxopentanoyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 134 shows mean concentration-time profiles of xanomeline following IM dosing of l-((((Tert-butoxycarbonyl)-L-alanyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 135 shows mean concentration-time profiles of xanomeline following IM dosing of l-((((Tert-butoxycarbonyl)-L-leucyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 136 shows mean concentration-time profiles of xanomeline following IM dosing of l-((((Tert-butoxycarbonyl)-L-prolyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 137 shows mean concentration-time profiles of xanomeline following IM dosing of l-((((S)-4-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-4-oxobutanoyl)oxy)methyl)-5-(4- (hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 138 shows mean concentration-time profiles of xanomeline following IM dosing of l-((((S)-5-(tert-butoxy)-2-((tert-butoxycarbonyl)amino)-5-oxopentanoyl)oxy)methyl)-5-(4- (hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 139 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-(octanoyloxy)ethyl)-l,2,3,6- din-l-ium acetate (5 mg / kg of xanomeline) to male SD rats.tetrahydropyridin-l-ium acetate (5 mg / kg of xanomeline) to male SD rats.Figure 141 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l ,2,5-thiadiazol-3 -yl)-l -(1 -((isopropoxy carbonyl)oxy)decyl)- 1 -methyl -1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 142 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-((propoxycarbonyl)oxy)decyl)-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 143 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -( 1 -(decanoyloxy)ethyl)-5-(4-(hexyloxy)- 1 ,2, 5-thiadiazol-3 -yl)- 1 -methyl- 1 ,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 144 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -[5-(4-hexoxy- 1 ,2,5-thiadiazol-3 -yl)- 1 -methyl-3 ,6-dihydro-2H-pyridin- 1 -ium- 1 -yl]propyl decanoate iodide (5 mg / kg of xanomeline) to male SD rats.Figure 145 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-((2-(2-(propionyloxy) phenyl)acetoxy) methyl)-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 146 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-((2-(2-(isobutyryloxy)phenyl) acetoxy)methyl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 147 shows mean concentration-time profiles of xanomeline following IM dosing of l-((2-(2-((cyclohexanecarbonyl)oxy)phenyl)acetoxy)methyl)-5-(4-(hexyloxy)-l,2,5- thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 148 shows mean concentration-time profiles of xanomeline following IM dosing of l-((2-(2-(benzoyloxy)phenyl)acetoxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 149 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -((2-(2-acetoxyphenyl)acetoxy)methyl)-5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3-yl)- 1 -methyl - 1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 150 shows mean concentration-time profiles of xanomeline following IM dosing of l-(((3-(2-acetoxyphenyl)propanoyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l- methyl- 1.2 .6-tetrahydropyri din- 1 -ium iodide (5 mg / kg of xanomeline) to male SD rats.1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 152 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -((benzoyloxy )methyl)-5-(4-(hexyloxy)- 1 ,2, 5-thiadiazol-3 -yl)- 1 -methyl- 1 ,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 153 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -((((cyclohexyloxy)carbonyl)oxy)methyl)-5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3-yl)- 1 -methyl -1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 154 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-((3-methylbutanoyl)oxy)ethyl)-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 155 shows mean concentration-time profiles of xanomeline following IM dosing of l-(l-(benzoyloxy)ethyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 156 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-((propoxycarbonyl)oxy)ethyl)-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 157 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3 -yl)- 1 -methyl- 1 -( 1 -(tridecanoyloxy)propyl)- 1 ,2,3,6- tetrahydropyridin-l-ium iodide (1 mg / kg of xanomeline) to male SD rats.Figure 158 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -( 1 -(((cy clohexyloxy)carbonyl)oxy)propyl)-5-(4-(hexyloxy)- 1 ,2, 5 -thiadi azol -3 -yl)- 1 -methyl-1,2,3,6-tetrahydropyridin-l-ium iodide (1 mg / kg of xanomeline) to male SD rats.Figure 159 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3-yl)- 1 -(1 -((isopropoxy carbonyl)oxy )hexyl)-l -methyl-1,2,3,6-tetrahydropyridin-l-ium iodide (1 mg / kg of xanomeline) to male SD rats.Figure 160 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3 -yl)- 1 -methyl- 1 -( 1 -((propoxy carbonyl)oxy)dodecyl)-1,2,3,6-tetrahydropyridin-l-ium iodide (1 mg / kg of xanomeline) to male SD rats.Figure 161 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-((propoxycarbonyl)oxy)hexyl)-l,2,3,6- tetrahydropyridin-l-ium iodide (2.5 mg / kg of xanomeline) to male SD rats.tetrahydropyridin-l-ium iodide (2.5 mg / kg of xanomeline) to male SD rats.Figure 163 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-(propionyloxy)hexadecyl)-l,2,3,6- tetrahydropyridin-l-ium iodide (2.5 mg / kg of xanomeline) to male SD rats.Figure 164 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-(l-(isobutyryloxy)ethyl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium chloride (5 mg / kg of xanomeline) to male SD rats.Figure 165 shows mean concentration-time profiles of xanomeline following IM dosing of l-(l-((butoxycarbonyl)oxy)ethyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 166 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3-yl)- 1 -(1 -(((hexyloxy)carbonyl)oxy)ethyl)- 1 -methyl -1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 167 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-(l-((isopropoxycarbonyl)oxy)ethyl)-l-methyl-1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 168 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -(1 -(((cyclohexyloxy)carbonyl)oxy)ethyl)-5 -(4-(hexyloxy)- 1 ,2, 5 -thiadi azol -3 -yl)- 1 -methyl-1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 169 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)- 1 ,2, 5-thiadiazol-3 -yl)- 1 -( 1 -((isopropoxy carbonyl)oxy)dodecyl)- 1 -methyl-1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 170 shows mean concentration-time profiles of xanomeline following IM dosing of [[5-(4-hexoxy-l,2,5-thiadiazol-3-yl)-l-methyl-3,6-dihydro-2H-pyridin-l-ium-l-yl]-phenyl- methyl] decanoate iodide (5 mg / kg of xanomeline) to male SD rats.Figure 171 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-(l-(isobutyryloxy)decyl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 172 shows mean concentration-time profiles of xanomeline following IM dosing of l-(l-(benzoyloxy)decyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.tetrahydropyridin-l-ium chloride (5 mg / kg of xanomeline) to male SD rats.Figure 174 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-(l-(isobutyryloxy)dodecyl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 175 shows mean concentration-time profiles of xanomeline following IM dosing of l-(l-(benzoyloxy)dodecyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 176 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l-(l-(palmitoyloxy)propyl)-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 177 shows mean concentration-time profiles of xanomeline following IM dosing of l-((benzoyloxy)(phenyl)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 178 shows mean concentration-time profiles of xanomeline following IM dosing of l-(cyclopropyl(decanoyloxy )methyl)-5-(4-(hexyloxy)-l, 2, 5-thiadiazol-3-yl)-l -methyl-1,2,3,6-tetrahydropyridin-l-ium formate (5 mg / kg of xanomeline) to male SD rats.Figure 179 shows mean concentration-time profiles of xanomeline following IM dosing of l-(cyclohexyl(decanoyloxy)methyl)-5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 180 shows mean concentration-time profiles of xanomeline following IM dosing of l-(cyclopropyl(dodecanoyloxy)methyl)-5-(4-(hexyloxy)-l, 2, 5-thiadiazol-3-yl)-l -methyl-1,2,3,6-tetrahydropyridin-l-ium formate (5 mg / kg of xanomeline) to male SD rats.Figure 181 shows mean concentration-time profiles of xanomeline following IM dosing of l-(cyclopropyl(palmitoyloxy)methyl)-5-(4-(hexyloxy)-l, 2, 5-thiadiazol-3-yl)-l -methyl-1,2,3,6-tetrahydropyridin-l-ium formate (5 mg / kg of xanomeline) to male SD rats.Figure 182 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -(cyclobutyl(decanoyloxy)methyl)-5-(4-(hexyloxy)- 1 ,2, 5-thiadiazol-3 -yl)- 1 -methyl- 1 ,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 183 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -(cyclobutyl(dodecanoyloxy)methyl)-5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3-yl)- 1 -methyl -1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 185 shows mean concentration-time profiles of xanomeline following IM dosing of 1 -(cyclopentyl(palmitoyloxy)methyl)-5-(4-(hexyloxy)- 1 ,2,5-thiadiazol-3-yl)- 1 -methyl -1,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 186 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-((icosanoyloxy)methyl)-l-methyl-l,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 187 shows mean concentration-time profiles of xanomeline following IM dosing of Synthesis of 5-(4-(hexyloxy)-l,2,5-thiadiazol-3-yl)-l-((((icosyloxy)carbonyl)oxy)methyl)-l- methyl-l,2,3,6-tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 188 shows mean concentration-time profiles of xanomeline following IM dosing of 1- (((3-(2-acetoxy-4,6-dimethylphenyl)-3-methylbutanoyl)oxy)methyl)-5-(4-(hexyloxy)-l,2,5- thiadiazol-3-yl)-l-methyl-l,2,3,6-tetrahydropyridin-l-ium chloride (5 mg / kg of xanomeline) to male SD rats.Figure 189 shows mean concentration-time profiles of xanomeline following IM dosing of 5-(4-(hexyloxy)- 1 ,2, 5-thiadiazol-3 -yl)- 1 -methyl- 1 -((2-phenylacetoxy)methyl)- 1 ,2,3,6- tetrahydropyridin-l-ium iodide (5 mg / kg of xanomeline) to male SD rats.Figure 190 shows the goodness of fit plots of xanomeline PPK modelFigure 191 shows the goodness of fit plots of trospium PPK modelFigure 192 shows the powder XRD pattern of xanomeline freebaseFigure 193 shows the powder XRD pattern of xanomeline oxypropyl pivalate chlorideFigure 194 shows the powder XRD pattern of xanomeline oxy ethyl pivalate chlorideFigure 195 shows the powder XRD pattern of xanomeline L-tartrateFigure 196 shows the powder XRD pattern of trospium chlorideFigure 197 shows the powder XRD pattern of trospium chloride dodecyl carbonateFigure 198 shows the powder XRD pattern of trospium acetate alkyl acetateFigure 199 shows the PLM image of trospium acetate alkyl acetateFigure 200 shows the powder XRD pattern of O-Acetyl trospium chlorideFigure 201 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride (1 mg / kg) to male Sprague Dawley (SD) rats.Figure 202 shows mean concentration-time profiles of trospium following SC dosing of trosoium chloride acetate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 204 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride butyrate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 205 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride valerate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 206 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride propanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 207 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride pivalate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 208 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride decanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 209 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride isopentanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 210 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride hexanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 211 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride dodecanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 212 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride tridecanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 213 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride tridecyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 214 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride octyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 215 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride methyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 216 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride pentyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 217 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride decyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 218 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride linoleate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 219 shows mean concentration-time profiles of trospium following SC dosing of trosoium chloride mono-tert-butyl adipate prodrug (1 mg / kg of trospium chloride) to male SDFigure 221 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride mono-tert-butyl suberate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 222 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride succinic acid prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 223 shows mean concentration-time profiles of trospium following SC dosing of trospium formate oxymethyl acetate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 224 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride oxymethyl hexanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 225 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride ethyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 226 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride dodecyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 227 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride isobutyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 228 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride isopropyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 229 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride butyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 230 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride mono tert-butyl succinate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 231 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride tert-butyl propionyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 232 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride suberate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 233 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride oxymethyl pentanoate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 234 shows mean concentration-time profiles of trospium following SC dosing of trospium formate oxymethyl pivalate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 235 shows mean concentration-time profiles of trospium following SC dosing of ride triethylsilyl ether prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 237 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride (5 mg / kg of trospium chloride) to male Sprague Dawley (SD) rats.Figure 238 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride acetate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 239 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride propanoate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 240 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride dodecanoate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 241 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride ethyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 242 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride dodecyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 243 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride methyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 244 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride isobutyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 245 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride butyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 246 shows mean concentration-time profiles of trospium following SC dosing of trospium chloride tert-butyl propionyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 247 shows mean concentration-time profiles of trospium following SC dosing of trospium mono-pamoate (5 mg / kg of trospium chloride) to male SD rats.Figure 248 shows mean concentration-time profiles of trospium following SC dosing of trospium hemi-pamoate (5 mg / kg of trospium chloride) to male SD rats.Figure 249 shows mean concentration-time profiles of trospium following IM dosing of trospium chloride acetate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 250 shows mean concentration-time profiles of trospium following IM dosing of trospium chloride dodecyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 251 shows mean concentration-time profiles of trospium following IM dosing of trospium acetate pamoate prodrug (5 mg / kg of trospium chloride) to male SD rats.rat.Figure 253 shows mean concentration-time profiles of trospium following IM dosing of trospium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 254 shows mean concentration-time profiles of trospium following IM dosing of trospium mono-pamoate (5 mg / kg of trospium chloride) to male SD rats.Figure 255 shows mean concentration-time profiles of trospium following IM dosing of trospium hemi-pamoate (5 mg / kg of trospium chloride) to male SD rats.Figure 256 shows mean concentration-time profiles of trospium following IM dosing of trospium dodecyl carbonate pamoate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 257 shows mean concentration-time profiles of prodrug following IM dosing of trospium chloride acetate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 258 shows mean concentration-time profiles of prodrug following IM dosing of trospium chloride dodecyl carbonate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 259 shows mean concentration-time profiles of trospium following IV dosing of trospium chloride (1 mg / kg of trospium chloride) to male SD rats.Figure 260 shows mean concentration-time profiles of trospium following IV dosing of trospium chloride dodecyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 261 shows mean concentration-time profiles of trospium following IV dosing of trospium chloride acetate prodrug (0.3 mg / kg of trospium chloride) to male SD rats.Figure 262 shows mean concentration-time profiles of prodrug following IV dosing of trospium chloride dodecyl carbonate prodrug (1 mg / kg of trospium chloride) to male SD rats.Figure 263 shows mean concentration-time profiles of prodrug following IV dosing of trospium chloride acetate prodrug (0.3 mg / kg of trospium chloride) to male SD rats.Figure 264 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride (10 mg / kg of trospium chloride) to male SD rats.Figure 265 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride pentadecanoate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 266 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride methyl carbonate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 267 shows an XRPD of trospium chloride acetate prodrug in the 2theta range of 5- 70 °.Figure 268 shows an XRPD of trospium chloride acetate prodrug in the 2theta range of 5-Figure 270 shows an XRPD of trospium chloride dodecyl carbonate prodrug in the 2theta range of 5-35 °.Figure 271 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride heptanoate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 272 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride hexyl carbonate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 273 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride heptyl carbonate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 274 shows mean concentration-time profiles of trospium following PO dosing of trospium formate oxymethyl acetate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 275 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride tetradecyl carbonate prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 276 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride triethoxysilyl ether prodrug (10 mg / kg of trospium chloride) to male SD rats.Figure 277 shows mean concentration-time profiles of trospium following PO dosing of O- Acetyl trospium acetate prodrug (30 mg / kg of trospium chloride) to male SD rats.Figure 278 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((oxetane-3-carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]- l'-ium chloride (30 mg / kg of trospium chloride) to male SD rats.Figure 279 shows mean concentration-time profiles of trospium following PO dosing of 3-(2,2-diphenyl-2-((tetrahydro-2H-pyran-4-carbonyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane- 8,r-pyrrolidin]-l'-ium chloride (30 mg / kg of trospium chloride) to male SD rats.Figure 280 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-(2-aminoacetoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium chloride HC1 salt (30 mg / kg of trospium chloride) to male SD rats.Figure 281 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-(((S)-2-aminopropanoyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium chloride HC1 salt (30 mg / kg of trospium chloride) to male SD rats.Figure 282 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((L-valyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride HC1 salt (30 mg / kg of trospium chloride) to male SD rats.pyrrolidin]-l'-ium triflate (30 mg / kg of trospium chloride) to male SD rats.Figure 284 shows mean concentration-time profiles of trospium following PO dosing of benzyl (2-oxo-l,l-diphenyl-2-(spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-3-yl-9-iumoxy)ethyl) phosphate (30 mg / kg of trospium chloride) to male SD rats.Figure 285 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((morpholine-4-carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium triflate (30 mg / kg of trospium chloride) to male SD rats.Figure 286 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-(((pyran-4-carbonyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium chloride (30 mg / kg of trospium chloride) to male SD rats.Figure 287 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((2-aminoacetoxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium trifluoroacetate TFA salt (30 mg / kg of trospium chloride) to male SD rats.Figure 288 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((((S)-2-aminopropanoyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane- 8,r-pyrrolidin]-l'-ium TFA salt (30 mg / kg of trospium chloride) to male SD rats.Figure 289 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((((S)-2-amino-3-methylbutanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium TFA salt (30 mg / kg of trospium chloride) to male SD rats.Figure 290 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((((S)-2-amino-3-phenylpropanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium chloride TFA salt (30 mg / kg of trospium chloride) to male SD rats.Figure 291 shows mean concentration-time profiles of trospium following IM dosing of O-Acetyl trospium acetate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 292 shows mean concentration-time profiles of trospium following IM dosing of trospium chloride undecanoate prodrug (5 mg / kg of trospium chloride) to male SD rats.Figure 293 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((tert-butoxy(hydroxy)phosphoryl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane- 8,r-pyrrolidin]-l'-ium chloride (4 mg / kg of trospium chloride) to male SD rats.l'-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 295 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((tetrahydro-2H-pyran-4-carbonyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane- 8,r-pyrrolidin]-l'-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 296 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(2-aminoacetoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium chloride HC1 salt (5 mg / kg of trospium chloride) to male SD rats.Figure 297 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((S)-2-aminopropanoyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium chloride HC1 salt (5 mg / kg of trospium chloride) to male SD rats.Figure 298 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((L-valyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride HC1 salt (5 mg / kg of trospium chloride) to male SD rats.Figure 299 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((piperidine-l-carbonyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium triflate (5 mg / kg of trospium chloride) to male SD rats.Figure 300 shows mean concentration-time profiles of trospium following IM dosing of benzyl (2-oxo-l,l-diphenyl-2-(spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-3-yl-9-iumoxy)ethyl) phosphate (5 mg / kg of trospium chloride) to male SD rats.Figure 301 shows mean concentration-time profiles of trospium following IM dosing of ((isopropoxycarbonyl)oxy)methyl 3-(((2-oxo-l,l-diphenyl-2-spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-3-yl-9-iumoxy)ethoxy)methyl) phosphate (5 mg / kg of trospium chloride) to male SD rats.Figure 302 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((morpholine-4-carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium triflate (5 mg / kg of trospium chloride) to male SD rats.Figure 303 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((pyran-4-carbonyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium chloride (2.5 mg / kg of trospium chloride) to male SD rats.Figure 304 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((2-aminoacetoxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- Dvrrolidinl-l'-ium trifluoroacetate TFA salt (5 mg / kg of trospium chloride) to male SD rats.8,r-pyrrolidin]-l'-ium TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 306 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((S)-2-amino-3-methylbutanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 307 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((S)-2-amino-3-phenylpropanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium chloride TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 308 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium trifluoroacetate (5 mg / kg of trospium chloride) to male SD rats.Figure 309 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-(((((2-phenyl-l,3-dioxan-5- yl)oxy)carbonyl)oxy)methoxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium trifluoroacetate (5 mg / kg of trospium chloride) to male SD rats.Figure 310 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((piperidine-l-carbonyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium triflate (5 mg / kg of trospium chloride) to male SD rats.Figure 311 shows mean concentration-time profiles of trospium following IM dosing of benzyl (2-oxo-l,l-diphenyl-2-(spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-3-yl-9-iumoxy)ethyl) phosphate (5 mg / kg of trospium chloride) to male SD rats.Figure 312 shows mean concentration-time profiles of trospium following IM dosing of ((isopropoxycarbonyl)oxy)methyl 3-(((2-oxo-l,l-diphenyl-2-spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-3-yl-9-iumoxy)ethoxy)methyl) phosphate (5 mg / kg of trospium chloride) to male SD rats.Figure 313 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((morpholine-4-carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium triflate (5 mg / kg of trospium chloride) to male SD rats.Figure 314 shows mean concentration-time profiles of trospium following IM dosing of 3-('2-('('('Dvran-4-carbonyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- ium chloride (5 mg / kg of trospium chloride) to male SD rats.pyrrolidin]-l'-ium trifluoroacetate TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 316 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((S)-2-aminopropanoyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane- 8,r-pyrrolidin]-l'-ium TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 317 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((S)-2-amino-3-methylbutanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 318 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((S)-2-amino-3-phenylpropanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium chloride TFA salt (5 mg / kg of trospium chloride) to male SD rats.Figure 319 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((bis(benzyloxy)phosphoryl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium trifluoroacetate (5 mg / kg of trospium chloride) to male SD rats.Figure 320 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-(((((2-phenyl-l,3-dioxan-5- yl)oxy)carbonyl)oxy)methoxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium trifluoroacetate (5 mg / kg of trospium chloride) to male SD rats.Figure 321 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((l,3-bis(palmitoyloxy)propan-2-yl)oxy)carbonyl)oxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium triflate (1 mg / kg of trospium chloride) to male SD rats.Figure 322 shows mean concentration-time profiles of trospium following IM dosing of 3-((6,22,27-trioxo-24-((palmitoyloxy)methyl)-2,2-diphenyl-3 ,5 ,23 ,26-tetraoxadotetracontan-l- oyl)oxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium trifluoroacetate (1 mg / kg of trospium chloride) to male SD rats.Figure 323 shows mean concentration-time profiles of trospium following IM dosing of 3-((4,21,26-trioxo-23-((palmitoyloxy)methyl)-2,2-diphenyl-3,5,22,25-tetraoxahentetracontan-l- oyl)oxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium trifluoroacetate (1 mg / kg of trospium chloride) to male SD rats.pyrrolidin]-l'-ium chloride HC1 salt (1 mg / kg of trospium chloride) to male SD rats.Figure 325 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((((5-methyl-2-oxo-l,3-dioxol-4-yl)methoxy)carbonyl)oxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium tritiate (1 mg / kg of trospium chloride) to male SD rats.Figure 326 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((oxetane-3-carbonyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium chloride (1 mg / kg of trospium chloride) to male SD rats.Figure 327 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((di-tert-butoxyphosphoryl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane- 8,r-pyrrolidin]-l'-ium chloride (1 mg / kg of trospium chloride) to male SD rats.Figure 328 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((bis(benzyloxy)phosphoryl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-l'-ium 2,2,2-trifluoroacetate (1 mg / kg of trospium chloride) to male SD rats.Figure 329 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((nonyloxy)carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 330 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-oxo-3,3-diphenyl-3-((propoxycarbonyl)oxy)propyl)spiro[bicyclo[3.2.1]octane-8,l’- pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 331 shows mean concentration-time profiles of trospium following PO dosing of trospium chloride acetate (10 mg / kg of trospium chloride) to male SD rats.Figure 332 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(octanoyloxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 333 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(isobutyryloxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-8-ium chloride (2.5 mg / kg of trospium chloride) to male SD rats.Figure 334 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((Methylthio)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-8- ium formate 12 mg / kg of trospium chloride) to male SD rats.ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 336 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-(((undecyloxy)carbonyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 337 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((formyloxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8- ium formate (4 mg / kg of trospium chloride) to male SD rats.Figure 338 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(benzoyloxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 339 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((pentadecyloxy)carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium chloride (3 mg / kg of trospium chloride) to male SD rats.Figure 340 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((17-((l,3-bis(palmitoyloxy)propan-2-yl)oxy)-17-oxoheptadecanoyl)oxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,r-pyrrolidin]-l'-ium triflate (1 mg / kg of trospium chloride) to male SD rats.Figure 341 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((triethoxysilyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 342 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((triethylsilyl)oxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 343 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((2-(trimethylsilyl)ethoxy)methoxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 344 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(benzyloxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 345 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((hexyloxy)carbonyl)oxy)-2,2-diphenyl acetoxy)spiro[bicyclo[3.2.1]octane-8,l'- Dvrrolidinl-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 347 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((2-morpholinoethoxy)carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium chloride hydrochloride (5 mg / kg of trospium chloride) to male SD rats.Figure 348 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((2-(2,5-dioxopyrrolidin-l-yl)ethoxy)carbonyl)oxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 349 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-(((propoxycarbonyl)oxy)methoxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium trifluoroacetate (5 mg / kg of trospium chloride) to male SD rats.Figure 350 shows mean concentration-time profiles of trospium following IM dosing of 3-(2,2-diphenyl-2-((propionyloxy)methoxy)acetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]- 8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 351 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((octanoyloxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8- ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 352 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((dodecanoyloxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 353 shows mean concentration-time profiles of trospium following IM dosing of3-(2-((20-(tert-Butoxy)-20-oxoicosanoyl)oxy)-2,2-diphenylacetoxy) spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium trifluoroacetate (5 mg / kg of trospium chloride) to male SD rats.Figure 354 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-((19-carboxynonadecanoyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'- pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 355 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((20-(tert-butoxy)-20-oxoicosanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 356 shows mean concentration-time profiles of trospium following IM dosing of boxynonadecanoyl)oxy)methoxy)-2,2-Figure 357 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((4-(tert-butoxy)-4-oxobutanoyl)oxy)methoxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-l'-ium formate (5 mg / kg of trospium chloride) to male SD rats.Figure 358 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(((3-carboxypropanoyl)oxy)methoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,F- pyrrolidin]-l'-ium chloride (5 mg / kg of trospium chloride) to male SD rats.Figure 359 shows mean concentration-time profiles of trospium following IM dosing of 3-(2-(methoxymethoxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-8-ium trifluoromethanesulfonate (5 mg / kg of trospium chloride) to male SD rats.Figure 360 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-(((nonyloxy)carbonyl)oxy)-2,2-diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l ’- pyrrolidin]-8-ium chloride (30 mg / kg of trospium chloride) to male SD rats.Figure 361 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-oxo-3,3-diphenyl-3-((propoxycarbonyl)oxy)propyl)spiro[bicyclo[3.2.1]octane-8,l’- pyrrolidin]-8-ium chloride (30 mg / kg of trospium chloride) to male SD rats.Figure 362 shows mean concentration-time profiles of trospium following PO dosing of 3-(2-((17-((l,3-bis(palmitoyloxy)propan-2-yl)oxy)-17-oxoheptadecanoyl)oxy)-2,2- diphenylacetoxy)spiro[bicyclo[3.2.1]octane-8,l'-pyrrolidin]-l'-ium triflate (7.5 mg / kg of trospium chloride) to male SD rats.DETAILED DESCRIPTIONTermsThe following explanations of terms and methods are provided to better describe the present disclosure and to guide those of ordinary skill in the art in the practice of the present disclosure. The singular forms “a,” “an,” and “the” refer to one or more than one, unless the context clearly dictates otherwise. The term “or” refers to a single element of stated alternative elements or a combination of two or more elements, unless the context clearly indicates otherwise. As used herein, “comprises” means “includes.” Thus, “comprising A or B,” means “including A, B, or A and B,” without excluding additional elements. All references, including patents and patent applications cited herein, are incorporated by reference in their entirety, unless otherwise soecified.to be understood as being modified by the term “about.” Accordingly, unless otherwise indicated, implicitly or explicitly, the numerical parameters set forth are approximations that may depend on the desired properties sought and / or limits of detection under standard test conditions / methods. When directly and explicitly distinguishing embodiments from discussed prior art, the embodiment numbers are not approximates unless the word “about” is expressly recited.Unless explained otherwise, all technical and scientific terms used herein have the same meaning as commonly understood by one of ordinary skill in the art to which this disclosure pertains. Although methods and materials similar or equivalent to those described herein can be used in the practice or testing of the present disclosure, suitable methods and materials are described below. The materials, methods, and examples are illustrative only and not intended to be limiting.“Administering” refers to any suitable mode of administration, including, oral administration, administration as a suppository, topical contact, parenteral, intravenous, intraperitoneal, intramuscular, intralesional, intranasal or subcutaneous administration, intrathecal administration, or the implantation of a slow-release device e.g., a mini-osmotic pump, to the subject.“Subject” refers to an animal, such as a mammal, including, but not limited to, primates (e.g., humans), cows, sheep, goats, horses, dogs, cats, rabbits, rats, mice and the like. In certain embodiments, the subject is a human subject.“Therapeutically effective amount” or “therapeutically sufficient amount” or “effective or sufficient amount” refers to a dose that produces therapeutic effects for which it is administered. The exact dose will depend on the purpose of the treatment, and will be ascertainable by one skilled in the art using known techniques (see, e.g. , Lieberman, Pharmaceutical Dosage Forms (vols. 1-3, 1992); Lloyd, The Art, Science and Technology of Pharmaceutical Compounding (1999); Pickar, Dosage Calculations (1999); and Remington: The Science and Practice of Pharmacy, 20th Edition, 2003, Gennaro, Ed., Lippincott, Williams & Wilkins). In sensitized cells, the therapeutically effective dose can often be lower than the conventional therapeutically effective dose for non- sensitized cells.“Neuronal plasticity” refers to the ability of the brain to change its structure and / or function continuously throughout a subject’s life. Examples of the changes to the brain include, but are not limited to, the ability to adapt or respond to internal and / or external stimuli, such as due to an iniurv. and the ability to produce new neurites, dendritic spines, and synapses.taurocholic acid, deoxycholic acid, chenodeoxycholic acid, glycochenodeoxy cholic acid, taurochenodeoxycholic acid, and lithocholic acid. Where sterol or bile acids are included, it is understood that they can be synthetically tethered by virtue of any available handle. For instance, cholesterol features a -OH moiety which is predominantly the method of attachment, whereas, bile acids may feature an -COOH or a -OH. Both of these moieties can serve as the attachment point to the compounds of the present disclosure.“Brain disorder” refers to a neurological disorder which affects the brain’s structure and function. Brain disorders can include, but are not limited to, Alzheimer’s, Parkinson’s disease, psychological disorder, depression, treatment resistant depression, addiction, anxiety, post- traumatic stress disorder, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, and substance use disorder.“Combination therapy” refers to a method of treating a disease or disorder, wherein two or more different pharmaceutical agents are administered in overlapping regimens so that the subject is simultaneously exposed to both agents. For example, the compounds of the present disclosure can be used in combination with other pharmaceutically active compounds. The compounds of the present disclosure can be administered simultaneously (as a single preparation or separate preparation) or sequentially to the other drug therapy. In general, a combination therapy envisions administration of two or more drugs during a single cycle or course of therapy.“Neurotrophic factors” refers to a family of soluble peptides or proteins which support the survival, growth, and differentiation of developing and mature neurons.“Modulate” or “modulating” or “modulation” refers to an increase or decrease in the amount, quality, or effect of a particular activity, function or molecule. By way of illustration and not limitation, agonists, partial agonists, antagonists, and allosteric modulators (e.g., a positive allosteric modulator) of a G protein-coupled receptor (e.g., 5HT2A) are modulators of the receptor.“Agonism” refers to the activation of a receptor or enzyme by a modulator, or agonist, to produce a biological response.“Agonist” refers to a modulator that binds to a receptor or enzyme and activates the receptor to produce a biological response. By way of example only, “5HT2A agonist” can be used to refer to a compound that exhibits an EC50 with respect to 5HT2A activity of no more than about 100 mM. In some embodiments, the term “agonist” includes full agonists or partial agonists. “Full agonist” refers to a modulator that binds to and activates a receptor with the maximum response that an aeonist can elicit at the receptor. “Partial agonist” refers to a modulator that binds to and“Anion” or “counterion” refers to a charged species (i.e. negative charge in the case of anion) which may form a salt with the cations of the present disclosure. Examples of suitable counterions include anionic counterions, including monovalent and divalent anions. As understood by those of ordinary skill in the art, when the counterion is divalent it is present in a 1:2 stoichiometry with the molecule of the present disclosure. Suitable counterions include halides, phosphates, sulfates, sulfonates, carboxylates, hydroxides and the like. It will also be understood that multiple anions or counterions may be present in a pharmaceutical composition or in a crystalline form. The representation of a single counterion should not be limiting to only having a single counterion present. Those of ordinary skill in the art will appreciate that counterions are readily substituted and where a single counterion species is depicted, all available counterions are considered.“Positive allosteric modulator” refers to a modulator that binds to a site distinct from the orthosteric binding site and enhances or amplifies the effect of an agonist.“Antagonism” refers to the inactivation of a receptor or enzyme by a modulator, or antagonist. Antagonism of a receptor, for example, is when a molecule binds to the receptor and does not allow activity to occur.“Antagonist” or “neutral antagonist” refers to a modulator that binds to a receptor or enzyme and blocks a biological response. An antagonist has no activity in the absence of an agonist or inverse agonist but can block the activity of either, causing no change in the biological response.“Composition” refers to a product comprising the specified ingredients in the specified amounts, as well as any product, which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. By “pharmaceutically acceptable” it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation.“Pharmaceutically acceptable excipient” refers to a substance that aids the administration of an active agent to and absorption by a subject. Pharmaceutical excipients useful in the present disclosure include, but are not limited to, binders, fillers, disintegrants, lubricants, coatings, sweeteners, flavors and colors. One of skill in the art will recognize that other pharmaceutical excipients are useful in the present disclosure. “Xanomeline” refers to the compound 3-(4- hexyloxy-l,2,5-thiadiazol-3-yl)-l-methyl-5,6-dihydro-2H-pyridine, or 3-(hexyloxy)-4-(l- methyl-l,2,5,6-tetrahydropyridin-3-yl)-l,2,5-thiadiazole. The compound may also be referred to as hexvloxv-TZTP, LY-246,708, LY-246708, Lumeron, Memcor, NNC 11-0232, or Kar-XT. leline has the formula:de has the formula:Compounds herein can include all stereoisomers, enantiomers, diastereomers, mixtures, racemates, atropisomers, and tautomers thereof. Where stereocenters exist, each stereoisomer and mixtures thereof are contemplated. A wavy line indicates that a stereocenter exists and each stereoisomer and mixtures thereof are contemplated.Non-limiting examples of optional substituents include hydroxyl groups, sulfhydryl groups, halogens, amino groups, nitro groups, nitroso groups, cyano groups, azido groups, sulfoxide groups, sulfone groups, sulfonamide groups, carboxyl groups, carboxaldehyde groups, imine groups, alkyl groups, halo-alkyl groups, alkenyl groups, halo-alkenyl groups, alkynyl groups, halo-alkynyl groups, alkoxy groups, aryl groups, aryloxy groups, aralkyl groups, arylalkoxy groups, heterocycloalkyl groups, heteroaryl groups, cycloalkyl groups, acyl groups, acyloxy groups, carbamate groups, amide groups, ureido groups, epoxy groups, and ester groups.Non-limiting examples of alkyl groups include straight, branched, and cyclic alkyl and alkylene groups. An alkyl group can be, for example, a Ci, C2, C3, C4, C5, Ce, C7, Cs, C9, C10, Cn, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, or C50 group that is substituted or unsubstituted.Alkyl groups can include branched and unbranched alkyl groups. Non-limiting examples of straight alkyl groups include methyl, ethyl, propyl, butyl, pentyl, hexyl, heptyl, octyl, nonyl, and decyl.Branched alkyl groups include any straight alkyl group substituted with any number of alkyl groups. Non-limiting examples of branched alkyl groups include isopropyl, isobutyl, secbutyl, and t-butyl.Non-limiting examples of substituted alkyl groups includes hydroxymethyl, chloromethyl, trifluoromethyl, aminomethyl, 1 -chloroethyl, 2-hydroxy ethyl, 1,2-difluoroethyl, and 3- carb oxy propyl.and spiro-bicycles and higher fused-, bridged-, and spiro- systems. A cycloalkyl group can be substituted with any number of straight, branched, or cyclic alkyl groups. Non-limiting examples of cyclic alkyl groups include cyclopropyl, 2-methyl-cycloprop-l-yl, cycloprop-2-en-l-yl, cyclobutyl, 2,3-dihydroxycyclobut-l-yl, cyclobut-2-en-l-yl, cyclopentyl, cyclopent-2-en-l-yl, cyclopenta-2,4-dien-l-yl, cyclohexyl, cyclohex-2-en-l-yl, cycloheptyl, cyclooctanyl, 2,5- dimethylcyclopent-l-yl, 3,5-dichlorocyclohex-l-yl, 4-hydroxycyclohex-l-yl, 3,3,5- trimethylcyclohex-l-yl, octahydropentalenyl, octahydro- 177-indenyl, 3a,4,5,6,7,7a-hexahydro- 3J / -inden-4-yl, decahydroazulenyl, bicyclo-[2.1.1]hexanyl, bicyclo[2.2.1]heptanyl, bicyclo[3.1.1]heptanyl, l,3-dimethyl[2.2.1]heptan-2-yl, bicyclo[2.2.2]octanyl, and bicyclo[3.3.3]undecanyl.Non-limiting examples of alkenyl groups include straight, branched, and cyclic alkenyl groups. The olefin or olefins of an alkenyl group can be, for example, E, Z, cis, trans, terminal, or exo-methylene. An alkenyl group can be, for example, a C2, C3, C4, C5, Ce, C7, Cs, C9, C10, Cn, C12, C13, C14, C15, C16, C17, C18, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, or C50 group that is substituted or unsubstituted. Non-limiting examples of alkenyl and alkenylene groups include ethenyl, prop-l-en-l-yl, isopropenyl, but-l-en-4-yl; 2-chloroethenyl, 4-hydroxybuten-l-yl, 7- hydroxy-7-methyloct-4-en-2-yl, and 7-hydroxy-7-methyloct-3,5-dien-2-yl.Non-limiting examples of alkynyl groups include straight, branched, and cyclic alkynyl groups. The triple bond of an alkynyl group can be internal or terminal. An alkynyl or alkynylene group can be, for example, a C2, C3, C4, C5, Ce, C7, Cs, C9, C10, Cn, C12, C13, C14, C15, Cie, C17, Cis, C19, C20, C21, C22, C23, C24, C25, C26, C27, C28, C29, C30, C31, C32, C33, C34, C35, C36, C37, C38, C39, C40, C41, C42, C43, C44, C45, C46, C47, C48, C49, or C50 group that is substituted or unsubstituted. Non-limiting examples of alkynyl groups include ethynyl, prop-2-yn-l-yl, prop-l-yn-l-yl, and 2- methyl-hex-4-yn-l-yl; 5-hydroxy-5-methylhex-3-yn-l-yl, 6-hydroxy-6-methylhept-3-yn-2-yl, and 5 -hydroxy-5 -ethylhept-3 -yn- 1 -yl .A halo-alkyl group can be any alkyl group substituted with any number of halogen atoms, for example, fluorine, chlorine, bromine, and iodine atoms. A halo-alkenyl group can be any alkenyl group substituted with any number of halogen atoms. A halo-alkynyl group can be any alkynyl group substituted with any number of halogen atoms.An alkoxy group can be, for example, an oxygen atom substituted with any alkyl, alkenyl, or alkvnvl eroup. An ether or an ether group comprises an alkoxy group. Non-limiting examples ips include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy.substituents, for example, alkyl groups and halogen atoms. A heterocycle can be aromatic (heteroaryl) or non-aromatic. Non-limiting examples of heterocycles include pyrrole, pyrrolidine, pyridine, piperidine, succinimide, maleimide, morpholine, imidazole, thiophene, furan, tetrahydrofuran, pyran, and tetrahydropyran.Non-limiting examples of heterocycles include: heterocyclic units having a single ring containing one or more heteroatoms, non-limiting examples of which include, diazirinyl, aziridinyl, azetidinyl, pyrazolidinyl, imidazolidinyl, oxazolidinyl, isoxazolinyl, thiazolidinyl, isothiazolinyl, oxathiazolidinonyl, oxazolidinonyl, hydantoinyl, tetrahydrofuranyl, pyrrolidinyl, morpholinyl, piperazinyl, piperidinyl, dihydropyranyl, tetrahydropyranyl, piperidin-2-onyl, 2,3,4,5-tetrahydro-l / T-azepinyl, 2,3-dihydro-l / T-indole, and 1,2,3,4-tetrahydroquinoline; and ii) heterocyclic units having 2 or more rings one of which is a heterocyclic ring, non-limiting examples of which include hexahydro- I / / -pyrrol izinyl, 3a,4,5,6,7,7a-hexahydro-l / 7- benzo[d]imidazolyl, 3a,4,5,6,7,7a-hexahydro-l / / -indolyl, 1,2,3,4-tetrahydroquinolinyl, and decahydro- l / 7-cycloocta[b]pyrrolyl.Non-limiting examples of heteroaryl include: i) heteroaryl rings containing a single ring, non-limiting examples of which include, 1,2,3,4-tetrazolyl, [l,2,3]triazolyl, [l,2,4]triazolyl, triazinyl, thiazolyl, l / T-imidazolyl, oxazolyl, isoxazolyl, isothiazolyl, furanyl, thiophenyl, pyrimidinyl, 2-phenylpyrimidinyl, pyridinyl, 3-methylpyridinyl, and 4-dimethylaminopyridinyl; and ii) heteroaryl rings containing 2 or more fused rings one of which is a heteroaryl ring, nonlimiting examples of which include: 7 / / -purinyl, 9 / 7-purinyl, 6-amino-9 / / -purinyl, 5H- pyrrolo[3,2-t ]pyrimidinyl, 7 / / -pyrrolo[2,3-t ]pyrimidinyl, pyrido[2,3-t ]pyrimidinyl, 4, 5,6,7- tetrahydro-l-77-indolyl, quinoxalinyl, quinazolinyl, quinolinyl, 8-hydroxy-quinolinyl, and isoquinolinyl. In some embodiments, heteroarylThe term "acyl" refers to the groups HC(O)-, alkyl-C(O)-, cycloalkyl-C(O)-, cycloalkenyl- C(O)-, aryl-C(O)-, heteroaryl-C(O)- and heterocyclyl-C(O)- where alkyl, cycloalkyl, cycloalkenyl, aryl, heteroaryl, and heterocyclyl are as described herein. By way of example acyl groups include acetyl and benzoyl groups.“Alkyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain saturated hydrocarbon having from one to about thirty carbon atoms, or from one■ carbon atoms, wherein an sp3-hybridized carbon of the alkyl residue is attached to molecule by a single bond. Examples include, but are not limited to, methyl, ethyl,pentyl, 2-methyl-2-pentyl, 3-methyl-2-pentyl, 4-methyl-2-pentyl, 2,2-dimethyl-l-butyl, 3,3- dimethyl-1 -butyl, 2-ethyl-l-butyl, n-butyl, isobutyl, sec-butyl, t-butyl, n-pentyl, isopentyl, neopentyl, tert-amyl, and hexyl, and longer alkyl groups, such as heptyl, octyl, and the like. Whenever it appears herein, a numerical range such as “C1-6alkyl” means that the alkyl group consists of 1 carbon atom, 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkyl” where no numerical range is designated. In some embodiments, the alkyl is a C1-30 alkyl, C5-25 alkyl, C7- 15 alkyl, Ci-10 alkyl, a C1-9 alkyl, a C1-8 alkyl, a C1-7 alkyl, a C1-6alkyl, a C1-5 alkyl, a C1-4 alkyl, a C1-3 alkyl, a C1-2 alkyl, or a Ci alkyl. Unless stated otherwise specifically in the specification, an alkyl group is optionally substituted, for example, with one or more oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, the alkyl is optionally substituted with one or more oxo, halogen, - CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, the alkyl is optionally substituted with one or more oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkyl is optionally substituted with one or more halogen.“Alkenyl” refers to an optionally substituted straight-chain, or optionally substituted branched-chain hydrocarbon having one or more carbon-carbon double-bonds and having from two to about thirty carbon atoms, about two to about twenty-four carbon atoms, about one to six carbon atoms wherein an sp2-hybridized carbon of the alkenyl residue is attached to the rest of the molecule by a single bond. The group may be in either the cis or trans conformation about the double bond(s), and should be understood to include both isomers. Examples include, but are not limited to, ethenyl (-CH=CH2), 1 -propenyl (-CH2CH=CH2), isopropenyl [-C(CH3)=CH2], butenyl, 1,3-butadienyl, and the like. Whenever it appears herein, a numerical range such as “C2- Ce alkenyl” means that the alkenyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkenyl” where no numerical range is designated. In some embodiments, the alkenyl is a C2-C10 alkenyl, a C2-C9 alkenyl, a C2-C8 alkenyl, a C2-C7 alkenyl, a C2-C6 alkenyl, a C2-C5 alkenyl, a C2-C4 alkenyl, a C2-C3 alkenyl, or a C2 alkenyl. Unless stated otherwise specifically in the specification, an alkenyl group is optionally substituted, for example, with one or more oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkenyl is optionally substituted with one or more oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some“Alkynyl” refers to an optionally substituted straight-chain or optionally substituted branched-chain hydrocarbon having one or more carbon-carbon triple-bonds and having from two to about ten carbon atoms, from two to about six carbon atoms. Examples include, but are not limited to, ethynyl, 2-propynyl, 2-butynyl, 1,3-butadiynyl, and the like. Whenever it appears herein, a numerical range such as “C2-C6 alkynyl” means that the alkynyl group may consist of 2 carbon atoms, 3 carbon atoms, 4 carbon atoms, 5 carbon atoms, or 6 carbon atoms, although the present definition also covers the occurrence of the term “alkynyl” where no numerical range is designated. In some embodiments, the alkynyl is a C2-C10 alkynyl, a C2-C9 alkynyl, a C2-C8 alkynyl, a C2-C7 alkynyl, a C2-C6 alkynyl, a C2-C5 alkynyl, a C2-C4 alkynyl, a C2-C3 alkynyl, or a C2 alkynyl. Unless stated otherwise specifically in the specification, an alkynyl group is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkynyl is optionally substituted with one or more oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkynyl is optionally substituted with one or more oxo, halogen, -CN, - CF3, -OH, or -OMe. In some embodiments, the alkynyl is optionally substituted with one or more halogen.“Alkoxy” refers to a radical of the formula -ORawhere Rais an alkyl radical as defined. Non-limiting examples of alkoxy groups include methoxy, ethoxy, propoxy, isopropoxy, and isobutoxy. In some embodiments, alkoxy is Ci-Ce alkoxy. Unless stated otherwise specifically in the specification, an alkoxy group may be optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an alkoxy is optionally substituted with one or more oxo, halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an alkoxy is optionally substituted with one or more oxo, halogen, -CN, -CF3, -OH, or -OMe. In some embodiments, the alkoxy is optionally substituted with one or more halogen.“Aminoalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more amines. In some embodiments, the alkyl is substituted with one amine. In some embodiments, the alkyl is substituted with one, two, or three amines. Hydroxyalkyl include, for example, aminomethyl, aminoethyl, aminopropyl, aminobutyl, or aminopentyl. In some embodiments, the hydroxyalkyl is aminomethyl.“Aryl” refers to a radical derived from a hydrocarbon ring system comprising hydrogen, 6 to 30 carbon atoms, and at least one aromatic ring. The aryl radical may be a monocyclic, bicyclic, :tracyclic ring system, which may include fused (when fused with a cycloalkyl or6-membered aryl. Aryl radicals include, but are not limited to, aryl radicals derived from the hydrocarbon ring systems of anthrylene, naphthylene, phenanthrylene, anthracene, azulene, benzene, chrysene, fluoranthene, fluorene, as-indacene, s-indacene, indane, indene, naphthalene, phenalene, phenanthrene, pleiadene, pyrene, and triphenylene. In some embodiments, the aryl is phenyl. Unless stated otherwise specifically in the specification, an aryl may be optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, an aryl is optionally substituted with one or more halogen, methyl, ethyl, -CN, - CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, an aryl is optionally substituted with one or more halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the aryl is optionally substituted with one or more halogen.“Cycloalkyl” refers to a stable, partially or fully saturated, monocyclic or polycyclic carbocyclic ring, which may include fused (when fused with an aryl or a heteroaryl ring, the cycloalkyl is bonded through a non-aromatic ring atom), bridged, or spiro ring systems. Representative cycloalkyls include, but are not limited to, cycloalkyls having from three to fifteen carbon atoms (C3-C15 cycloalkyl), from three to ten carbon atoms (C3-C10 cycloalkyl), from three to eight carbon atoms (C3-C8 cycloalkyl), from three to six carbon atoms (C3-C6 cycloalkyl), from three to five carbon atoms (C3-C5 cycloalkyl), or three to four carbon atoms (C3-C4 cycloalkyl). In some embodiments, the cycloalkyl is a 3- to 6-membered cycloalkyl. In some embodiments, the cycloalkyl is a 5- to 6-membered cycloalkyl. Monocyclic cycloalkyls include, for example, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl, and cyclooctyl. Polycyclic cycloalkyls or carbocycles include, for example, adamantyl, norbornyl, decalinyl, bicyclo[3.3.0]octane, bicyclo[4.3.0]nonane, cis-decalin, trans-decalin, bicyclo[2.1.1]hexane, bicyclo[2.2.1]heptane, bicyclo[2.2.2]octane, bicyclo[3.2.2]nonane, and bicyclo[3.3.2]decane, and 7,7-dimethyl-bicyclo[2.2.1]heptanyl. Partially saturated cycloalkyls include, for example, cyclopentenyl, cyclohexenyl, cycloheptenyl, and cyclooctenyl. Unless stated otherwise specifically in the specification, a cycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a cycloalkyl is optionally substituted with one or more oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a cycloalkyl is optionally substituted with one or more oxo, halogen, methvl. ethvl. -CN, -CF3, -OH, or -OMe. In some embodiments, the cycloalkyl is optionally th one or more halogen.embodiments, the alkyl is substituted with one, two, or three deuteriums. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six deuteriums. Deuteroalkyl include, for example, CD3, CH2D, CHD2, CH2CD3, CD2CD3, CHDCD3, CH2CH2D, or CH2CHD2. In some embodiments, the deuteroalkyl is CD3.“Haloalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more halogens. In some embodiments, the alkyl is substituted with one, two, or three halogens. In some embodiments, the alkyl is substituted with one, two, three, four, five, or six halogens. Haloalkyl include, for example, trifluoromethyl, difluoromethyl, fluoromethyl, trichloromethyl, 2,2,2-trifluoroethyl, 1,2-difluoroethyl, 3-bromo-2-fluoropropyl, 1,2-dibromoethyl, and the like. In some embodiments, the haloalkyl is trifluoromethyl. In some embodiments, haloalkyl is Ci-Ce haloalkyl.“Halo” or “halogen” refers to bromo, chloro, fluoro, or iodo. In some embodiments, halogen is fluoro or chloro. In some embodiments, halogen is fluoro.“Heteroalkyl” refers to an alkyl group in which one or more skeletal atoms of the alkyl are selected from an atom other than carbon, e.g., oxygen, nitrogen (e.g., -NH-, -N(alkyl)-), sulfur, or combinations thereof. A heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. In one aspect, a heteroalkyl is a Ci-Ce heteroalkyl wherein the heteroalkyl is comprised of 1 to 6 carbon atoms and one or more atoms other than carbon, e.g., oxygen, nitrogen (e.g. -NH-, -N(alkyl)-), sulfur, or combinations thereof wherein the heteroalkyl is attached to the rest of the molecule at a carbon atom of the heteroalkyl. Examples of such heteroalkyl are, for example, -CH2OCH3, -CH2CH2OCH3, -CH2CH2OCH2CH2OCH3, or -CH(CH3)OCH3. Unless stated otherwise specifically in the specification, a heteroalkyl is optionally substituted for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroalkyl is optionally substituted with one or more oxo, halogen, methyl, ethyl, -CN, - CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroalkyl is optionally substituted with one or more oxo, halogen, methyl, ethyl, -CN, -CF3, -OH, or -OMe. In some embodiments, the heteroalkyl is optionally substituted with one or more halogen.“Hydroxyalkyl” refers to an alkyl radical, as defined above, that is substituted by one or more hydroxyls. In some embodiments, the alkyl is substituted with one hydroxyl. In some embodiments, the alkyl is substituted with one, two, or three hydroxyls. Hydroxyalkyl include, for exanwle. hydroxymethyl, hydroxy ethyl, hydroxypropyl, hydroxybutyl, or hydroxypentyl. In nents, the hydroxy alkyl is hydroxymethyl.and from one to 8 heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur. Unless stated otherwise specifically in the specification, the heterocycloalkyl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with an aryl or a heteroaryl ring, the heterocycloalkyl is bonded through a non-aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heterocycloalkyl radical may be optionally oxidized; the nitrogen atom may be optionally quaternized.Representative heterocycloalkyls include, but are not limited to, heterocycloalkyls having from two to fifteen carbon atoms (C2-C15 heterocycloalkyl), from two to ten carbon atoms (C2-C10 heterocycloalkyl), from two to eight carbon atoms (C2-C8 heterocycloalkyl), from two to six carbon atoms (C2-C6 heterocycloalkyl), from two to five carbon atoms (C2-C5 heterocycloalkyl), or two to four carbon atoms (C2-C4 heterocycloalkyl). In some embodiments, the heterocycloalkyl is a 3- to 6-membered heterocycloalkyl. In some embodiments, the cycloalkyl is a 5- to 6- membered heterocycloalkyl. Examples of such heterocycloalkyl radicals include, but are not limited to, aziridinyl, azetidinyl, dioxolanyl, oxetanyl, thienyl[l,3]dithianyl, decahydroisoquinolyl, imidazolinyl, imidazolidinyl, isothiazolidinyl, isoxazolidinyl, morpholinyl, octahydroindolyl, octahydroisoindolyl, 2-oxopiperazinyl, 2-oxopiperidinyl, 2-oxopyrrolidinyl, oxazolidinyl, piperidinyl, piperazinyl, 4-piperidonyl, pyrrolidinyl, pyrazolidinyl, quinuclidinyl, thiazolidinyl, tetrahydrofuryl, trithianyl, tetrahydropyranyl, thiomorpholinyl, thiamorpholinyl, 1-oxo-thiomorpholinyl, 1,1-dioxo-thiomorpholinyl, 1,3- dihydroisobenzofuran- 1 -yl, 3 -oxo- 1 ,3 -dihydroisobenzofuran- 1 -yl, methyl -2-oxo- 1 ,3 -dioxol-4-yl, and 2-oxo-l,3-dioxol-4-yl. In some embodiments, heterocycloalkyl is aziridinyl, azetidinyl, morpholinyl, piperidinyl, piperazinyl, oxetanyl, tetrahydrofuryl, tetrahydropyranyl, or thiomorpholinyl. The term heterocycloalkyl also includes all ring forms of the carbohydrates, including but not limited to, the monosaccharides, the disaccharides, and the oligosaccharides. It is understood that when referring to the number of carbon atoms in a heterocycloalkyl, the number of carbon atoms in the heterocycloalkyl is not the same as the total number of atoms (including the heteroatoms) that make up the heterocycloalkyl (i.e. skeletal atoms of the heterocycloalkyl ring). Unless stated otherwise specifically in the specification, a heterocycloalkyl is optionally substituted, for example, with oxo, halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heterocycloalkyl is optionally substituted with one or more oxo, halogen, methyl, CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heterocycloalkyl issome embodiments, the heterocycloalkyl is optionally substituted with one or more oxo. In some embodiments, heterocyclyl contains 1-3 heteroatoms selected from N, O, and S. In some embodiments, heterocyclyl contains 1-3 heteroatoms selected from N and O. In some embodiments, heterocyclyl contains 1-2 heteroatoms selected from N and O. In some embodiments, heterocyclyl contains 1 heteroatom selected from N, O, and S. In some embodiments, heterocyclyl contains 1 heteroatom selected from N and O.“Heteroaryl” refers to a 5- to 14-membered ring system radical comprising hydrogen atoms, one to thirteen carbon atoms, one to six heteroatoms selected from the group consisting of nitrogen, oxygen, phosphorous, and sulfur, and at least one aromatic ring, he heteroaryl radical may be a monocyclic, bicyclic, tricyclic, or tetracyclic ring system, which may include fused (when fused with a cycloalkyl or heterocycloalkyl ring, the heteroaryl is bonded through an aromatic ring atom) or bridged ring systems; and the nitrogen, carbon, or sulfur atoms in the heteroaryl radical may be optionally oxidized; the nitrogen atom may be optionally quatemized. In some embodiments, the heteroaryl is a 5- to 10-membered heteroaryl. In some embodiments, the heteroaryl is a 5- to 6-membered heteroaryl. Examples include, but are not limited to, azepinyl, acridinyl, benzimidazolyl, benzothiazolyl, benzindolyl, benzodi oxolyl, benzofuranyl, benzooxazolyl, benzothiazolyl, benzothiadiazolyl, benzo[b][l,4]dioxepinyl, 1,4-benzodioxanyl, benzonaphthofuranyl, benzoxazolyl, benzodi oxolyl, benzodioxinyl, benzopyranyl, benzopyranonyl, benzofuranyl, benzofuranonyl, benzothienyl (benzothiophenyl), benzotri azolyl, benzo[4,6]imidazo[l,2-a]pyridinyl, carbazolyl, cinnolinyl, dibenzofuranyl, dibenzothiophenyl, furanyl, furanonyl, isothiazolyl, imidazolyl, indazolyl, indolyl, indazolyl, isoindolyl, indolinyl, isoindolinyl, isoquinolyl, indolizinyl, isoxazolyl, naphthyridinyl, oxadiazolyl, 2-oxoazepinyl, oxazolyl, oxiranyl, 1-oxidopyridinyl, 1-oxidopyrimidinyl, 1-oxidopyrazinyl, 1-oxidopyridazinyl, 1 -phenyl- IH-pyrrolyl, phenazinyl, phenothiazinyl, phenoxazinyl, phthalazinyl, pteridinyl, purinyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, quinazolinyl, quinoxalinyl, quinolinyl, quinuclidinyl, isoquinolinyl, tetrahydroquinolinyl, thiazolyl, thiadiazolyl, triazolyl, tetrazolyl, triazinyl, and thiophenyl (i.e., thienyl). In some embodiments, heteroaryl is imidazolyl, indazolyl, indolyl, pyrrolyl, pyrazolyl, pyridinyl, pyrazinyl, pyrimidinyl, pyridazinyl, triazolyl, or tetrazolyl. Unless stated otherwise specifically in the specification, a heteroaryl is optionally substituted, for example, with halogen, amino, nitrile, nitro, hydroxyl, alkyl, alkenyl, alkynyl, haloalkyl, alkoxy, aryl, cycloalkyl, heterocycloalkyl, heteroaryl, and the like. In some embodiments, a heteroaryl is optionally substituted with one or more halogen, -CN, -CF3, -OH, -OMe, -NH2, or -NO2. In some embodiments, a heteroaryl isembodiments, heteroaryl contains 1-3 heteroatoms selected from N, O, and S. In some embodiments, heteroaryl contains 1-3 heteroatoms selected from N and O. In some embodiments, heteroaryl contains 1-2 heteroatoms selected from N and O. In some embodiments, heteroaryl contains 1 heteroatom selected from N, O, and S. In some embodiments, heteroaryl contains 1 heteroatom selected from N and O.Certain compounds according to Formulae (F), (2’), (1), (2), (1-F), and (I) disclosed herein are isotopically enriched, meaning that they have an isotope present in greater than its natural abundance at one or more position. The term "isotopic enrichment factor" as used herein means the ratio between the isotopic abundance and the natural abundance of a specified isotope. In a compound of this disclosure, when a particular position is designated as having a particular isotope, such as deuterium, it is understood that the abundance of deuterium at that position is substantially greater than the natural abundance of deuterium, which is about 0.015% (on a mol / mol basis). A position designated as a particular isotope will have a minimum isotopic enrichment factor of at least 3000 (45% incorporation of the indicated isotope). Thus, isotopically enriched compounds disclosed herein having deuterium will have a minimum isotopic enrichment factor of at least 3000 (45% deuterium incorporation) at each atom designated as deuterium in the compound. Such compounds may be referred to herein as “deuterated” compounds. In one embodiment, deuterated compounds disclosed herein have an isotopic enrichment factor for each designated atom of at least 3500 (52.5%), at least 4000 (60% deuterium incorporation), at least 4500 (67.5% deuterium incorporation), at least 5000 (75% deuterium), at least 5500 (82.5% deuterium incorporation), at least 6000 (90% deuterium incorporation), at least 6333.3 (95% deuterium incorporation), at least 6466.7 (97% deuterium incorporation), at least 6600 (99% deuterium incorporation), or at least 6633.3 (99.5% deuterium incorporation).In some embodiments, the present disclosure provides a deuterated analogue of any compound disclosed herein. A deuterated analogue can include a compound herein where one or moreJH atoms is replaced with a deuterium atom.CompoundsDisclosed herein are analogs of xanomeline. In one embodiment the disclosed analogs function as prodrugs of xanomeline, releasing xanomeline as an active metabolite under suitable conditions, such as physiological conditions following administration of the analog to a subject. In one embodiment, the analogs of xanomeline disclosed herein have Formula (X-I):wherein PG is an optional progroup that together with the nitrogen atom to which it is attached forms an N-oxide, or has the formula -(CRJR2)-OR3;LG is an optional leaving group, provided that only one LG is present in Formula (X-I). In one embodiment, LG is an oxygen atom, that together with the adjacent LG substituted carbon atoms forms an epoxide ring.When PG is present, it is attached to a quaternary nitrogen atom. Accordingly, a counterion also is present in such PG-substituted compounds (not illustrated in Formula (X-I)). Examples of suitable counterions include anionic counterions, including monovalent and divalent anions. As understood by those of ordinary skill in the art, when the counterion is divalent it is present in a 1 :2 stoichiometry with the molecule of Formula (X-I). Suitable counterions include halides, phosphates, sulfates, sulfonates, carboxylates, hydroxides and the like.In certain embodiments, compounds of Formula (X-I) are represented by Formula (lb):wherein R1and R2are independently selected from hydrogen and Ci-6 alkyl;R3is selected from -C(O)OR4, -C(O)R5, -Si(R6)3, -CH(R7)OR8,-CH(R7)NRaC(O)Rd, -CH(R7)NRCRC, -CH(R7)NRaC(O)ORd, -CH(R7)OC(O)NReRe; -CH(R7)OC(O)R7, and - P(O)OR10(OR10),R4is independently selected from -C(R7)2-OC(O)C(R7)2NRCRC, -C(R7)2-OC(O)C(R7)3, -CH(R7)RX, -CH(R7)OCH(R7)RX, -(CH2)m-Rb, -(CHRa)m-Rb, -(CRaRa)m-Rb, alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more RA; m is independently for each occurrence 2 or 3;Rxishydrogen, (C1-6) alkyl and (C3-s) cycloalkyl; each Rbis independently selected from the group consisting of -S-S-(CHRa)m-NRcRc, - OSi(Rd)3, -OC(O)Rd, -OC(O)R9; each Rcis independently Ra, or, alternatively, two Rcare taken together with the nitrogen atom to which they are bonded to form a 4 to 8-membered cycloheteroalkyl, which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different groups selected from oxo, -CH2ORa, -C(O)Raand Rdgroups; each Rdis independently selected from (C1-6) alkyl, 5-membered heteroaryl, 6-membered heteroaryl and 6-membered aryl, each optionally substituted with 1, 2 or 3 groups selected from halogen, Ci-4 alkyl, and -ORa; with respect to the group -NReRe; each Reis Ra, wherein at least one of the Ragroups is substituted with at least one group selected from -OC1-6alkyl, -OC(O)C1-6alkyl, -OH, -SC1-6alkyl, and -SH;R5is -Si(Rd)3, -C(R8)2-NRCRCor -C(R5)2-C(R7)2-Ryalkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more RA;R6is alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, or hydrogen, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more RA;R7is independently hydrogen, alkyl, alkenyl, haloalkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl is unsubstituted or substituted with one or more -ORa, -NRCRC, -C(O)ORa, -N(Ra)C(O)ORa,RyisR8is -Si(Rd)3, or CH(R5)OC(O)NHRf;Rfis -Si(Rd)3, -C(R5)2-NRCRCor -C(R5)2-C(R5)2-Ry;R9is a Ce-i5 alkylene or alkenylene chain;wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl is unsubstituted or substituted with one or more RB; n is independently for each occurrence 2 or 3; each Rgis independently -OH, -NH2, -N(Rn)C(O)R7, -N(Rn)C(O)OR12, -OC(O)R13, - OC(O)OR14, -OC(O)NRCRC; each RAis independently alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, halogen, an amino acid side chain, -OR11, -C(O)OR12, -N(R13)C(O)OR14, -N(R13)C(O)R14, - C(O)R14, -OC(O)R15, -OC(O)OR16, -OP(O)OR17[N(R18)R19], -N(R18)R19, -C(O)N(R18)R19, - OC(O)N(R18)R19, or -OP(O)OR10(OR10), wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more alkyl, aryl, halogen, -S-R13, -OR13, -NR(R18)R19, -C(O)R14, -OC(O)R15, -OC(O)OR16, or -OC(O)N(R18)R19; each of R11, R12, R13, R14, R15, R16, or R17is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, and heteroaryl is unsubstituted or substituted with one or more RB; each of R18and R19is independently hydrogen, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl, wherein alkyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more RB; or R18and R19together with the atom to which they are attached form a heterocyclylalkyl ring or heteroaryl ring, each of which is unsubstituted or substituted with one or more RB; each RBis independently halogen, amino, cyano, hydroxyl, alkyl, alkenyl, heteroalkyl, cycloalkyl, heterocyclylalkyl, aryl, heteroaryl, arylalkyl, -OC(O)R18, -C(O)R18, -C(O)OR18, NHC(O)OR18, or heteroarylalkyl, wherein cycloalkyl, heterocyclylalkyl, aryl, or heteroaryl is unsubstituted or substituted with one or more halogen, amino, cyano, hydroxyl, alkyl, acetyl, or benzoyl, and X' is a pharmaceutically acceptable counterion.In some embodiments, compounds of Formulas (X-I) and (lb) have Formula (Ic):In some embodiments of Formula (X-I), compounds disclosed herein have Formula (If) orWith reference to Formulas (If) and (Ig), an elimination reaction yields xanomeline.In some embodiments of Formula (X-I), the LG groups comprise an epoxide, such that in one embodiment compounds of Formula (X-I) have Formula (Ih):In some embodiments, compounds of Formula (X-I) are N-oxide compounds of Formulas (li) and / or (Ij):In some embodiments, the present disclosure provides compounds of Formulas (X-I), (lb), (Ic), (Id), (le), (If), (Ig) (Ih), (li), and (Ij) that are isotopically enriched. In one embodiment, a compound of Formulas (X-I), (lb), (Ic), (Id), (le), (If), (Ig), (Ih), (li), and / or (Ij) is enriched in deuterium.In some embodiments, the disclosed xanomeline analogs have Formula (I), (II), (III), (IV), (V), (VI), (VII), (VIII), (IX), (X), (XI), (XII), (XIII), (XIV), or (XV):p pR6’=wle, Et, iPr, tBu, Ph in any combination(IV),6’=l\ / le, Et, iPr, tBu, Ph in any combination(V),Xp;1 pC^2 V ’l^eH’O ’ ^nh^3fcoMme§^ioCnF3SO3'PhS03. H2PO4l^6’=IVle, Et, iPr, tBu, Ph in any combination(VI),LG = Cl, Br, I, OH, OMe, OAc(VII),In some embodiments of the Formulas above, including Formulas (X-I), (lb), (Ic), (Id), (le), (I), (II), (III), (IV), (V) and (VI), R1and R2are hydrogen. In some embodiments of the Formulas above, at least one of R1and R2is other than hydrogen, such as in compounds wherein at least one of R1and R2is C1-6alkyl. In some embodiments of Formulas (X-I), (lb), (Ic), (Id), (le), (I), (II), (III), (IV), (V) and (VI), R1and R2are the same. In some embodiments, R1and R2are different, such in compounds wherein one of R1and R2is hydrogen, and the other is C1-6alkyl. When R1and R2are different, the carbon to which they are bonded is chiral. Chiral compounds are provided herein in racemic and optically active forms. Certain embodiments of chiral compounds disclosed herein are specifically illustrated herein, such as in Table 1. Where such compounds are illustrated, all stereoisomers are specifically contemplated. For example, where the compound illustrated has the ^'-configuration at a chiral carbon, the opposite or Reconfiguration of that carbon atom also is contemplated herein.In some embodiments of the Formulas above, including Formulas (X-I), (lb), (Ic), (Id), (le), (I), (II), (III), (IV), (V) and (VI), R4and R5or R6each are alkyl, such as branched or unbranched alkyl. In some embodiments, the alkyl or branched alkyl is unsubstituted.In some embodiments of Formulas (X-I), (lb), (Ic), (Id), (I), (II) and (III), R4or R5are ' alkyl. In some embodiments, R4or R5are C1-6alkyl, such as methyl, ethyl, propyl,In some embodiments (X-I), (lb), (Ic), (Id), (I), (II) and (III), R4or R5are substituted alkyl. In some embodiments, R4or R5are haloalkyl, such as perhaloalkyl.Disclosed herein are analogs of trospium chloride or trospium salts. In one embodiment the disclosed analogs function as prodrugs of trospium, releasing trospium as an active metabolite under suitable conditions, such as physiological conditions following administration of the analog to a subject. In one embodiment, the disclosed trospium analogs have Formula (T-wherein R1is hydrogen, halo, -OR2;R2is selected from C1-30 alkyl, Rx, -C(O)OR3, -C(O)R4, -CH(R5)OR6, -Si(R5)3, -Si(OR5)3, -S(O)2R5, -C(R5)2OR5, -C(R5)2SR5, -C(R5)2S(O)R5, -C(R5)2S(O)2R5, -C(R5)2O-Si(R5)3, - C(R5)2O-Si(OR5)3, -C(R5)2S-Si(R5)3, -C(R5)2S-Si(OR5)3, -C(R5)2S(O)Si(R5)3, -C(R5)2S(O)Si(OR5)3, -C(R5)2S(O)2Si(R5)3, -C(R5)2S(O)2Si(OR5)3, -CH(R5)NRaC(O)Rd, -CH(R5)NRCRC, -CH(R5)NRaC(O)ORd, -CH(R5)OC(O)NReRe; -C(R5)2OC(O)OR3, -C(R5)2OC(O)R4, and -P(O)OR9(OR10);R3is selected from alkyl, alkenyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl, and -(CH2)m-Rb, -(CHRa)m-Rb, wherein alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl is unsubstituted or substituted with one or more group selected from halogen, Ra, -ORa, -NRCRC, -C(O)ORaand -N(Ra)C(O)ORa, -C(R5)2-OC(O)C(R5)2NRCRC, - C(R5)2-OC(O)C(R5)3, -CH(R5)Ry, -CH(R5)OCH(R5)Ry, -(CH2)m- Rb, -(CHRa)m-Rb, -(CRaRa)m-Rb;R4is selected from -Si(Rd)3, -C(R5)2-NRCRC, -C(R5)2-C(R5)2-RZ; alkyl, alkenyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl, and -(CH2)m-Rb, -(CHRa)m-Rb, wherein alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, heterocyclylalkyl is unsubstituted or substituted with one or more group selected from halogen, Ra, -ORa, -NRCRC, -C(O)ORaand -N(Ra)C(O)ORa, -C(R5)2- OC(O)C(R5)2NRCRC, -C(R5)2-OC(O)C(R5)3, -CH(R5)Ry, -CH(R5)OCH(R5)Ry, -(CH2)m- Rb, -(CHRa)m-Rb, -(CRaRa)m-Rb; each R5is independently hydrogen, alkyl, alkenyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, or heterocyclylalkyl wherein alkyl, aryl, heteroaryl, heteroalkyl, cycloalkyl, 'kyl is unsubstituted or substituted with one or more group selected from halogen, CRC, -C(O)ORaand -N(Ra)C(O)ORa;each Rfis independently -OH, -NH2, -N(Rn)C(O)R7, -N(Rn)C(O)OR12, -OC(O)R13, - OC(O)OR14, -OC(O)NRCRC, and each of R11, R12, R13and R14is independently Raor Rasubstituted or substituted with one or more halogen;Rais, for each occurrence, independently selected from the group consisting of hydrogen, (C1-6) alkyl and (C3-8) cycloalkyl; each Rbis independently selected from the group consisting of -S-S-(CHRa)m-NRcRc, -OSi(Rd)3, -C(O)ORa, -OC(O)Rd, -OC(O)R7; each Rcis independently hydrogen, Ra, or, alternatively, two Rcare taken together with the nitrogen atom to which they are bonded to form a 4 to 8-membered cycloheteroalkyl, which may optionally include one or more of the same or different additional heteroatoms and which may optionally be substituted with one or more of the same or different groups selected from oxo, -CH20Ra, -C(O)Raand Rdgroups; each Rdis independently selected from (C1-6) alkyl, 5-membered heteroaryl, 6- membered heteroaryl and 6-membered aryl, each optionally substituted with 1, 2 or 3 groups selected from halogen, C1-4 alkyl, and -ORa; m is independently for each occurrence 2 or 3; each Reis Ra, wherein at least one of the Ragroups is substituted with at least one group selected from -OC1-6alkyl, -OC(O)C1-6alkyl, -OH, -SC1-6alkyl, and -SH;Rxis selected from the group consisting ofX" is a pharmaceutically acceptable counterion, provided that when R1is hydrogen, the compound is enriched in deuterium. In one embodiment, R1is not hydrogen.In certain embodiments, the disclosed compounds, including compounds of Formula (T-I), are enriched in a heavy isotope, such as deuterium.In particular embodiments of Formula (T-I), R1is halo or -OR2, wherein R2is selected from halo and -S(O)2R5.In certain embodiments, R1is selected from the group consisting of chloro, bromo and iodo. In certain examples of such embodiments, the compounds can act as intermediates. Examples of such compounds include those wherein R1 is a leaving group. Leaving groups include, without limitation, halides, and sulfonates, such as tosylate, nosylate, mesylate, triflate and the like.In certain embodiments of compounds according to Formula (T-I), R1is -OR2. In one such embodiment of Formula (T-I), R2is -S(O)2R5. In another embodiment, R2is selected from - C(O)OR3and -C(O)R4.In one embodiment of Formula (T-I), R2is -C(O)OR3and R3is alkyl. In anotherR3is alkenyl.In one embodiment of Formula (T-I), R2is -C(R5)2OC(O)OR3. In another embodiment, of Formula (T-I), R2is -C(R5)2OC(O)R4. In certain examples of such embodiments of Formula (T-I), at least one R5is hydrogen, such as in compounds wherein one R5is hydrogen, and the other is alkyl. In certain embodiments of Formula (T-I), wherein R2is -C(R5)2OC(O)OR3, R3is selected from alkyl and alkenyl. In certain other embodiments of Formula (T-I), R2is -C(O)R4and R4is selected from alkyl and alkenyl.In one embodiment of Formula (T-I), R2is Rxwherein RxIn certain embodiments of Formula (T-I), R1is -OR2and R2is -Si(R5)3 or -Si(OR5)3. In other embodiments, R2is -C(R5)2OC(O)OR3or -C(R5)2OC(O)R4.In one aspect, the present disclosure is directed to a compound of Formula (!’):Formula (!’) wherein:X' is absent or is an anion;R1is:(i) -o-;haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2.24alkynyl, -(Ci-24alkylene)-Si(Riij)2-Ci.24alkyl, -Si(Riij)2-Ci-24alkyl, -(C2.30alkenylene)-Si(Riij)2-Ci-24alkyl, — (C2.24alkenylene)-Si(R11-i)2-C2-24alkenyl, -Si(R11-’)2-C2.24alkenyl, -(Ci-C24alkylene)-Si(R11-i)2-C2-24alkenyl, -(Ci-24alkylene)-S(O)-Ci-24alkyl, -(Ci-24alkylene)- S(O)2-Ci-24alkyl, -(Ci-24alkylene)-S(O)-Ci-24alkylene, -(Ci-24alkylene)-S(O)2-Ci-24alkylene, -(Ci-24alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24alkylene)-(O-CH2CH2)i- 50-O-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -Ci- 6 alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(O)-(Ce- 10 aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, Ci-22alkyl or C2.24alkenyl;R4is:(ii-a) -C(O)-Ci-24alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2.30alkenyl, -C(O)-C2.24alkynyl, -C(O)-(Ci-24alkylene)-Ce-i4aryl, -C(O)-(C2.24alkenylene)-Ce-i4aryl, - C(O)-(C2.24alkynylene)-Ce-io aryl, -C(O)-(Ci-24alkylene)-C(O)-O-Ci-24alkyl, - C(O)-(Ci-24alkylene)-C(O)-O-C2.24alkenylene, -C(O)-(C2.24alkenylene)-C(O)-O- Ci-24alkyl, -C(O)-C(O)-O-Ci-24alkyl, -C(O)-C(O)-OH, -C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)-(C2.24alkynylene)-C(O)-O- Ci-24alkyl, -C(O)-(C2.24alkynylene)-C(O)-OH, -C(O)-(Ci-24alkylene)-C(O)- (cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-C(O)-(bile acid), - C(O)-(C2.24alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2.24alkenylene)-C(O)-(bile acid), -C(O)-(Ci-24alkylene)-O-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-O-C(O)-(bile acid), -C(O)-(C2.24alkynylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2.24alkynylene)- C(O)-(bile acid), -C(O)-(Ci-24alkylene)-C(O)OH, -C(O)-O-(Ci-24alkylene)-membered heterocycle), -C(0)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24 alkylene)-(Ce-i4 aryl), - C(O)-(C1 -22 alkylene)-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)- (5- to 10-membered heteroaryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(C6-i4 aryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci- 24 alkylene)-(bile acid), -C(O)-(Ci-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkylene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkyl ene)-0-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-O-(bile acid), -C(O)- (cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i -5o-0-Rlia, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted,Rliais H, deuterium, Ci-24 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24 alkyl, -C(O)-O-Ci-24haloalkyl, -C(O)-O-C2-30 alkenyl, - C(O)-O-C2-24 alkynyl, -C(O)-O-(Ci.24alkylene)-C6-i4 aryl, -C(O)-O-(C2-24 alkenylene)-C6-i4 aryl, -C(O)-O-(Ci-24alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2- 24alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci.24alkylene)-C(O)OH, -C(O)-O- (C2-24 alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, -C(O)-O-C3-i5cycloalkyl, -C(O)- O-(3- to 10-membered heterocycle), -C(O)-O-(5- to 10-membered heteroaryl), - C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(Ce-i4 aryl) -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered heterocycle) - C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(C2-24 alkenylene)-(Ce-i4 aryl) -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(0)-0-(C2- 24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-O-(Ci-24 alkylene)- (cholesterol or dihydrocholesterol), -C(O)-O-(C2-24 alkylene)-(bile acid), -C(O)- (C1-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkyl ene)-0-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)- (C1-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O- (bile acid), C(O)-(Ci-24 alkylene)-C(O)-(cholesterol or dihydrocholesterol), -Rllb, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRllbis H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-c) -Si(Rsi)3, wherein each RS1independently is C1-24 alkyl, C2-30 alkenyl, Ce-io aryl, -O-C1-24 alkyl, -O-C2-30 alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;(ii-d) -C(O)-CH(Riid)2, -C(O)-(Ci-24alkylene)-C(O)-O-CH(Riid)2or -C(O)-(Ci-24alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlld)2, wherein the alkylene is unsubstituted or is optionally substituted, wherein each Rlldindependently is -CH2-O-C(O)-Ci-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or -CH2-O-P(O)2-O-(CI-6alkylene)-N+(Riid’)3wherein each Rlldindependently is C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-e) -C(O)-O-CH(Riie)2, -C(O)-O-(Ci-24alkylene)-C(O)-O-CH(Riie)2or -C(O)- O-(Ci-24 alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlie)2, wherein the alkylene is unsubstituted or is optionally substituted; wherein each Rlieindependently is -CH2-O-C(O)-Ci-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, -CH2-O-P(O)2-O-(CI.24 alkylene)-N(Riie’)2or - CH2-O-P(O)2-O-(CI-24 alkylene)-N+(Rlie)3, wherein the alkyl, alkenyl, or alkylene is unsubstituted or is optionally substituted; wherein each Rlieis independently H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-f) -C(O)O-C(O)-CHRiif-N(Riif)2, -C(O)O-(Ci-i2alkylene)-C(O)-CHRiif-N(Riif)2, -C(O)O-(Ci-i2alkylene)-O-C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-NRiif-C(O)-O-Ci-24alkyl, -C(O)-(Ci-24alkylene)-NRiif-C(O)- CHRiif-N(Riif)2, or -C(O)-(Ci-24alkylene)-NR "r-C(O)-CHR"l-N(R "r)-C(O)-O- Ci-24 alkyl, or salts thereof, wherein the alkyl and alkylene are unsubstituted or optionally substituted, wherein each Rllfindependently is H or C1-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1-6together with the atoms to which they are attached, combine to form a 4- to 10-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted or salts thereof; and each Rllfindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4- to 10- membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted;(ii-g) -P(O)(ORiig)2, -P(O)2(ORiig), -P(O)(ORiig)-O-(Ci-20alkylene)-O-Ci-20alkyl, -P(O)(O-(Ci-20alkylene)-O-C(O)-Riig))2, -P(O)(O-(Ci-20alkylene)-O-C(O)-O- Riig))2, -P(O)2(O-(Ci-20alkylene)-O-C(O)-O-Riig)), -P(O)2(O-(Ci-20alkylene)- C(O)-O-Riig)),-P(O)(N(Riig)2)2, or -P(O)2(O-(Ci-20alkylene)-O-C(O)-Riig)), wherein the alkyl or alkylene is unsubstituted or is optionally substituted, wherein each Rllgindependently is H, C1-20 alkyl, or Ce-io aryl, or two Rllg, together with the atoms to which they are attached, combine to form 5- to 10-membered heterocyclyl wherein alkyl and heterocyclyl are unsubstituted or is optionally substituted;(ii-h) -S(O)2-N(Rllh)2, wherein each Rllhindependently is H or C1-20 alkyl;(ii-i) -C(0)-(Ci-2o alkylene)-(Ce-io aryl) or -C(0)-(Ci-2o alkylene)-0-(Ce-io aryl), wherein the alkylene is unsubstituted or is optionally further substituted, the Ce-io aryl is substituted by one or more R111, and the aryl is optionally further optionally substituted, wherein R111is -O-C(O)-C1-6alkyl, -O-C(O)-C3-8 cycloalkyl, -O-C(0)-Ce-io aryl or C1-6alkyl, wherein the alkyl, cycloalkyl, and aryl is unsubstituted or is optionally further substituted; or(ii-j) -(Ci-24 alkylene)-Si(R11-i)2-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)-Ci-24 alkyl, - (Ci-24alkylene)-S(O)2-Ci-24alkyl, -O-(Ci-24alkylene)-Si(Riij)2-Ci-24alkyl, -O- (Ci-24 alkylene)-Si(O)-Ci-24 alkyl, or -O-(Ci-24 alkylene)-Si(O)2-Ci-24 alkyl,, wherein the alkylene and alkyl are unsubstituted or are optionally further substituted,wherein the alkyl and cycloalkyl are unsubstituted or are optionally substituted;each R5, R6, R5, and R6independently are hydrogen, deuterium, C1-24 alkyl, -Ci-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)- C2-24 alkynyl, -(C1-24 alkylene)-Si(Riij)2-Ci-24 alkyl, -Si(Riij)2-Ci-24 alkyl, -(C2-3o alkenylene)-Si(R11-i)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Rllj)2-C2-24 alkenyl, - Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)- S(O)-Ci-24 alkyl, -(C1-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(O-CH2CH2)i- 5o-0-Riv, -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i-50-O-Riv, C6-io aryl, 5- to 10- membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;R7is C1-20 alkyl, C3-io cycloalkyl, Ce-io aryl, bile acid, cholesterol, dihydrocholesterol, -(C1-20 alkyl ene)-O-(C 1-6 alkyl), -(C1-20 alkylene)-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-(Ci-6alkyl), 3- to 10-membered heterocyclyl; 5- to 10-membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)- C(O)-O-(3- to 10-membered heterocyclyl); -(C1-20 alkyl ene)-C(0)-0-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10- membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl); -alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHRAA-NRN2, - (C1-20 alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)s, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(Ci- 6 alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(Ci- 6 alkylene)-C(O)- cholesterol, or -(C1-6alkylene)-NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6alkylene)-NRN- dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, or -NRN- dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; wherein RAAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-Ci.6alkyl, -C(O)- NH2, -S-C1-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; andRA 2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)- NH2, -S-C1-6 alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl.;(ii-o) -(C1-6alkylene)-(optionally substituted Ce-io aryl)-R110wherein:Rii0is -O-C(O)H, -0-C(0)-Ci-2o alkyl, -O-C1-20 alkyl, -O-C(O)-O- C1-20 alkyl, -0-C(0)-N(Rn'110)2, -O-C(O)-(3- to 10-membered cycloalkyl), -O- C(O)-C3-8 cycloalkyl, -O-C(O)-O-C3-8cycloalkyl, -O-C(O)-N(Rn iio)-C3.8cycloalkyl, wherein each Rn'110independently is H or C1-20 alkyl; n is 0 or 1; andR"'° is H, C1-6alkyl, -O-C(O)-(ii-p) -C(O)-(O)m-(Ci-6alkylene)-N(Rii-p’)-Rii-p, wherein: m is 0 or 1;(ii-q) -C(O)-NRiiq-(Ci -20 alkylene, C 1-20 alkenylene, or C1-20 alkynylene)- (optionally substituted Ce-io aryl), -C(O)-NRliq’-(C1-20 alkylene, C1-20 alkenylene, or C1-20 alkynylene)-(optionally substituted 5- to 10-membered heteroaryl), -C(O)-NRliq- (optionally substituted Ce-io aryl), -C(O)-NRliq-(optionally substituted 5- to 10- membered heteroaryl), -C(0)-NRiiq’-(Ci-2o alkylene)-O-C(O)-Riiq’, -C(O)-N(Riiq’)2or - C(0)-NRiik’-(Ci-2o alkylene)-C(O)-O-Riiqwherein each Rliqindependently is H or C1-20 alkyl;(iii) -(Ci -24 alkylene)-(5- to 10-membered heteroaryl), wherein the alkylene and heteroaryl are unsubstituted or are optionally substituted; or(iv) -(Ci-24 alkylene)-(O-CH2CH2)i-50-O-Rlv, and R1Vis H, C1-24 alkyl, or C2-24 alkenyl, wherein the alkylene, alkyl, and alkenyl are unsubstituted or are optionally substituted;R2is CH3, CH2D, CHD2, or CD3; andR3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium;(v) -O-C(O)-N(Rala)Ra2aor -NRXA-C(O)-ORa2a; wherein RXAis H or C1-12 alkyl, wherein the C1-12 alkyl is optionally substituted or unsubstituted;Ralais H, Ce-io aryl, or Ci-3o alkyl, wherein each Ce-io aryl or Ci-3o alkyl is optionally substituted or unsubstituted;Ra2ais:(i-a) -Ci-30alkyl, -(Ci-30alkylene)-O-C(O)Rla, -(Ci-30alkylene)-C(O)-ORla, -(Ci-3o alkylene)-(Ce-io arylene)-O-C(O)-Rla; wherein Rlais optionally substituted or unsubstituted C1-12 alkyl or optionally substituted or unsubstituted 5-to 10-membered heteroaryl; or(ii-a) Ce-io aryl, -(Ce-io arylene)-(Ci-i2 alkylene)-O-C(O)-R2a, or -(5- to 10- membered heteroarylene)-(Ci-i2 alkylene)-O-C(O)-R2a; wherein R2ais optionally substituted or unsubstituted C1-12 alkyl or -(C1-12 alkylene)-NR2aR2a, wherein the C1-12 alkylene is optionally substituted or unsubstituted; and each R2aand R2aindependently is H or optionally substituted or unsubstituted C1-12 alkyl.(vi) -(C1-6alkylene)-(5- to 10-membered heteroaryl optionally substituted by one or more oxo or C1-6alkyl) or -(C1-6alkylene)-Ce-io aryl;Riv'(vii) wherein:R5and R6each independently are hydrogen, C1-20 alkyl optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl optionally substituted with C1-6alkoxy, or R5and R6combine to form oxo; or R5and R6can be taken together to form a C3-8 cycloalkyl or 3- to 10-membered heterocyclyl;R1Vis C1-20 alkyl; andR1Vis H or C1-6alkyl;wherein:R5, R6, R5, and R6each independently are hydrogen, C1-20 alkyl optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl optionally substituted with C1-6alkoxy, or (i) R5and R6combine to form oxo or (ii) R5and R6combine to form oxo, or (i) R5and R6can be taken together to form a C3-8 cycloalkyl or 3- to 10-membered heterocyclyl, or (ii) R5and R6, together with the atom to which they are attached, combine to form C3-8 cycloalkyl or 3- to 10-membered heterocyclyl; andRvis C1-20 alkyl, C3-8 cycloalkyl, mono or dialkyl amino, or 3- to 10-membered heterocyclyl; orwherein: each R5and R6independently are as defined for Formula (1’);R4Tis Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the Ce-io aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;RNis H, Ci-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted; andRNis H, Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;wherein: R5and R6are each independently H, C1-6alkyl, or Ce-io aryl.L2is a bond, -(Ci-8alkylene)-C(O)-*, -C(O)-(Ci-8alkylene)-C(O)-*, -C(O)-*, -(Ci-8alkylene)-O-C(O)-(Ci-8 alkylene)-C(O)-*,or -P(O)(OH)-*, wherein -* indicates attachment to M;M is -O-R4, -NR’-(CI-20 alkylene)-R4, -0-(Ci-2o alkylene)-R4, -0-(Ci-2o alkylene)-O-R4or -(Ci -20 alkylene)-R4, wherein the C1-6alkylene is optionally substituted with hydroxyl;R’ is H or C1-6alkyl;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; each Rcindependently is C1-6alkyl; and each X independently is a pharmaceutically acceptable anion.R5R6., wherein R5and R6independently are as defined for Formula (1 ’); andRing A is:(i) Ce-i4 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl;(iv) 5- to 10-membered heteroaryl;(v) cholesterol, dihydrocholesterol, or a bile acid; wherein the aryl, heterocycle, cycloalkyl, heteroaryl, cholesterol, dihydrocholesterol, or bile acid are unsubstituted or are optionally substituted.(xii)each R5, R6, R5, and R6independently are hydrogen, deuterium, C1-24 alkyl, -Ci-24 so alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)- S(O)-Ci-24 alkyl, -(C1-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(Ci- 24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i -5O-0-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;R7is C1-20 alkyl, C3-10 cycloalkyl, Ce-io aryl, bile acid, cholesterol, dihydrocholesterol, - (C1-20 alkyl ene)-O-(C 1-6 alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)-O-C(O)- O-(C1-6alkyl), -(C1-20 alkyl ene)-O-C(O)-(C 1-6 alkyl), 3- to 10-membered heterocyclyl; 5- to 10- membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), -(C1-20 alkyl ene)-C(O)-O-(3- to 10-membered heterocyclyl); -(C1-20 alkylene)-C(O)-O-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -O- C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(O)-O-(3- to 10- membered heterocyclyl); -(C1-20 alkylene)-NRN-C(O)-O-(5- to 10-membered heteroaryl), - CHRAA-NRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHR^-NR^, -(C1-20 alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)O- C(0)-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(C1-6alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)- cholesterol, or -(C1-6alkylene)-NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)-NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN- dihydrocholesterol, or -NRN-dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted;C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; andR2is H, Ci-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;(xiii)Y1, and Y4each independently are O, NRN, or CH2;Y2and Y3each independently are O, NRN, or a bond; each RNindependently is H or C1-6alkyl;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are each hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-24alkyl, -O-C(O)-C2-30 alkenyl, -C(O)-Ci-24alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(R11-i)2-Ci-24 alkyl, - Si(Riij)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Riij)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Riij)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)- C1-24 alkyl, -(Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24 alkylene)- (O-CH2CH2)I -50-O-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -(C1-6alkylene)-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2-24 alkenyl;L is a bond, C1-24 alkylene, C2-24 alkenylene, Ce-io arylene, -(C1-6alkyl)-(Ce-io arylene)- or C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is optionally substituted;R4is H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, terol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(Ci-10 to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-memberedalkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(O)-O-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-(cholesterol), -(C1-10 alkylene)-(dihydrocholesterol), -(C1-10 alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-O-(C1-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkyl ene)-O-C(O)-O-(C 1-6 alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkyl ene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(O)-O-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkyl ene)-C(O)-O-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -0CHRiid2, - (C1-6alkylene)-C(O)NRN-(Ci-6alkylene)-C(O)-OH, -(Ci-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, alkenylene, or alkyl is unsubstituted or is optionally substituted; n is 1 to 20;RAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(0)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;-OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-Ci-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI.6 alkylene)-N+(Rlld)3, wherein the alkyl, alkenyl, or alkylene is optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl.In one aspect, the present disclosure is directed to a compound of Formula (1):Formula (1) wherein:X' is absent or is an anion;R1is:(i) -o-;wherein: each R5and R6independently are hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(Riij)2-Ci-24 alkyl, -Si(Riij)2-Ci-24 alkyl, -(C2-3o alkenylene)-Si(Riij)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Rllj)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)-Ci-24 alkyl, -(C1-24 alkylene)- S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-so-0-Rlv, -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i- 50-O-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -Ci- 6 alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(O)-(Ce- ), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- toR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2-24 alkenyl;R4is:(ii-a) -C(O)-Ci-24 alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -C(O)-(Ci-24 alkylene)-Ce-i4 aryl, -C(O)-(C2-24 alkenylene)-Ce-i4 aryl, - C(O)-(C2-24 alkynylene)-Ce-io aryl, -C(O)-(Ci-24 alkylene)-C(O)-O-Ci-24 alkyl, - C(O)-(Ci-24 alkylene)-C(O)-O-C2-24 alkenylene, -C(O)-(C2-24 alkenylene)-C(O)-O- C1-24 alkyl, -C(O)-C(O)-O-C 1-24 alkyl, -C(O)-C(O)-OH, -C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-O- C1-24 alkyl, -C(O)-(C2-24 alkynylene)-C(O)-OH, -C(O)-(Ci-24alkylene)-C(O)- (cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-C(O)-(bile acid), - C(O)-(C2-24 alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkenylene)-C(O)-(bile acid), -C(O)-(Ci-24 alkylene)-O-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkynylene)- C(O)-(bile acid), -C(O)-(Ci-24alkylene)-C(O)OH, -C(O)-(C2-24 alkenylene)- C(O)OH, -C(O)-Ce-i4 aryl, -C(O)-C3-is cycloalkyl, -C(O)-(3- to 10-membered heterocycle), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24 alkylene)-(C6-i4 aryl), -C(O)-(Ci-22 alkylene)-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-(5- to 10- membered heteroaryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(Ce-i4 aryl), -C(O)-(C2-24 alkenylene)-(3- to 10- membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Cn 24 alkylene)-(bile acid), -C(O)-(Ci-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkylene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkyl ene)-O-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-O-(bile acid), -C(O)- (cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i -5o-0-Rlia, wherein the alkyl, alkenyl, alkynyl, alkylene,Rliais H, deuterium, C1-24 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24 alkyl, -C(O)-O-Ci-24haloalkyl, -C(O)-O-C2-30 alkenyl, - C(O)-O-C2-24 alkynyl, -C(O)-O-(Ci.24alkylene)-C6-i4 aryl, -C(O)-O-(C2-24 alkenylene)-C6-i4 aryl, -C(O)-O-(Ci-24alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2- 24 alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci-24alkylene)-C(O)OH, -C(O)-O- (C2-24 alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, -C(O)-O-C3-i5 cycloalkyl, -C(O)- O-(3- to 10-membered heterocycle), -C(O)-O-(5- to 10-membered heteroaryl), - C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(Ce-i4 aryl) -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered heterocycle) - C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(C2-24 alkenylene)-(Ce-i4 aryl) -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-O-(C2- 24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-O-(Ci-24 alkylene)- (cholesterol or dihydrocholesterol), -C(O)-O-(C2-24 alkylene)-(bile acid), -C(O)- (C1-24 alkylene)-O-(Ce-i4 aryl), -C(O)-(Ci-24 alkyl ene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)- (C1-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O- (bile acid), C(O)-(Ci-24 alkylene)-C(O)-(cholesterol or dihydrocholesterol), - C(O)-(C1 -24 alkylene)-C(O)-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(0)-0-(Ci.24 alkylene)-(0-CH2CH2)i-5o-0- Rllb, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRllbis H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-c) -Si(Rsi)3, wherein each RS1independently is C1-24 alkyl, C2-30 alkenyl, Ce-io aryl, -O-C1-24 alkyl, -O-C2-30 alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;(ii-d) -C(O)-CH(Riid)2, -C(O)-(Ci-24alkylene)-C(O)-O-CH(Riid)2or -C(O)-(Ci-24alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlld)2, wherein the alkylene is unsubstituted or is optionally substituted,wherein each Rlldindependently is C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-e) -C(O)-O-CH(Riie)2, -C(O)-O-(Ci-24alkylene)-C(O)-O-CH(Riie)2or -C(O)- O-(Ci-24 alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlie)2, wherein the alkylene is unsubstituted or is optionally substituted; wherein each Rlieindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, -CH2-O-P(O)2-O-(CI-24alkylene)-N(Riie’)2or - CH2-O-P(O)2-O-(CI-24 alkylene)-N+(Rlie)s, wherein the alkyl, alkenyl, or alkylene is unsubstituted or is optionally substituted; wherein each Rlieis independently H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-f) -C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-NRiif-C(O)-O-Ci-24alkyl, -C(O)-(Ci- 24 alkylene)-NRiif-C(O)-CHRiif-N(Riif)2, or -C(O)-(Ci-24alkylene)-NRiif-C(O)- CHRllf-N(Rllf)-C(O)-O-Ci-24 alkyl, or salts thereof, wherein the alkyl and alkylene are unsubstituted or optionally substituted, wherein each Rllfindependently is H, C1-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1-6alkyl, -C(O)-NH2, -S-CI-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, 5- to 10-membered heteroaryl, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4- to 10-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted or salts thereof; and each Rllfindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4- to 10- membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted;(ii-g) -P(O)(ORiig)2, -P(O)2(ORiig), -P(O)(ORiig)-O-(Ci-20alkylene)-O-Ci-20alkyl, -P(O)(O-(Ci-20alkylene)-O-C(O)-Riig))2, -P(O)(O-(Ci-20alkylene)-O-C(O)-O- Riig))2, -P(O)2(O-(Ci-20alkylene)-O-C(O)-O-Riig)), -P(O)2(O-(Ci-20alkylene)- C(O)-O-Riig)),-P(O)(N(Riig)2)2, or -P(O)2(O-(Ci-20alkylene)-O-C(O)-Riig)), wherein the alkyl or alkylene is unsubstituted or is optionally substituted,form 5- to 10-membered heterocyclyl wherein alkyl and heterocyclyl are unsubstituted or is optionally substituted;(ii-h) -S(O)2-N(Riih)2, wherein each Rllhindependently is H or C1-20 alkyl;(ii-i) -C(0)-(Ci-2o alkylene)-(Ce-io aryl) or -C(0)-(Ci-2o alkylene)-0-(Ce-io aryl), wherein the alkylene is unsubstituted or is optionally further substituted, the Ce-io aryl is substituted by one or more R111, and the aryl is optionally further optionally substituted, wherein R111is -O-C(O)-C1-6alkyl, -O-C(O)-C3-8 cycloalkyl, -O- C(0)-Ce-io aryl or C1-6alkyl, wherein the alkyl, cycloalkyl, and aryl is unsubstituted or is optionally further substituted; or(ii-j) -(Ci-24 alkylene)-Si(R11-i)2-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)-Ci-24 alkyl, - (Ci-24alkylene)-S(O)2-Ci-24alkyl, -O-(Ci-24alkylene)-Si(Riij)2-Ci-24alkyl, -O- (Ci-24 alkylene)-Si(O)-Ci-24 alkyl, or -O-(Ci-24 alkylene)-Si(O)2-Ci-24 alkyl,, wherein the alkylene and alkyl are unsubstituted or are optionally further substituted, wherein each R"1independently is C1-6alkyl or two R"1, together with the atom to which they are attached, combine to form a C3-8 cycloalkyl, wherein the alkyl and cycloalkyl are unsubstituted or are optionally substituted;(iii) -(Ci -24 alkylene)-(5- to 10-membered heteroaryl), wherein the alkylene and heteroaryl are unsubstituted or are optionally substituted; or(iv) -(Ci-24 alkylene)-(0-CH2CH2)i-5o-0-Rlv, and R1Vis H, Ci-24 alkyl, or C2.24 alkenyl, wherein the alkylene, alkyl, and alkenyl are unsubstituted or are optionally substituted;R2is CH3, CH2D, CHD2, or CD3; andR3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium.These embodiments are applicable to all of embodiments of Formulae (! )’ , Formulae (1) and subformulae as applicable:Embodiments related to R1d of any one of the previous embodiments, whereinThe compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with one or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with two or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with one or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with three or more fluorine or deuterium.The compound of any four of the previous embodiments, wherein R3is Ce alkyl optionally substituted with five or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with six or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with seven or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with eight or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with nine or more fluorine or deuterium.The compound of any one of the previous embodiments, wherein R3is Ce alkyl optionally substituted with 10 or more fluorine or deuterium.Embodiments related to R4The compound of any one of the previous embodiments, wherein R4is -C(O)-Ci-22 alkyl optionally substituted with one or more C1-6aryl.The compound of any one of the previous embodiments, wherein R4is -C(O)-C3-i5 cycloalkyl optionally substituted with one or more Ci-8 alkyl.The compound of any one of the previous embodiments, wherein -C(O)-(4- to 10- membered heterocycle optionally substituted with mono or dialkyl amino, 4- to 10-membered heterocycle, or C1-6alkyl).The compound of any one of the previous embodiments, wherein R4is -C(O)-(C2-6 alkenyl)-(5- to 10-membered heteroaryl optionally substituted by one or more oxo or C1-6alkyl).The compound of any one of the previous embodiments, wherein R4is -C(O)-(Ci-22 CH2CH2)I-IO-OH.The compound of any one of the previous embodiments, wherein R4is -C(O)-(Ci-22 alkylene)-(0-CH2CH2)3-io-OH.The compound of any one of the previous embodiments, wherein R4is -C(O)-(Ci-22 alkylene)-(0-CH2CH2)4-io-OH.The compound of any one of the previous embodiments, wherein R4is -C(O)-(Ci-22 alkylene)-(0-CH2CH2)5-io-OH.The compound of any one of the previous embodiments, wherein R4is -C(O)-O-C3-i5 cycloalkyl optionally substituted with one or more Ci-s alkyl.The compound of any one of the previous embodiments, wherein R4is -C(O)-O(4- to 10- membered heterocycle optionally substituted by mono or dialkyl amino, 4- to 10-membered heterocycle, or C1-6alkyl), orThe compound of any one of the previous embodiments, wherein R4is -C(O)-O-(C1-6alkenyl)-(5- to 10-membered heteroaryl optionally substituted by one or more oxo or C1-6alkyl),Embodiments related to R5and R6The compound of any one of the previous embodiments, wherein R5is H.The compound of any one of the previous embodiments, wherein R5and R6are both H.The compound of any one of the previous embodiments, wherein R5is methyl.The compound of any one of the previous embodiments, wherein R5is ethyl.The compound of any one of the previous embodiments, wherein R5is propyl.The compound of any one of the previous embodiments, wherein R5is isopropyl.The compound of any one of the previous embodiments, wherein R5is butyl.The compound of any one of the previous embodiments, wherein R5is isobutyl.The compound of any one of the previous embodiments, wherein R5is sec-butyl.The compound of any one of the previous embodiments, wherein R5is t-butyl.The compound of any one of the previous embodiments, wherein R5is a Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, or Ci5alkyl.The compound of any one of the previous embodiments, wherein R5is a C15-20 alkyl.The compound of any one of the previous embodiments, wherein R5is a C15 alkyl.The compound of any one of the previous embodiments, wherein R5is a Ci6 alkyl.The compound of any one of the previous embodiments, wherein R5is a C17 alkyl.The compound of any one of the previous embodiments, wherein R5is a Cis alkyl.>mpound of any one of the previous embodiments, wherein R5is a C19 alkyl.The compound of any one of the previous embodiments, wherein R5is a C22 alkyl.The compound of any one of the previous embodiments, wherein R5is a C2, C3, C4, C5, C6, C7, C8, C9, C10, Cn, C12, C13, C14, or C15 alkenyl.The compound of any one of the previous embodiments, wherein R5is a C15-20 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C20-29 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C15 alkenyl. The compound of any one of the previous embodiments, wherein R5is a Ci6 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C17 alkenyl. The compound of any one of the previous embodiments, wherein R5is a Cis alkenyl. The compound of any one of the previous embodiments, wherein R5is a C19 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C20 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C21 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C22 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C23 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C24 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C25 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C26 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C27 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C28 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C29 alkenyl. The compound of any one of the previous embodiments, wherein R5is a cyclopropyl. The compound of any one of the previous embodiments, wherein R5is a cyclobutyl. The compound of any one of the previous embodiments, wherein R5is a cyclopentyl. The compound of any one of the previous embodiments, wherein R5is a cyclohexyl.The compound of any one of the previous embodiments, wherein R5is an oxetanyl.The compound of any one of the previous embodiments, wherein R5is a tetrahydrofuranyl .The compound of any one of the previous embodiments, wherein R5is a 2- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R5is a 3- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R5is a inyl.I l lThe compound of any one of the previous embodiments, wherein R5is a 3- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R5is a 4- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R5is phenyl, wherein the phenyl is optionally substituted.The compound of any one of the previous embodiments, wherein R5is a phenyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R5is a phenyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R5is benzyl, wherein the benzyl is optionally substituted.The compound of any one of the previous embodiments, wherein R5is benzyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R5is benzyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R5is a pyridine.The compound of any one of the previous embodiments, wherein R5is 2-pyridine.The compound of any one of the previous embodiments, wherein R5is 3-pyridine.The compound of any one of the previous embodiments, wherein R5is 4-pyridine.The compound of any one of the previous embodiments, wherein R6is H.The compound of any one of the previous embodiments, wherein R6is a Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, or Ci5alkyl.The compound of any one of the previous embodiments, wherein R6is a C15-20 alkyl.The compound of any one of the previous embodiments, wherein R6is a C15 alkyl.The compound of any one of the previous embodiments, wherein R6is a Ci6 alkyl.The compound of any one of the previous embodiments, wherein R6is a C17 alkyl.The compound of any one of the previous embodiments, wherein R6is a Cis alkyl.The compound of any one of the previous embodiments, wherein R6is a C19 alkyl.The compound of any one of the previous embodiments, wherein R6is a C20 alkyl.The compound of any one of the previous embodiments, wherein R6is a C21 alkyl.The compound of any one of the previous embodiments, wherein R6is a C22 alkyl.The compound of any one of the previous embodiments, wherein R6is a C15-20 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C20-30 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C15 alkenyl. The compound of any one of the previous embodiments, wherein R6is a Ci6 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C17 alkenyl. The compound of any one of the previous embodiments, wherein R6is a Cis alkenyl. The compound of any one of the previous embodiments, wherein R6is a C19 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C20 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C21 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C22 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C23 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C24 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C25 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C26 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C27 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C28 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C29 alkenyl. The compound of any one of the previous embodiments, wherein R6is a cyclopropyl. The compound of any one of the previous embodiments, wherein R6is a cyclobutyl. The compound of any one of the previous embodiments, wherein R6is a cyclopentyl. The compound of any one of the previous embodiments, wherein R6is a cyclohexyl.The compound of any one of the previous embodiments, wherein R6is an oxetanyl.The compound of any one of the previous embodiments, wherein R6is a tetrahydrofuranyl .The compound of any one of the previous embodiments, wherein R6is a 2- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R6is a 3- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R6is a tetrahydropyranyl .The compound of any one of the previous embodiments, wherein R6is a 2- tetrahvdroDvranyl .The compound of any one of the previous embodiments, wherein R6is a 4- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R6is phenyl, wherein the phenyl is optionally substituted.The compound of any one of the previous embodiments, wherein R6is a phenyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R6is a phenyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R6is benzyl, wherein the benzyl is optionally substituted.The compound of any one of the previous embodiments, wherein R6is benzyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R6is benzyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R6is a pyridine.The compound of any one of the previous embodiments, wherein R6is 2-pyridine.The compound of any one of the previous embodiments, wherein R6is 3-pyridine.The compound of any one of the previous embodiments, wherein R6is 4-pyridine.The compound of any one of the previous embodiments, wherein R5is C1-24 alkyl optionally substituted with Ce-io aryl.The compound of any one of the previous embodiments, wherein R5is Ce-io aryl optionally substituted with C1-6alkoxy.The compound of any one of the previous embodiments, wherein R5is 5- to 10- membered heterocyclyl optionally substituted with C1-6alkoxy.The compound of any one of the previous embodiments, wherein R5is C3-C8 cycloalkyl optionally substituted with C1-6alkoxy.In some embodiments, the compound of Formula (1) is of Formula (1-i),R2is CH3, CH2D, CHD2, or CD3; andR3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium.In some embodiments, the compound of Formula (1) is of Formula (1-ii-a-i),Formula (1-ii-a-i) wherein:X" is absent or is an anion;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are as defined for Formula (1); each R4is independently absent, H, deuterium, fluorine, or CH3, optionally substituted by one or more deuterium; andL is -Ci -24 alkylene, -C1-24 haloalkylene, -C2.3o alkenylene, or -C2.24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is unsubstituted or is optionally substituted.In some embodiments, the compound of Formula (1) is of Formula (1-ii-a-i), wherein each R5and R6independently are hydrogen, Ci-i8 alkyl, C2.3o alkenyl, C3-8 cycloalkyl, 3- to 10- membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl, wherein the Ci-i8 alkyl or C2.3o alkenyl is optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, or 3- to 10-membered heteroaryl, and the Ce-io aryl is optionally substituted with OH, or C1-6alkoxy, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl.These embodiments are applicable to the compounds of Formula (1-ii-a-i):Embodiments Related to X~Embodiments Related to R4The compound of any one of the previous embodiments, wherein at least one R4is absent.The compound of any one of the previous embodiments, wherein two R4are absent.The compound of any one of the previous embodiments, wherein at least one R4is hydrogen.The compound of any one of the previous embodiments, wherein each R4is hydrogen.The compound of any one of the previous embodiments, wherein at least one R4is CH3.The compound of any one of the previous embodiments, wherein one R4is hydrogen and the remaining two R4are CH3.The compound of any one of the previous embodiments, wherein each R4is CH3.Embodiments Related to LIn some embodiments, L is -C1-24 alkylene, -C2-30 alkenylene, -C2-24 alkynylene, wherein the alkyl, alkenyl, alkynyl is unsubstituted or is optionally substituted.In some embodiments, L is -C1-24 alkylene, -C1-24 haloalkylene, -C2-30 alkenylene, -C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is unsubstituted.In some embodiments, L is -C1-24 alkylene, or -C2-30 alkenyl, wherein the alkylene, alkenylene, alkynylene is unsubstituted or is optionally substituted.In some embodiments, L is a bond, unsubstituted or optionally substituted C1-24 alkylene, or unsubstituted or optionally substituted C2-30 alkenylene.The compound of any one of the previous embodiments, wherein L is a bond.The compound of any one of the previous embodiments, wherein L is a Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, Cn, C12, C13, C14, or C15 alkylene.The compound of any one of the previous embodiments, wherein L is a C15-20 alkylene.The compound of any one of the previous embodiments, wherein L is a C15 alkylene.The compound of any one of the previous embodiments, wherein L is a Ci6 alkylene.The compound of any one of the previous embodiments, wherein L is a C17 alkylene.The compound of any one of the previous embodiments, wherein L is a Cis alkylene.The compound of any one of the previous embodiments, wherein L is a C19 alkylene.The compound of any one of the previous embodiments, wherein L is a C20 alkylene. >mpound of any one of the previous embodiments, wherein L is a C21 alkylene.Ce, C7, C8, C9, C10, Cn, C12, C13, C14, or C15 alkenylene.The compound of any one of the previous embodiments, wherein L is a C15-20 alkenylene.The compound of any one of the previous embodiments, wherein L is a C20-29 alkenylene.The compound of any one of the previous embodiments, wherein L is a C15 alkenylene.The compound of any one of the previous embodiments, wherein L is a Ci6 alkenylene.The compound of any one of the previous embodiments, wherein L is a C17 alkenylene.The compound of any one of the previous embodiments, wherein L is a Ci8alkenylene.The compound of any one of the previous embodiments, wherein L is a C19 alkenylene.The compound of any one of the previous embodiments, wherein L is a C20 alkenylene.The compound of any one of the previous embodiments, wherein L is a C21 alkenylene.The compound of any one of the previous embodiments, wherein L is a C22 alkenylene.The compound of any one of the previous embodiments, wherein L is a C23 alkenylene.The compound of any one of the previous embodiments, wherein L is a C24 alkenylene.The compound of any one of the previous embodiments, wherein L is a C25 alkenylene.The compound of any one of the previous embodiments, wherein L is a C26 alkenylene.The compound of any one of the previous embodiments, wherein L is a C27 alkenylene.The compound of any one of the previous embodiments, wherein L is a C28 alkenylene.The compound of any one of the previous embodiments, wherein L is a C29 alkenylene.The compound of any one of the previous embodiments, wherein L is a Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, Cn, C12, C13, C14, or C15 haloalkyl.The compound of any one of the previous embodiments, wherein L is haloalkyl, wherein the haloalkyl comprises at least one fluorine.The compound of any one of the previous embodiments, wherein L is branched.The compound of any one of the previous embodiments, wherein L is linear.The compound of any one of the previous embodiments, wherein L comprises at least one cis alkene.The compound of any one of the previous embodiments, wherein L comprises at least one trans alkene.The compound of any one of the previous embodiments, wherein L is substituted withC6-10 arvl.In some embodiments, L is substituted by one or more phenyl groups.In some embodiments, L has a c / 77-di phenyl substitution.In some embodiments, L is substituted by a cyclopentyl ring.In some embodiments, L is substituted by a cyclohexyl ring.In some embodiments, L has two substituents which form a cyclohexyl ring.In some embodiments, L has two substituents on a single carbon which come together to form a cyclohexyl ring.Embodiments Related to R5and R6The compound of any one of the previous embodiments, wherein R5is H.The compound of any one of the previous embodiments, wherein R5and R6are both H.The compound of any one of the previous embodiments, wherein R5is methyl.The compound of any one of the previous embodiments, wherein R5is ethyl.The compound of any one of the previous embodiments, wherein R5is propyl.The compound of any one of the previous embodiments, wherein R5is isopropyl.The compound of any one of the previous embodiments, wherein R5is butyl.The compound of any one of the previous embodiments, wherein R5is isobutyl.The compound of any one of the previous embodiments, wherein R5is sec-butyl.The compound of any one of the previous embodiments, wherein R5is t-butyl.The compound of any one of the previous embodiments, wherein R5is a Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, or Ci5alkyl.The compound of any one of the previous embodiments, wherein R5is a C15-20 alkyl.The compound of any one of the previous embodiments, wherein R5is a C15 alkyl.The compound of any one of the previous embodiments, wherein R5is a Ci6 alkyl.The compound of any one of the previous embodiments, wherein R5is a C17 alkyl.The compound of any one of the previous embodiments, wherein R5is a Cis alkyl.The compound of any one of the previous embodiments, wherein R5is a C19 alkyl.The compound of any one of the previous embodiments, wherein R5is a C20 alkyl.The compound of any one of the previous embodiments, wherein R5is a C21 alkyl.The compound of any one of the previous embodiments, wherein R5is a C22 alkyl.The compound of any one of the previous embodiments, wherein R5is a C2, C3, C4, C5,C6. C7. Cs. C9, C10, Cn, C12, C13, C14, or C15 alkenyl.>mpound of any one of the previous embodiments, wherein R5is a C15-20 alkenyl.The compound of any one of the previous embodiments, wherein R5is a Ci6 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C17 alkenyl. The compound of any one of the previous embodiments, wherein R5is a Cis alkenyl. The compound of any one of the previous embodiments, wherein R5is a C19 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C20 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C21 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C22 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C23 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C24 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C25 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C26 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C27 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C28 alkenyl. The compound of any one of the previous embodiments, wherein R5is a C29 alkenyl. The compound of any one of the previous embodiments, wherein R5is a cyclopropyl. The compound of any one of the previous embodiments, wherein R5is a cyclobutyl. The compound of any one of the previous embodiments, wherein R5is a cyclopentyl. The compound of any one of the previous embodiments, wherein R5is a cyclohexyl. The compound of any one of the previous embodiments, wherein R5is an oxetanyl.The compound of any one of the previous embodiments, wherein R5is a tetrahydrofuranyl .The compound of any one of the previous embodiments, wherein R5is a 2- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R5is a 3- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R5is a tetrahydropyranyl .The compound of any one of the previous embodiments, wherein R5is a 2- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R5is a 3- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R5is a 4- inyl.The compound of any one of the previous embodiments, wherein R5is a phenyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R5is a phenyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R5is benzyl, wherein the benzyl is optionally substituted.The compound of any one of the previous embodiments, wherein R5is benzyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R5is benzyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R5is a pyridine.The compound of any one of the previous embodiments, wherein R5is 2-pyridine.The compound of any one of the previous embodiments, wherein R5is 3-pyridine.The compound of any one of the previous embodiments, wherein R5is 4-pyridine.The compound of any one of the previous embodiments, wherein R6is H.The compound of any one of the previous embodiments, wherein R6is a Ci, C2, C3, C4, C5, C6, C7, C8, C9, C10, C11, C12, C13, C14, or Ci5alkyl.The compound of any one of the previous embodiments, wherein R6is a C15-20 alkyl.The compound of any one of the previous embodiments, wherein R6is a C15 alkyl. The compound of any one of the previous embodiments, wherein R6is a Ci6 alkyl. The compound of any one of the previous embodiments, wherein R6is a C17 alkyl.The compound of any one of the previous embodiments, wherein R6is a Cis alkyl. The compound of any one of the previous embodiments, wherein R6is a C19 alkyl. The compound of any one of the previous embodiments, wherein R6is a C20 alkyl. The compound of any one of the previous embodiments, wherein R6is a C21 alkyl. The compound of any one of the previous embodiments, wherein R6is a C22 alkyl.The compound of any one of the previous embodiments, wherein R6is a C2, C3, C4, C5, C6, C7, C8, C9, C10, Cn, C12, C13, C14, or C15 alkenyl.The compound of any one of the previous embodiments, wherein R6is a C15-20 alkenyl.The compound of any one of the previous embodiments, wherein R6is a C20-29 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C15 alkenyl.The compound of any one of the previous embodiments, wherein R6is a Ci6 alkenyl.>mpound of any one of the previous embodiments, wherein R6is a C17 alkenyl.The compound of any one of the previous embodiments, wherein R6is a C20 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C21 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C22 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C23 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C24 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C25 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C26 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C27 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C28 alkenyl. The compound of any one of the previous embodiments, wherein R6is a C29 alkenyl. The compound of any one of the previous embodiments, wherein R6is a cyclopropyl. The compound of any one of the previous embodiments, wherein R6is a cyclobutyl.The compound of any one of the previous embodiments, wherein R6is a cyclopentyl. The compound of any one of the previous embodiments, wherein R6is a cyclohexyl. The compound of any one of the previous embodiments, wherein R6is an oxetanyl. The compound of any one of the previous embodiments, wherein R6is a tetrahydrofuranyl .The compound of any one of the previous embodiments, wherein R6is a 2- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R6is a 3- tetrahy drofuranyl .The compound of any one of the previous embodiments, wherein R6is a tetrahydropyranyl .The compound of any one of the previous embodiments, wherein R6is a 2- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R6is a 3- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R6is a 4- tetrahy dropyranyl .The compound of any one of the previous embodiments, wherein R6is phenyl, wherein the ohenvl is optionally substituted.The compound of any one of the previous embodiments, wherein R6is a phenyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R6is benzyl, wherein the benzyl is optionally substituted.The compound of any one of the previous embodiments, wherein R6is benzyl, optionally substituted by a Ci-Ce alkoxy.The compound of any one of the previous embodiments, wherein R6is benzyl, optionally substituted by -OMe.The compound of any one of the previous embodiments, wherein R6is a pyridine.The compound of any one of the previous embodiments, wherein R6is 2-pyridine.The compound of any one of the previous embodiments, wherein R6is 3-pyridine.The compound of any one of the previous embodiments, wherein R6is 4-pyridine.In some embodiments, the compound of Formula (1) is of Formula (1 -ii-a-ii),Formula (1-ii-a-ii) wherein:X' is absent or is an anion;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are as defined for Formula (1); and n is 0 to 20.In some embodiments of the compound of Formula (1 -ii-a-ii),R2is CH3;R3is C1-6alkyl; each R5and R6independently are hydrogen, Ci-i8 alkyl, C2-30 alkenyl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl, wherein the Cuis" alkenyl is optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-R5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl; and n is 0 to 20.These embodiments are applicable to the compounds of Formula (1-ii-a-ii):Embodiments Related to X~The compound of any one of the previous embodiments, wherein X' is a pharmaceutically acceptable anion.Embodiments Related to R5and R6The compound of any one of the previous embodiments, wherein R5is a C1-6alkyl.The compound of any one of the previous embodiments, wherein R6is a C1-6alkyl.Embodiments Related to R2The compound of any one of the previous embodiments, wherein R2is CH3.Embodiments Related to nThe compound of any one of the previous embodiments, wherein n is 0 to 4.The compound of any one of the previous embodiments, wherein n is 5 to 9.The compound of any one of the previous embodiments, wherein n is 10 to 14.The compound of any one of the previous embodiments, wherein n is 15 to 20.The compound of any one of the previous embodiments, wherein n is 0.The compound of any one of the previous embodiments, wherein n is 1.The compound of any one of the previous embodiments, wherein n is 2.The compound of any one of the previous embodiments, wherein n is 3.The compound of any one of the previous embodiments, wherein n is 4.The compound of any one of the previous embodiments, wherein n is 5.The compound of any one of the previous embodiments, wherein n is 6.The compound of any one of the previous embodiments, wherein n is 7.The compound of any one of the previous embodiments, wherein n is 8.The compound of any one of the previous embodiments, wherein n is 9.>mpound of any one of the previous embodiments, wherein n is 10.The compound of any one of the previous embodiments, wherein n is 13. The compound of any one of the previous embodiments, wherein n is 14. The compound of any one of the previous embodiments, wherein n is 15. The compound of any one of the previous embodiments, wherein n is 16. The compound of any one of the previous embodiments, wherein n is 17. The compound of any one of the previous embodiments, wherein n is 18. The compound of any one of the previous embodiments, wherein n is 19. The compound of any one of the previous embodiments, wherein n is 20.In some embodiments, the compound of Formula (!’) is of Formula (1-ii-a-iii’),Formula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are as defined for Formula (1);L is a bond, Ci-24 alkylene, or -Ci-24 alkylene-O-*, wherein * indicates attachment toRing A and the alkylene is unsubstituted or optionally substituted; andRing A is:(i) Ce-i4 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-i5 cycloalkyl;(iv) 5- to 10-membered heteroaryl;(v) cholesterol, dihydrocholesterol, or a bile acid; wherein the aryl, heterocycle, cycloalkyl, heteroaryl, cholesterol, dihydrocholesterol, or bile acid are unsubstituted or are optionally substituted. ne embodiments of the compound of Formula (1-ii-a-iii’), X' is absent or is aneach R5and R6independently are hydrogen, Ci-is alkyl, C2-30 alkenyl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl, wherein the C1-18 alkyl or C2-30 alkenyl is optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10- membered heterocyclyl, or 3- to 10-membered heteroaryl, and the Ce-io aryl is optionally substituted with OH, or C1-6alkoxy, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl;L is a bond, C1-24 alkylene optionally substituted with one or more -Ce-io aryl, or -C1-24 alkylene-O-* wherein -* indicates attachment to Ring A; andRing A is:(i) Ce-i4 aryl, wherein the aryl is optionally substituted by one or more mono- or di-C1-6alkyl amino, 4- to 10-membered heterocycle, -O-C(O)-(Ci-24 alkyl), -C(O)-O-(Ci- 24 alkyl), -O-C(O)-(C3-8 cycloalkyl), -O-C(O)-O-(Ci-6alkylene)-O-C(O)-(Ci-24 alkyl), -O- C(O)-(Ci-24 alkylene)-C(O)-O-(Ci-6alkyl), -O-C(O)-(Ci-6alkylene)-C(O)-O- (cholesterol), -O-C(O)-(Ce-i4 aryl), or Ce-io aryl optionally substituted with one or more halogen, or C1-6alkyl,(ii) 4- to 10-membered heterocycle, wherein the heterocycle is optionally substituted by one or more -OH, oxo, mono- or di-C1-6alkyl amino, 4- to 10-membered heterocycle, C1-6alkyl, or -(C1-6alkylene)-OH,(iii) C3-15 cycloalkyl optionally substituted by one or more C1-8 alkyl, or(iv) 5- to 10-membered heteroaryl optionally substituted by one or more oxo, - C1-6alkyl, C1-6alkoxy, or -C(O)-(Ce-i4 aryl), wherein the Ce-14 aryl is optionally substituted by one or more halogen.In some embodiments, the compound of Formula (1) is of Formula (1 -ii-a-iii),Formula (1-ii-a-iii) wherein: absent or is an anion;:H3, CH2D, CHD2, or CD3;L is a bond, C1-24 alkylene, or -C1-24 alkylene-O-*, wherein * indicates attachment to Ring A; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl;(iv) 5- to 10-membered heteroaryl;(v) cholesterol, dihydrocholesterol, or a bile acid; wherein the aryl, heterocycle, cycloalkyl, heteroaryl, cholesterol, dihydrocholesterol, or bile acid are unsubstituted or are optionally substituted.In some embodiments of the compound of Formula ( 1 -ii-a-iii), X' is absent or is an anion;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are hydrogen, Ci-is alkyl, C2-3o alkenyl, C3-s cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl, wherein the Ci-is alkyl or C2-3o alkenyl is optionally substituted with Ce-io aryl, C3-s cycloalkyl, 3- to 10- membered heterocyclyl, or 3- to 10-membered heteroaryl, and the Ce-io aryl is optionally substituted with OH, or C1-6alkoxy, orR5and R6combine to form oxo, C3-s cycloalkyl, or 3- to 10-membered heterocyclyl;L is a bond, C1-24 alkylene, or -C1-24 alkylene-O-* wherein -* indicates attachment to Ring A; andRing A is:(i) Ce-14 aryl, wherein the aryl is optionally substituted by one or more mono- or di-C1-6alkyl amino, 4- to 10-membered heterocycle, or C1-6alkyl,(ii) 4- to 10-membered heterocycle, wherein the heterocycle is optionally substituted by one or more mono- or di-C1-6alkyl amino, 4- to 10-membered heterocycle, or C1-6alkyl,(iii) C3-i5 cycloalkyl optionally substituted by one or more C1-8 alkyl, or(iv) 5- or 6-membered heteroaryl optionally substituted by one or more oxo or Ci -6 alkyl.Embodiments Related to X~The compound of any one of the previous embodiments, wherein X' is a pharmaceutically acceptable anion.Embodiments Related to LThe compound of any one of the previous embodiments, wherein L is a bond.The compound of any one of the previous embodiments, wherein L is a C1-4 alkylene. The compound of any one of the previous embodiments, wherein L is a C5-9 alkylene. The compound of any one of the previous embodiments, wherein L is a C10-14 alkylene. The compound of any one of the previous embodiments, wherein L is a C15-20 alkylene. The compound of any one of the previous embodiments, wherein L is a Ci alkylene. The compound of any one of the previous embodiments, wherein L is a C2 alkylene. The compound of any one of the previous embodiments, wherein L is a C3 alkylene. The compound of any one of the previous embodiments, wherein L is a C4 alkylene. The compound of any one of the previous embodiments, wherein L is a C5 alkylene. The compound of any one of the previous embodiments, wherein L is a Ce alkylene. The compound of any one of the previous embodiments, wherein L is a C7 alkylene. The compound of any one of the previous embodiments, wherein L is a Cs alkylene. The compound of any one of the previous embodiments, wherein L is a C9 alkylene. The compound of any one of the previous embodiments, wherein L is a C10 alkylene. The compound of any one of the previous embodiments, wherein L is a Cn alkylene. The compound of any one of the previous embodiments, wherein L is a C12 alkylene. The compound of any one of the previous embodiments, wherein L is a C13 alkylene. The compound of any one of the previous embodiments, wherein L is a C14 alkylene. The compound of any one of the previous embodiments, wherein L is a C15 alkylene. The compound of any one of the previous embodiments, wherein L is a Ci6 alkylene. The compound of any one of the previous embodiments, wherein L is a C17 alkylene. The compound of any one of the previous embodiments, wherein L is a Cis alkylene. The compound of any one of the previous embodiments, wherein L is a C19 alkylene. The compound of any one of the previous embodiments, wherein L is a C20 alkylene.The compound of any one of the previous embodiments, wherein L is a C1-24 alkylene stituted with one or more phenyl.The compound of any one of the previous embodiments, wherein L is a C1-24 alkylene, wherein the C1-24 alkylene is gem-di phenyl substituted.The compound of any one of the previous embodiments, wherein L is a C1-12 alkylene optionally substituted with two Ce phenyl.The compound of any one of the previous embodiments, wherein L is a C7 alkylene optionally substituted with two Ce phenyl.The compound of any one of the previous embodiments, wherein L is a C7 alkylene, wherein the C7 alkylene is gem-di phenyl substituted.The compound of any one of the previous embodiments, wherein L is a C1-4 alkylene- O*.The compound of any one of the previous embodiments, wherein L is a C5-9 alkylene- O*.The compound of any one of the previous embodiments, wherein L is a C10-14 alkylene- O*.The compound of any one of the previous embodiments, wherein L is a C15-20 alkylene- O*.The compound of any one of the previous embodiments, wherein L is a Ci alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C2 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C3 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C4 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C5 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a Ce alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C7 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a Cs alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C9 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C10 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a Cn alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C12 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C13 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C14 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a C15 alkylene-O*. The compound of any one of the previous embodiments, wherein L is a Ci6 alkylene-O*. >mpound of any one of the previous embodiments, wherein L is a C17 alkylene-O*.The compound of any one of the previous embodiments, wherein L is a C20 alkylene-O* The compound of any one of the previous embodiments, wherein L is a C1-4 alkenylene. The compound of any one of the previous embodiments, wherein L is a C5-9 alkenylene. The compound of any one of the previous embodiments, wherein L is a C10-14 alkenylene.The compound of any one of the previous embodiments, wherein L is a C15-20 alkenylene.The compound of any one of the previous embodiments, wherein L is a Ci alkenylene. The compound of any one of the previous embodiments, wherein L is a C2 alkenylene. The compound of any one of the previous embodiments, wherein L is a C3 alkenylene. The compound of any one of the previous embodiments, wherein L is a C4 alkenylene. The compound of any one of the previous embodiments, wherein L is a C5 alkenylene. The compound of any one of the previous embodiments, wherein L is a Ce alkenylene. The compound of any one of the previous embodiments, wherein L is a C7 alkenylene. The compound of any one of the previous embodiments, wherein L is a Cs alkenylene. The compound of any one of the previous embodiments, wherein L is a C9 alkenylene. The compound of any one of the previous embodiments, wherein L is a C10 alkenylene. The compound of any one of the previous embodiments, wherein L is a Cn alkenylene. The compound of any one of the previous embodiments, wherein L is a C12 alkenylene. The compound of any one of the previous embodiments, wherein L is a C13 alkenylene. The compound of any one of the previous embodiments, wherein L is a C14 alkenylene. The compound of any one of the previous embodiments, wherein L is a C15 alkenylene. The compound of any one of the previous embodiments, wherein L is a Ci6 alkenylene. The compound of any one of the previous embodiments, wherein L is a C17 alkenylene. The compound of any one of the previous embodiments, wherein L is a Cis alkenylene. The compound of any one of the previous embodiments, wherein L is a C19 alkenylene. The compound of any one of the previous embodiments, wherein L is a C20 alkenylene. The compound of any one of the previous embodiments, wherein L is a C1-4 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C5-9 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C10-14The compound of any one of the previous embodiments, wherein L is a Ci alkenylene- o*.The compound of any one of the previous embodiments, wherein L is a C2 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C3 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C4 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C5 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a Ce alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C7 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a Cs alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C9 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C10 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a Cn alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C12 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C13 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is a C14 alkenylene- O*.The compound of any one of the previous embodiments, wherein L is straight chain (z.e., linear).The compound of any one of the previous embodiments, wherein L is branched.Related to Ring Awherein m is 0 to 6; andRAis -C(O)-(optionally substituted Ce-io aryl), -C(O)-(optionally substituted 5- to 10- membered heteroaryl), -C(O)-(optionally substituted 3- to 10-membered heterocyclyl), -C(O)- (optionally substituted C3-C15 cycloalkyl), -(optionally substituted Ce-io aryl), -(optionally substituted 5- to 10-membered heteroaryl), -(optionally substituted 3- to 10-membered heterocyclyl), -C(optionally substituted C3-C15 cycloalkyl), halogen, cyano, hydroxyl, C1-6alkoxy, monoalkylamino, dialkylamino, or C1-6alkyl.In some embodiments, RAis dimethylamino.In some embodiments, RAis methoxy.In some embodiments, RAis methyl.In some embodiments, RAis phenyl substituted with chloro.In some embodiments, RAis piperidinyl.The compound of any one of the previous embodiments, wherein Ring A is Ce-14 aryl.The compound of any one of the previous embodiments, wherein Ring A is phenyl.The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with -C(O)-O-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with -C(O)-O-(Ci-4 alkyl). The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with -C(O)-O-(Ci-3 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with -C(O)-O-(Ci alkyl).The compound of any one of the previous embodiments, wherein Ring A is biphenyl optionally substituted with one -C(O)-O-(C4 alkyl) and two halo.The compound of any one of the previous embodiments, wherein Ring A is biphenyl optionally substituted with one -C(O)-O-(C4 alkyl) and two fluoro.The compound of any one of the previous embodiments, wherein Ring A is Cio aryl.The compound of any one of the previous embodiments, wherein Ring A is naphthyl.The compound of any one of the previous embodiments, wherein Ring A is C14 aryl.The compound of any one of the previous embodiments, wherein Ring A is anthracenyl.The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(Ci-24 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -0-C(0)-(Ci-2o alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(Ci-i4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(Ci-4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(Ci-3 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(Ci alkyl). The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more - C(O)-O-(Ci-24 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -C(0)-0-(Ci-2o alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -C(O)-O-(Ci-i4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -C(O)-O-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl stituted with one or more -C(O)-O-(Ci-4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -C(O)-O-(Ci alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(C3-8 cycloalkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(C3-7 cycloalkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(C4-7 cycloalkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(Cs-8 cycloalkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-(cyclohexyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-O-(C1-6alkylene)-O-C(O)-(Ci-24 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-O-(Ci-3 alkylene)-O-C(O)-(Ci-24 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-O-(Ci alkylene)-O-C(O)-(Ci-24 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-O-(Ci alkylene)-0-C(0)-(Ci-2o alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-O-(Ci alkylene)-O-C(O)-(Ci-i6 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-O-(Ci alkylene)-O-C(O)-(Ci6 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-O-(Ci alkylene)-O-C(O)-(Cis alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-O-(Ci alkylene)-O-C(O)-(Ci4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one or more -O-C(O)-O-(C1-6alkylene)-O-C(O)-(Ci-24 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl ODtionallv substituted with one or more -O-C(O)-(Ci-24 alkylene)-C(O)-O-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(Ci-i9 alkylene)-C(O)-O-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(Ci-i8 alkylene)-C(O)-O-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(Ci-i6 alkylene)-C(O)-O-(C1-6alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(Ci8 alkylene)-C(O)-O-(Ci-4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(Ci8 alkylene)-C(O)-O-(C4 alkyl).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(C1-6alkylene)-C(O)-O-(cholesterol).The compound of any one of the previous embodiments, wherein Ring A is phenyl optionally substituted with one -O-C(O)-(C2 alkylene)-C(O)-O-(cholesterol).The compound of any one of the previous embodiments, wherein cholesterol isThe compound of any one of the previous embodiments, wherein Ring A is -O-C(O)- phenyl.The compound of any one of the previous embodiments, wherein Ring A is C3-15 cycloalkyl optionally substituted by one or more C1-8 alkyl.>mpound of any one of the previous embodiments, wherein Ring A is C1-15The compound of any one of the previous embodiments, wherein Ring A is Ce cycloalkyl optionally substituted by one or more Ci-8 alkyl.The compound of any one of the previous embodiments, wherein Ring A is cyclopropyl.The compound of any one of the previous embodiments, wherein Ring A is cyclobutyl.The compound of any one of the previous embodiments, wherein Ring A is cyclopentyl. The compound of any one of the previous embodiments, wherein Ring A is cyclohexyl. The compound of any one of the previous embodiments, wherein Ring A is cycloheptyl. The compound of any one of the previous embodiments, wherein Ring A is cyclooctyl. The compound of any one of the previous embodiments, wherein Ring A is cyclononyl. The compound of any one of the previous embodiments, wherein Ring A is cyclopropyl. The compound of any one of the previous embodiments, wherein Ring A is cyclodecane. The compound of any one of the previous embodiments, wherein Ring A is cycloundecane.The compound of any one of the previous embodiments, wherein Ring A is C13 cycloalkane.The compound of any one of the previous embodiments, wherein Ring A is C14 cycloalkane.The compound of any one of the previous embodiments, wherein Ring A is C15 cycloalkane.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 4- to 10-membered heterocycle.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 4-membered heterocycle.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 5-membered heterocycle.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 6-membered heterocycle.The compound of any one of the previous embodiments, wherein Ring A comprises a carbohydrate.The compound of any one of the previous embodiments, wherein Ring A comprises a 6- membered carbohydrate.The compound of any one of the previous embodiments, wherein Ring A comprises aalkylene)-OH.The compound of any one of the previous embodiments, wherein Ring A is a 6- membered heterocycle optionally substituted with three -OH and one -(CH2)-0H.The compound of any one of the previous embodiments, wherein Ring A isThe compound of any one of the previous embodiments, wherein Ring A isThe compound of any one of the previous embodiments, wherein Ring A is a 4- to 10- membered heterocyclic ring optionally substituted with one or more oxo.The compound of any one of the previous embodiments, wherein Ring A is a 6- to 10- membered heterocyclic ring optionally substituted with one or more oxo.The compound of any one of the previous embodiments, wherein Ring A is a 6- to 10- membered heterocyclic ring comprising one sulfur atom, wherein the 6- to 10-membered heterocyclic ring is optionally substituted with one or more oxo.The compound of any one of the previous embodiments, wherein Ring A is an 8- membered heterocyclic ring optionally substituted with one or more oxo.The compound of any one of the previous embodiments, wherein Ring A is an 8- membered heterocyclic ring comprising one sulfur atom.The compound of any one of the previous embodiments, wherein Ring A is an 8- membered heterocyclic ring comprising one sulfur atom and two nitrogen atoms.The compound of any one of the previous embodiments, wherein Ring A is an 8- membered heterocyclic ring comprising one sulfur atom and two nitrogen atoms, wherein the 8- membered heterocyclic ring is optionally substituted with one oxo.The compound of any one of the previous embodiments, wherein Ring A isThe compound of any one of the previous embodiments, wherein Ring A is 4- to 10- membered heterocyclic ring optionally substituted by mono or dialkyl amino, 4- to 10- membered heterocycle, or C1-6alkyl.The compound of any one of the previous embodiments, wherein Ring A is 4- to 6- membered heterocyclic ring optionally substituted by mono or dialkyl amino, 4- to 10- membered heterocycle, or C1-6alkyl.The compound of any one of the previous embodiments, wherein Ring A is a 4- to 6- membered heterocyclyl optionally substituted by mono or dialkyl amino, 4- to 10-membered heterocycle, or C1-6alkyl.The compound of any one of the previous embodiments, wherein Ring A comprises one or more oxygen atom.The compound of any one of the previous embodiments, wherein Ring A comprises one oxygen atom and one nitrogen atom.The compound of any one of the previous embodiments, wherein Ring A is oxiranyl, oxetanyl, tetrahydrofuranyl, or tetrahydropyranyl.The compound of any one of the previous embodiments, wherein Ring A comprises one or more nitrogen atoms.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 5- to 10-membered heteroaryl ring.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 8-membered heteroaryl ring.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 9-membered heteroaryl ring.The compound of any one of the previous embodiments, wherein Ring A is an optionally substituted 10-membered heteroaryl ring.C(O)-(phenyl), wherein the phenyl is optionally substituted with one or more halo.The compound of any one of the previous embodiments, wherein Ring A is a 9- membered heteroaryl ring substituted with one methoxy, one -Ci alkyl, and one -C(O)-(phenyl), wherein the phenyl is optionally substituted with one or more halo.The compound of any one of the previous embodiments, wherein Ring A is a 9- membered heteroaryl ring substituted with one methoxy, one -C1-3 alkyl, and one -C(O)- (phenyl), wherein the phenyl is optionally substituted with one chloro.The compound of any one of the previous embodiments, wherein Ring A is a 9- membered heteroaryl ring substituted with one methoxy, one -Ci-alkyl, and one -C(O)-(phenyl), wherein the phenyl is substituted with one chloro.The compound of any one of the previous embodiments, wherein Ring A isThe compound of any one of the previous embodiments, wherein Ring A is pyridinyl optionally substituted by mono or dialkylamino or C3-8 heterocyclyl.The compound of any one of the previous embodiments, wherein Ring A morpholinyl.The compound of any one of the previous embodiments, wherein Ring A is piperazinyl optionally substituted by one or more C1-6alkyl.The compound of any one of the previous embodiments, wherein Ring A is l,3-dioxol-2- one optionally substituted with one or more C1-6alkyl.The compound of any one of the previous embodiments, wherein Ring A comprises one or more sulfur atoms.The compound of any one of the previous embodiments, wherein Ring A is thiophenyl, thiazole, or thiadi azole.The compound of any one of the previous embodiments, wherein Ring A is cholesterol.The compound of any one of the previous embodiments, wherein Ring A is dihydrocholesterol.- >mpound of any one of the previous embodiments, wherein Ring A is a bile acid.>mpound of any one of the previous embodiments, wherein Ring A is cholic acid.The compound of any one of the previous embodiments, wherein Ring A is taurocholic acid.The compound of any one of the previous embodiments, wherein Ring A is deoxycholic acid.The compound of any one of the previous embodiments, wherein Ring A is chenodeoxycholic acid.The compound of any one of the previous embodiments, wherein Ring A is glycochenodeoxycholic acid.The compound of any one of the previous embodiments, wherein Ring A is taurochenodeoxycholic acid.The compound of any one of the previous embodiments, wherein Ring A is lithocholic acid.In some embodiments, the compound of Formula (!’) is of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1, and Y4each independently are O, NRN, or CH2;Y2and Y3each independently are O, NRN, or a bond; each RNindependently is H or C1-6alkyl;R2is CH3. CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are each hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-24alkyl, -O-C(O)-C2-30 alkenyl, -C(O)-Ci-24alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(R11-i)2-Ci-24 alkyl, - Si(Riij)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Riij)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Riij)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Rllj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)- C1-24 alkyl, -(Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 )2-Ci-24 alkylene, -(Ci-24 alkylene)-(O-CH2CH2)i-50-O-Rlv, -C(O)-(Ci-24 alkylene)- 50-O-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-memberedC(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted; each Rlljindependently is C1-6alkyl or two R"1, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2-24 alkenyl;L is a bond, C1-24 alkylene, C2-24 alkenylene, Ce-io arylene, -(C1-6alkyl)-(Ce-io arylene)- or C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is optionally substituted;R4is H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-10 alkylene)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(O)-O-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-(cholesterol), -(C1-10 alkylene)-(dihydrocholesterol), -(C1-10 alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-O-(C1-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkyl ene)-O-C(O)-O-(C 1-6 alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkyl ene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(O)-O-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkyl ene)-C(O)-O-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkvlenel-R^NR^, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - )-0-C(0)-0-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -0CHRiid2, -heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, alkenylene, or alkyl is unsubstituted or is optionally substituted; n is 1 to 20;R is H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(0)-0-Ci6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;R2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Rlld)3, wherein the alkyl, alkenyl, or alkylene is optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl.In some embodiments of Formula (1 -ii-a-iv’),X' is absent or is an anion;Y1, and Y4each independently are O, NRN, or CH2;Y2and Y3each independently are O, NRN, or a bond; each RNindependently is H or C1-6alkyl;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are hydrogen, C1-18 alkyl, C2-3o alkenyl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl, wherein the Cuis alkyl or C2-3o alkenyl is optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10- membered heterocyclyl, or 3- to 10-membered heteroaryl, and the Ce-io aryl is optionally substituted with OH, or C1-6alkoxy, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl;L is a bond, C1-24 alkylene, C2-24 alkenylene, Ce-io arylene, or C2-24 alkynylene;alkylene)-(5- to 10-membered heteroaryl), -(Ci-io alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(Ci-io alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-(cholesterol), -(C1-10 alkylene)-(dihydrocholesterol), -(C1-10 alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-O-(C1-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkyl ene)-O-C(O)-O-(C 1-6 alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkyl ene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkyl ene)-C(0)-0-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - (C1-6alkylene)-C(O)NRN-(Ci-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), -C(O)- O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl; n is 1 to 20;RAis H, -C(0)-NRN-CHRAA2-C(0)-0H; CI.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-CI.6 alkyl, -C(0)-NH2, -S-Ci.6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Riid)3; each Rlldindependently is C1-6alkyl; and the heterocyclyl, heteroaryl, alkylene, alkenylene, alkynylene, cholesterol, dihydrocholesterol, bile acid, amino, monoalkylamine, dialkylamine, trialkylammonium, or C1-24 alkyl are unsubstituted or are optionally substituted.In some embodiments of the compound of Formula ( 1 -ii-a-iv’), X' is absent or is an anion;R2is CH3, CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more deuterium;L is a C1-20 alkylene opti...

Claims

Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544ClaimsWhat is claimed is:

1. A compound of F ormula ( 1’ ) :Formula (1’) wherein:X' is absent or is an anion;R1is:(i) -o-;wherein: each R5and R6independently are hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(Ci-24 alkylene)-Si(Ruj)2-Ci-24 alkyl, -Si(Ruj)2-Ci-24 alkyl, -(62-30 alkenylene)-Si(Ruj)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Ruj)2-C2-24 alkenyl, -Si(R11-’)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Ruj)2-C2-24 alkenyl, -(C1-24 alkylene)-S(O)-Ci-24 alkyl, -(C1-24 alkylene)- S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(C1-24 alkylene)-(0-CH2CH2)i-5o-0-Riv, -C(O)-(Ci-24alkylene)-(O-CH2CH2)i- 50- O-Riv, C6-10 aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-s cycloalkyl, -C1-6alkylene-(C6-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-s cycloalkyl), or -C(O)-(4- to 10- membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orDate of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544R5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted; each R“j independently is C1-6alkyl or two Rllj, together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2-24 alkenyl;R4is:(ii-a) -C(O)-Ci-24 alkyl, -C(O)-Ci-24haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, -C(O)-(Ci-24 alkylene)-Ce-i4 aryl, -C(O)-(C2-24 alkenylene)-C6-i4 aryl, - C(O)-(C2-24 alkynylene)-C6-io aryl, -C(O)-(Ci-24alkylene)-C(O)-O-Ci-24 alkyl, - C(O)-(Ci-24 alkylene)-C(O)-O-C2-24 alkenylene, -C(O)-(C2-24 alkenylene)-C(O)-O- C1-24 alkyl, -C(O)-C(O)-O-Ci-24 alkyl, -C(O)-C(O)-OH, -C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-O- C1-24 alkyl, -C(O)-(C2-24 alkynylene)-C(O)-OH, -C(O)-(Ci-24alkylene)-C(O)- (cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-C(O)-(bile acid), - C(O)-(C2-24alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkenylene)-C(O)-(bile acid), -C(O)-(Ci-24alkylene)-O-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)-O-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24alkynylene)- C(O)-(bile acid), -C(O)-(Ci-24 alkylene)-C(O)OH, -C(O)-O-(Ci-24alkylene)-C(O)- O-(Ci-4alkyl), -C(0)-0-(CH2CH20)O-20-(CI.4 alkyl), C(O)-(C2-24 alkenylene)- C(O)OH, -C(O)-Ce-i4aryl, -C(O)-C3-i5 cycloalkyl, -C(O)-(3- to 10-membered heterocycle), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24 alkylene)-(Ce-i4 aryl), -C(O)-(Ci-22 alkylene)-(3- to 10-membered heterocycle), -C(O)-(Ci-24alkylene)-(5- to 10- membered heteroaryl), -C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(C6-i4aryl), -C(O)-(C2-24 alkenylene)-(3- to 10- membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(C1 -24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)- (bile acid), -C(O)-(Ci-24 alkylene)-O-(Ce-i4aryl), -C(O)-(Ci-24 alkylene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-memberedDate of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 heteroaryl), -C(O)-(Ci-24 alkylene)-O-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24alkylene)-(O- CH2CH2)i -5o-0-Rlia, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted,Rliais H, deuterium, C1-24 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24alkyl, -C(O)-O-Ci-24haloalkyl, -C(0)-0-C2-3o alkenyl, -C(O)- O-C2-24 alkynyl, -C(O)-O-(Ci-24 alkylene)-Ce-i4 aryl, -C(O)-O-(C2-24 alkenylene)- C6-i4 aryl, -C(O)-O-(Ci.24alkylene)-C(O)-O-Ci.24 alkyl, -C(O)-O-(C2-24 alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci-24alkylene)-C(O)OH, -C(O)-O-(C2- 24 alkenylene)-C(O)OH, -C(O)-O-C6-i4 aryl, -C(O)-O-C3-i5 cycloalkyl, -C(O)-O- (3- to 10-membered heterocycle), -C(O)-O-(5- to 10-membered heteroaryl), - C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(Ce-i4aryl) -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered heterocycle) - C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(C2-24 alkenylene)-(C6-i4 aryl) -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(O)-O-(C2- 24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-O-(Ci-24 alkylene)- (cholesterol or dihydrocholesterol), -C(O)-O-(C2-24 alkylene)-(bile acid), -C(O)- (C1-24 alkylene)-O-(Ce-i4aryl), -C(O)-(Ci-24 alkylene)-O-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-O-(5- to 10-membered heteroaryl), -C(O)- (C1-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-O- (bile acid), C(O)-(Ci-24alkylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)- (Ci-24alkylene)-C(O)-(bile acid), -C(O)-(cholesterol or dihydrocholesterol), - C(O)-(bile acid), -(bile acid), or -C(O)-O-(Ci-24alkylene)-(O-CH2CH2)i-50-O-Riib', wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRiib’ is H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-c) -S1(RS1)3,Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein each RS1independently is C1-24 alkyl, C2-30 alkenyl, Ce-io aryl, -O-C1-24 alkyl, -O-C2 -30 alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;(ii-d) -C(O)-CH(Riid)2, -C(O)-(Ci-24 alkylene)-C(O)-O-CH(Riid)2or -C(O)-(Ci.24alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlld)2, wherein the alkylene is unsubstituted or is optionally substituted, wherein each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or -CH2-O-P(O)2-O-(CI-6alkylene)-N+(Riid’)3wherein each Rlldindependently is C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-e) -C(O)-O-CH(Riie)2, -C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Riie)2or -C(O)-O- (C1-24 alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rlie)2, wherein the alkylene is unsubstituted or is optionally substituted; wherein each Rlieindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, -CH2-O-P(O)2-O-(CI-24 alkylene)-N(Riie’)2or - CH2-O-P(O)2-O-(CI-24 alkylene)-N+(Rlie)3, wherein the alkyl, alkenyl, or alkylene is unsubstituted or is optionally substituted; wherein each Rlieis independently H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-f) -C(O)O-C(O)-CHRiif-N(Riif)2, -C(O)O-(Ci-i2alkylene)-C(O)-CHRiif- N(Riif’)2, -C(O)O-(Ci-i2 alkylene)-O-C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-N(Riif’)2, -C(O)-CHRiif-NRiif-C(O)-O-Ci-24 alkyl, -C(O)-(Ci.24alkylene)-NRiif’-C(O)- CHRiif-N(Riif)2, or -C(O)-(Ci.24alkylene)-NRiif’-C(O)-CHRiif-N(Riif’)-C(O)-O- C1-24 alkyl, or salts thereof, wherein the alkyl and alkylene are unsubstituted or optionally substituted, wherein each Rllfindependently is H or C1-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1-6alkyl, -C(O)-NH2, -S-C1-6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4-Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 to 10-membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted or salts thereof; and each Rllfindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted, or one Rllf’ and Rllf, together with the atoms to which they are attached, combine to form a 4- to 10- membered heterocyclyl, wherein the heterocyclyl is unsubstituted or is optionally substituted;(ii-g) -P(O)(ORiig)2, -P(O)2(ORiig), -P(O)(ORiig)-O-(Ci-20alkylene)-O-Ci-20alkyl, -P(O)(O-(Ci-20alkylene)-O-C(O)-Riig))2, -P(O)(O-(Ci-20alkylene)-O-C(O)-O- Rllg))2, -P(O)2(O-(Ci-20alkylene)-O-C(O)-O-Riig)), -P(O)2(O-(Ci-20alkylene)- C(O)-O-Riig)),-P(O)(N(Riig)2)2, or -P(O)2(O-(Ci-20alkylene)-O-C(O)-Riig)), wherein the alkyl or alkylene is unsubstituted or is optionally substituted, wherein each Rllgindependently is H, C1-20 alkyl, or Ce-io aryl, or two Rllg, together with the atoms to which they are attached, combine to form 5- to 10-membered heterocyclyl wherein alkyl and heterocyclyl are unsubstituted or is optionally substituted;(ii-h) -S(O)2-N(Riih)2, wherein each Rllhindependently is H or C1-20 alkyl;(ii-i) -C(0)-(Ci-2o alkylene)-(C6-io aryl) or -C(0)-(Ci-2o alkylene)-0-(C6-io aryl), wherein the alkylene is unsubstituted or is optionally further substituted, the Ce-io aryl is substituted by one or more R111, and the aryl is optionally further optionally substituted, wherein R111is -O-C(O)-C1-6alkyl, -O-C(O)-C3-s cycloalkyl, -O-C(0)-Ce-io aryl or C1-6alkyl, wherein the alkyl, cycloalkyl, and aryl is unsubstituted or is optionally further substituted; or(ii-j) -(Ci-24 alkylene)-Si(Ruj)2-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)-Ci-24 alkyl, - (Ci-24alkylene)-S(O)2-Ci-24alkyl, -O-(Ci-24alkylene)-Si(Riij)2-Ci-24alkyl, -O-(Ci-24 alkylene)-Si(O)-Ci-24 alkyl, or -O-(Ci-24 alkylene)-Si(O)2-Ci-24 alkyl,, wherein the alkylene and alkyl are unsubstituted or are optionally further substituted,Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein each Rlljindependently is C1-6alkyl or two R11-’, together with the atom to which they are attached, combine to form a C3-8 cycloalkyl, wherein the alkyl and cycloalkyl are unsubstituted or are optionally substituted;each R5, R6, R5, and R6independently are hydrogen, deuterium, C1-24 alkyl, -Ci-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)- C2-24 alkynyl, -(C1-24 alkylene)-Si(Ruj)2-Ci-24 alkyl, -Si(Ruj)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Ruj)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Ruj)2-C2-24 alkenyl, - Si(R“j)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Ruj)2-C2-24 alkenyl, -(C1-24 alkylene)- S(O)-Ci-24 alkyl, -(C1-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci-24alkylene)-(O-CH2CH2)i-50- O-Riv, -C(O)-(Ci-24alkylene)-(O-CH2CH2)i-50-O-Riv, C6-io aryl, 5- to 10- membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(C6-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-8 cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;R7is C1-20 alkyl, C3-10 cycloalkyl, Ce-io aryl, bile acid, cholesterol, dihydrocholesterol, -(C1-20 alkylene)-O-(C1-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-(Ci-6alkyl), 3- to 10-membered heterocyclyl; 5- to 10-membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)- C(O)-O-(3- to 10-membered heterocyclyl); -(C1-20 alkylene)-C(O)-O-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-20Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10- membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl); -(Ci- 20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-C alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(C1-20 alkylene)-N+(C1-6alkyl)s, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alky lene)O-C(O)-(C 1-20 alkylene)-N+(C1-6alkyl)s, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alky lene)-N+(C 1-6 alkyl)s, -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(C1-6alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)- cholesterol, or -(C1-6alkylene)-NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NN- cholesterol, -(C1-6alkylene)-NRN- dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)- NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, or -NN- dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; whereinoptionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-Ci.6alkyl, -C(O)- NH2, -S-C1-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; andRAA2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)-NH2, - S-C1-6 alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl.;(ii-o) — (C1-6alkylene)-(optionally substituted Ce-io aryl)-R110wherein:Rii0is -O-C(O)H, -0-C(0)-Ci-2o alkyl, -O-C1-20 alkyl, -O-C(O)-O- C1-20 alkyl, -0-C(0)-N(Rn'110)2, -O-C(O)-(3- to 10-membered cycloalkyl), -O-Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544C(O)-C3-8 cycloalkyl, -O-C(O)-O-C3-s cycloalkyl, -O-C(O)-N(Rn iio)-C3-8cycloalkyl, wherein each Rn'110independently is H or C1-20 alkyl; n is 0 or 1 ; andR"'° is H, C1-6alkyl, -O-C(O)-wherein: m is 0 or 1;R"_pis cholesterol, dihydrocholesterol, or a bile acid; andR"'pis H or C1-6alkyl(ii-q) -C(O)-NRiiq-(Ci -20 alkylene, C1-20 alkenylene, or C1-20 alkynylene)- (optionally substituted Ce-io aryl), -C(O)-NRliq-(C1-20 alkylene, C 1-20 alkenylene, or C1-20 alkynylene)-(optionally substituted 5- to 10-membered heteroaryl), -C(O)-NRliq- (optionally substituted Ce-io aryl), -C(O)-NRliq-(optionally substituted 5- to 10- membered heteroaryl), -C(0)-NRiiq’-(Ci-2o alkylene)-O-C(O)-Riiq’, -C(O)-N(Riiq’)2or - C(0)-NRiik’-(Ci-2o alkylene)-C(O)-O-Riiqwherein each Rliqindependently is H or C1-20 alkyl;(in) -(Ci -24 alkylene)-(5- to 10-membered heteroaryl), wherein the alkylene and heteroaryl are unsubstituted or are optionally substituted; or(iv) -(Ci-24alkylene)-(O-CH2CH2)i-50-O-Rlv, and R1Vis H, C1-24 alkyl, or C2-24 alkenyl, wherein the alkylene, alkyl, and alkenyl are unsubstituted or are optionally substituted;R2is CH3, CH2D, CHD2, or CD3; andR3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium;(v) -O-C(O)-N(Rala)Ra2aor -NRXA-C(O)-ORa2a; wherein RXAis H or C1-12 alkyl, wherein the C1-12 alkyl is optionally substituted or unsubstituted;Ralais H, Ce-io aryl, or Ci-3o alkyl, wherein each Ce-io aryl or Ci-3o alkyl is optionally substituted or unsubstituted;Ra2ais:(i-a) -Ci-30alkyl, -(Ci-30alkylene)-O-C(O)Rla, -(Ci-30alkylene)-C(O)-ORla, -(Ci-30alkylene)-(C6-ioarylene)-0-C(0)-Rla;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein Rlais optionally substituted or unsubstituted C1-12 alkyl or optionally substituted or unsubstituted 5 -to 10-membered heteroaryl; or(ii-a) Ce-ioaryl, -(C6-io arylene)-(Ci-i2 alkylene)-0-C(0)-R2a, or -(5- to 10- membered heteroarylene)-(Ci-i2 alkylene)-O-C(O)-R2a; wherein R2ais optionally substituted or unsubstituted C1-12 alkyl or -(C1-12 alkylene)-NR2aR2a, wherein the C1-12 alkylene is optionally substituted or unsubstituted; and each R2aand R2aindependently is H or optionally substituted or unsubstituted C1-12 alkyl.(vi) — (C1-6alkylene)-(5- to 10-membered heteroaryl optionally substituted by one or more oxo or C1-6alkyl) or -(C1-6alkylene)-Ce-io aryl;wherein:R5and R6each independently are hydrogen, C1-20 alkyl optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl optionally substituted with C1-6alkoxy, or R5and R6combine to form oxo; or R5and R6can be taken together to form a C3-8 cycloalkyl or 3- to 10-membered heterocyclyl;R1Vis C1-20 alkyl; andR1Vis H or C1-6alkyl;wherein:R5, R6, R5, and R6each independently are hydrogen, C1-20 alkyl optionally substituted with Ce-io aryl, C3-8 cycloalkyl, 3- to 10-membered heterocyclyl, 3- to 10-membered heteroaryl, or Ce-io aryl optionally substituted with C1-6alkoxy, or (i) R5and R6combine to form oxo or (ii) R5and R6combine to form oxo, or (i) R5and R6can be taken together to form a C3-8 cycloalkyl or 3- to 10-membered heterocyclyl, or (ii) R5and R6, together with the atom to which they are attached, combine to form C3-8 cycloalkyl or 3- to 10-membered heterocyclyl; andDate of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Rvis C1-20 alkyl, C3-8 cycloalkyl, mono or dialkyl amino, or 3- to 10-membered heterocyclyl; or tixtwherein: each R5and R6independently are as defined for Formula (1 ’);R4Tis Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the Ce-io aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;RNis H, Ci-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted; andRNis H, Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;wherein: R5and R6are each independently H, C1-6alkyl, or Ce-io aryl.L2is a bond, -(Ci-8alkylene)-C(O)-*, -C(O)-(Ci-8alkylene)-C(O)-*, -C(O)-*, -(C1-8 alkylene)-O-C(O)-(Ci-8 alkylene)-C(O)-*,or -P(O)(OH)-*, wherein -* indicates attachment to M;M is -O-R4, -NR’-(CI-20 alkylene)-R4, -O-(Ci-20 alkylene)-R4, -O-(Ci-20 alkylene)-O-R4or -(C1-20 alkylene)-R4, wherein the C1-6alkylene is optionally substituted with hydroxyl;R’ is H or C1-6alkyl;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; each Rcindependently is C1-6alkyl; and each X independently is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544R5R6( ;z(xi) wherein R5and R6independently are as defined for Formula (1 ’); andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl;(iv) 5- to 10-membered heteroaryl;(v) cholesterol, dihydrocholesterol, or a bile acid; wherein the aryl, heterocycle, cycloalkyl, heteroaryl, cholesterol, dihydrocholesterol, or bile acid are unsubstituted or are optionally substituted;(xii)each R5, R6, R5, and R6independently are hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, - C(O)-Ci-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(Riij)2-Ci-24 alkyl, -Si(Rllj)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Ruj)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Ruj)2- C2-24 alkenyl, -Si(R“j)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Ruj)2-C2-24 alkenyl, -(C1-24 alkylene)- S(O)-Ci-24 alkyl, -(C1-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(Ci- 24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci.24alkylene)-(O-CH2CH2)i.50-O-Riv, -C(O)-(Ci-24alkylene)-(O-CH2CH2)i-50-O-Riv, C6-10 aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-s cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-s cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR5and R6combine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the cycloalkyl or heterocyclyl are unsubstituted or are optionally substituted;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544R7is Ci-20 alkyl, C3-10 cycloalkyl, Ce-io aryl, bile acid, cholesterol, dihydrocholesterol, -(Ci- 20 alkylene)-O-(C1-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(Ci- 6 alkyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkyl), 3- to 10-membered heterocyclyl; 5- to 10- membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(0)-0-(3- to 10-membered heterocyclyl); -(C1-20 alkylene)-C(0)-0-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -O-C(O)- (C1-20 alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10- membered heterocyclyl); -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), - CHRAA-NRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHRAA-NRN2, -(C1-20 alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)-C(O)-O-(Ci-20 alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)O- C(0)-(Ci-2o alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(Ci-6alkyl)3, — (C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(C1-6alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)- cholesterol, or -(C1-6alkylene)-NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)-NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN- dihydrocholesterol, or -NRN-dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; wherein RAAis H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)-NH2, -S-C1 6alkyl, -NH- C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or C1-6alkyl; andRA 2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci-6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;Y1, and Y4each independently are O, NRN, or CH2;Y2and Y3each independently are O, NRN, or a bond;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 each RNindependently is H or C1-6alkyl;R2is CH3. CH2D, CHD2, or CD3;R3is C1-6alkyl optionally substituted with one or more fluorine and / or deuterium; each R5and R6independently are each hydrogen, deuterium, Ci-24 alkyl, -Ci-24 haloalky 1, C2.30alkenyl, -O-C(O)-Ci-24alkyl, -O-C(O)-C2.30alkenyl, -C(O)-Ci-24alkyl, -C(O)-Ci-24haloalkyl, -C(0)-C2.3o alkenyl, -C(O)-C2.24 alkynyl, -(Ci-24 alkylene)-Si(Ruj)2-Ci-24 alkyl, - Si(Riij)2-Ci-24alkyl, -(C2.30alkenylene)-Si(Riij)2-Ci-24alkyl, -(C2.24alkenylene)-Si(Riij)2-C2.24alkenyl, -Si(R11-’)2-C2.24 alkenyl, -(C1-C24 alkylene)-Si(R11j)2-C2.24 alkenyl, -(Ci-24 alkylene)-S(O)- Ci-24 alkyl, — (Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(Ci-24 alkylene)-S(O)-Ci-24 alkylene, -(Ci-24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci-24alkylene)-(0-CH2CH2)i-5o-0-Rlv, -C(O)-(Ci-24alkylene)- (0-CH2CH2)I-5O-0-R1V, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10-membered heterocyclyl, C3-s cycloalkyl, -C1-6alkylene-(Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-s cycloalkyl), -(C1-6alkylene)-(4- to 10-membered heterocyclyl), - C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), -C(O)-(C3-s cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, alkenylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted; each Rlljindependently is C1-6alkyl or two R11- , together with the atom to which they are attached combine to form a 3-8-membered ring, each R1Vis independently H, deuterium, C1-22 alkyl or C2.24 alkenyl;L is a bond, Ci-24 alkylene, C2-24 alkenylene, Ce-io arylene, -(C1-6alkyl)-(Ce-io arylene)- or C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is optionally substituted;R4is H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(Ci-io alkylene)-(5- to 10-membered heteroaryl), -(Ci-io alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(Ci-io alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), -(Ci-io alkylene)-(cholesterol), -(Ci-io alkylene)-(dihydrocholesterol), -(Ci-io alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)- C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)-Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)-NRNC(O)- dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-O-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHR^-NR^, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(O)-O-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkylene)-C(O)-O-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - (Ci-6alkylene)-C(O)NRN-(C1-6alkylene)-C(O)-OH, -(C1-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, alkenylene, or alkyl is unsubstituted or is optionally substituted; n is 1 to 20;R is H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)-NH2, -S-C1 6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;R2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-e alkyl, -C(O)-NH2, -S-C1-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Rlld)3, wherein the alkyl, alkenyl, or alkylene is optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl.

2. A compound of Formula (2’)Formula (2’) whereinX' is absent or is an anion; andR1Tis:(i) halogen, -O-C1-6alkyl, -O-(C1-6alkylene)-C6-io aryl, -O-C1-6haloalkyl, -O- S(O)2-Ci-6alkyl, -O-S(O)2-Ci-6haloalkyl, -0-S(0)2-C6-io aryl, -O-S(O)2-O-Ci-6alkyl, -O- S(O)2-O-C1-6haloalkyl, or -0-S(0)2-0-C6-ioaryl, wherein the alkyl, alkylene, aryl, or haloalkyl is optionally substituted; orwherein: n is 0 or 1 ;Y is -O-, -S-, -S(O)-, or -S(O)2-; each R2Tand R3Tindependently are hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2-30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci-24 haloalkyl, -C(0)-C2-C3o alkenyl, -C(O)-C2-24 alkynyl, -(Ci-24 alkylene)-Si(Ruj)2-Ci-24 alkyl, -Si(Ruj)2-Ci-24 alkyl, -(62-30 alkenylene)-Si(Ruj)2-Ci-24 alkyl, -(C2-24 alkenylene)-Si(Ruj)2-C2-24 alkenyl, -Si(R11-’)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Riij)2-C2-24 alkenyl, -S(O)2-O-Ci-6alkyl, S(O)2-O-Ci-6haloalkyl, -S(O)2-O-Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Ce-io aryl, -(C1-24 alkylene)-S(O)-Ci-24 alkyl, -(C1-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, -(C1-24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci-24alkylene)- (O-CH2CH2)i-50-O-Riv, -C(O)-(Ci-24alkylene)-(O-CH2CH2)i-50-O-Riv, C6-io aryl, 5- to 10- membered heteroaryl, 4- to 10-membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene- (Ce-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-s cycloalkyl), -C1-6alkylene-(4- to 10-membered heterocyclyl), -C(0)-(Ce-io aryl), -C(O)- (5- to 10-membered heteroaryl), -C(O)-(C3-s cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orR2Tand R3Tcombine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the heterocyclyl, or cycloalkyl is unsubstituted or is optionally substituted; each R1Vis independently H, deuterium, C1-24 alkyl or C1-24 alkenyl; each Rlljindependently is C1-6alkyl or two Rllj, together with the atom to which they are attached combine to form a 3-8-membered ring;R4Tis:(ii-a) -C(O)-Ci-24alkyl, -(CH2CH20)O-20-(CI-4 alkyl), -C(0)-0-(CH2CH20)o-20- (C1-4 alkyl), -C(O)-Ci-24 haloalkyl, -C(O)-C2-30 alkenyl, -C(O)-C2-24 alkynyl, - C(O)-(Ci-24 alkylene)-C6-io aryl, -C(O)-(C2-24 alkenylene)-C6-io aryl, -C(O)-(C2-24 alkynylene)-C6-io aryl, -C(O)-(Ci-24alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-(C2-24 alkenylene)-C(O)-O-Ci-24 alkyl, -C(O)-C(O)-O-Ci-24 alkyl, -C(O)-C(O)-OH, - C(O)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-C(O)-(bile acid), -C(O)- (C2-24 alkynylene)-C(O)-O-Ci-24 alkyl, -C(O)-(C2-24 alkynylene)-C(O)-OH, -C(O)- (Ci-24alkylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24alkylene)- C(O)-(bile acid), -C(O)-(C2-24alkenylene)-C(O)-(cholesterol or dihydrocholesterol), -C(O)-(C2-24alkenylene)-C(O)-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-O-(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkynylene)-C(O)-(bile acid), -C(O)-(Ci-24alkylene)-C(O)-NH-Ci-24 alkyl, -C(O)- (C2-24alkenylene)-C(O)-NH-Ci-24 alkyl, -C(O)-C(O)-NH -C1-24 alkyl, -C(O)-C(O)- NH2, -C(O)-C(O)-NH-(cholesterol or dihydrocholesterol), -C(O)-C(O)-NH-(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-NH-Ci-24 alkyl, -C(O)-(C2-24 alkynylene)-Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544C(0)-NH2, -C(O)-(Ci-24alkylene)-C(O)-NH(cholesterol or dihydrocholesterol), - C(O)-(Ci-24 alkylene)-C(O)-NH(bile acid), -C(O)-(C2-24 alkenylene)-C(O)- NH(cholesterol or dihydrocholesterol), -C(O)-(C2-24 alkenylene)-C(O)-NH(bile acid), -C(O)-(C2-24 alkynylene)-C(O)-NH-(cholesterol or dihydrocholesterol), - C(O)-(C2-24 alkynylene)-C(O)-NH(bile acid), -C(O)-(C2-24 alkynylene)-O-C(O)-O- Ci-24 alkyl, -C(O)-(Ci-24 alkylene)-C(O)OH, -C(O)-(C2-24 alkenylene)-C(O)OH, - C(O)-Ce-i4aryl, -C(O)-C3-i5 cycloalkyl, -C(O)-(3- to 10-membered heterocycle), - C(O)-(5- to 10-membered heteroaryl), -C(O)-(Ci-24alkylene)-(3- to 10-membered cycloalkyl), -C(O)-(Ci-24alkylene)-(C6-i4aryl), -C(O)-(Ci-24 alkylene)-(3- to 10- membered heterocycle), -C(O)-(Ci-24alkylene)-(5- to 10-membered heteroaryl), - C(O)-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-(C2-24 alkenylene)-(C6-i4aryl), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(C2-24 alkenylene)-(C3-i5 cycloalkyl), -C(O)-(C2-24 alkenylene)-(3- to 10- membered heterocycle), -C(O)-(C2-24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)-(C1 -24 alkenylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkenylene)-(bile acid), -C(O)-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-(Ci-24 alkylene)-(bile acid), -C(O)-(Ci-24 alkylene)-O-(C6-i4aryl), -C(O)- (Ci-24 alkylene)-0-(3- to 10-membered heterocycle), -C(O)-(Ci-24 alkylene)-0-(5- to 10-membered heteroaryl), -C(O)-(Ci-24 alkylene)-O-(bile acid), -C(O)- (cholesterol or dihydrocholesterol), -C(O)-(bile acid), -(bile acid), or -C(O)-(Ci-24 alkylene)-(O-CH2CH2)i-50-O-Rlia, -C(O)-OH, or Ce-io aryl, wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, RliaisH, Ci -24 alkyl or C1-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted;(ii-b) -C(O)-O-Ci-24 alkyl, -C(O)-O-Ci-24haloalkyl, -C(O)-O-C2-30 alkenyl, -C(O)- O-C2-24 alkynyl, -C(O)-O-(Ci-24 alkylene)-C6-io aryl, -C(O)-O-(C2-24 alkenylene)- C6-io aryl, -C(O)-O-C(O)-O-Ci-24alkyl, -C(O)-O-C(O)-OH, -C(O)-O-(Ci-24alkylene)-C(O)-O-Ci-24 alkyl, -C(O)-O-(C2-24alkenylene)-C(O)-O-Ci-24 alkyl, - C(O)-O-(C2-24alkenylene)-O-C(O)-O-Ci-24 alkyl, -C(O)-O-(Ci-24alkylene)- C(O)OH, -C(O)-O-(C2-24 alkenylene)-C(O)OH, -C(O)-O-C6-i4aryl, -C(O)-O-C3-i5Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 cycloalkyl, -C(O)-O-(3- to 10-membered heterocycle), -C(O)-O-(5- to 10- membered heteroaryl), -C(O)-O-(Ci-24 alkylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(Ci-24 alkylene)-(C6-i4aryl), -C(O)-O-(Ci-24 alkylene)-(3- to 10- membered heterocycle) -C(O)-O-(Ci-24 alkylene)-(5- to 10-membered heteroaryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered cycloalkyl), -C(O)-O-(C2-24 alkenylene)-(C6-i4aryl), -C(O)-O-(C2-24 alkenylene)-(3- to 10-membered heterocycle), -C(0)-0-(C2 -24 alkenylene)-(5- to 10-membered heteroaryl), -C(O)- O-(Ci-24 alkylene)-(cholesterol or dihydrocholesterol), -C(O)-O-(Ci-24 alkylene)- (bile acid), -C(O)-O-(C2-24 alkenylene)-(cholesterol or dihydrocholesterol), -C(O)- O-(C2-24 alkenylene)-(bile acid), -C(O)-O-(cholesterol or dihydrocholesterol), - C(O)-O-(bile acid), or -C(0)-0-(Ci-24alkylene)-(0-CH2CH2)i-5o-0-Riib', -C(O)- (Ci-24 alkylene)-C(O)NRN-(Ci-24 alkylene)-C(O)-ORN, -C(O)-O-(Ci-24alkylene)- C(O)OH, -C(O)-O-(Ci-24 alkylene)-C(O)NRN2, -C(O)-O-C3-s cycloalkyl, -C(O)- O-(Ci-24alkylene)-OH, -C(O)-O-(C2-30 alkenylene)-OH, -C(O)-O-(C2-24 alkynylene)-OH, -C(O)-O-(cholesterol or dihydrocholesterol), or -C(O)-O-(bile acid), wherein the alkyl, alkenyl, alkynyl, alkylene, alkenylene, alkynylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, andRiib’ is H, deuterium, C1-22 alkyl or C2-24 alkenyl, wherein the alkyl or alkenyl is unsubstituted or is optionally substituted, wherein each RNindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-c) -O-Si(Riic)3, or -O-Liic-Si(Riic)2-Liic, wherein each R11Cindependently is C1-24 alkyl, C2-24 alkenyl, Ce-io aryl, -O-Ci -24 alkyl, -O-C2-24 alkenyl, or -OH, wherein the alkyl, alkenyl, or aryl is unsubstituted or is optionally substituted;L11Cis Ci-24 alkylene; andL11Cis Ci-24 alkyl, wherein the alkylene and alkyl is unsubstituted or is optionally substituted;(ii-d) -C(O)-Liid-((C(O))n-iid-Riid,Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein Llldis a C1-24 alkylene, C2-24 alkenylene, C2-24 alkynylene,C3-8 cycloalkylene, or a bond, n-iid is 0 or 1; andwherein each R5and R6independently are as defined for R5and R6of Formula (1), respectively;R2is CH3, CH2D, CHD2, or CD3;X' is absent or is an anion; andR3is a C1-6alkyl optionally substituted with at least one deuterium or halogen; orwherein X' is absent or is an anion;(ii-e) -C(O)-(Ci-24 alkylene)-(C6-io aryl), wherein the Ce-io aryl is optionally substituted by one or more Rlie, wherein Rlieis -O-C(O)-C1-6alkyl, -O-C(O)-C3-s cycloalkyl, -O- C(0)-Ce-io aryl or C1-6alkyl;(ii-f) — C(O)-CHRiif-N(Riif)2, -C(O)-CHRiif-NRiif-C(O)-O-Ci-24 alkyl, -C(O)- (C1-24 alkylene)-NRiif-C(O)-CHRiif-N(Riif)2, or -C(O)-(Ci-24alkylene)-NRiif’- C(O)-CHRllf-N(Rllf)-C(O)-O-Ci-24- alkyl, or salts thereof, wherein the alkyl and alkylene are unsubstituted or optionally substituted, wherein each Rllfindependently is H or C1-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1-6alkyl, -C(O)-NH2, -S-C1-6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl, or salts thereof; andDate of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 each Rllfindependently is H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted, or two Rllf, together with the atom to which they are attached, combine to form a 3- to 10- membered heterocyclyl; or Rllfand one Rllf, together with the atom to which they are attached, combine to form a 3- to 10- membered heterocyclyl;(ii-g) -C(O)-CH(Riig)2, -C(O)-(Ci-24 alkylene)-C(O)-O-CH(Riig)2or -C(O)-(Ci-24alkylene)-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Rllg)2, wherein the alkylene is unsubstituted or is optionally substituted, wherein each Rllgindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or -CH2-O-P(O)2-O-(CI-6 alkylene)-N(Riig’)3wherein each Rllgindependently is C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(ii-h) -C(O)-O-CH(Riih)2, -C(O)-O-C(O)-O-CH(Riih)2, -C(O)-O-(Ci-24alkylene)- C(O)-O-C(O)-O-CH(Riih)2, -C(O)-O-C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Riih)2, - C(O)-O-(Ci-24 alkylene)-C(O)-O-CH(Riih)2, or -C(O)-O-(Ci-24alkylene)-C(O)-O- (Ci-24 alkylene)-C(O)-O-CH(Rlih)2, wherein the alkylene is unsubstituted or is optionally substituted; wherein each Rllhindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, -CH2-O-P(O)2-O-(CI-24 alkylene)-N(Riih’)2or - CH2-O-P(O)2-O-(CI-24 alkylene)-N(Rllh)3, wherein the alkyl, alkenyl, alkylene is unsubstituted or is optionally substituted; wherein each Rllhis independently H or C1-6alkyl, wherein the alkyl is unsubstituted or is optionally substituted;(h-i) -P(O)(ORiii)2, -P(O)2(ORiii), -P(O)(ORiii)-O-(Ci-24 alkylene)-O-Ci-24 alkyl, - P(O)(O-(Ci-24 alkylene)-C(O)-Riii))2, -P(O)(O-(Ci-24alkylene)-O-C(O)-Riii))2, - P(O)(O-(Ci-24 alkylene)-O-C(O)-O-Riii))2, -P(O)2(O-(Ci-24 alkylene)-O-C(O)- R )), -P(O)2(O-(Ci-24 alkylene)-O-C(O)-O-Riii)), -P(O)2(O-(Ci-24 alkylene)-C(O)- O-R111)) or -P(O)(N(RU1)2)2, wherein the alkyl or alkylene is unsubstituted or is optionally substituted,Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein each R111independently is H, deuterium, or C1-20 alkyl, wherein alkyl is unsubstituted or is optionally substituted;(ii-j) C1-6alkyl;(ii-k) -C(O)-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-O-(Ci-i2 alkylene)-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-C(O)-O-(Ci-i2alkylene)-(optionally substituted pyrimidine)-(C1-6alkylene)- (optionally substituted thiazolium), -C(O)-(Ci-i2alkylene)-C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-O-C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), -C(O)-(Ci-i2 alkylene)-NR1-(optionally substituted pyrimidine)- (C1-6alkylene)-(optionally substituted thiazolium), -C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), or -C(O)-(Ci-i2 alkylene)- NR1-C(O)-NR1-(optionally substituted pyrimidine)-(C1-6alkylene)-(optionally substituted thiazolium), wherein the alkylene is unsubstituted or is optionally substituted, and wherein each R1independently is H or unsubstituted or optionally substituted C1-6alkyl;(ii-1) -0(0)41^, -C(O)-(Ci-i2alkylene)-RAA, -C(0)-NH-(Ci-i2 alkylene)^, - C(0)-0-(Ci-i2 alkylene)^, -C(0)-(0)m-(Ci-2o alkylene)-O-C(O)CHRii l-N(Rii- p)2, -C(O)-(O)m-(Ci-20 alkylene)-N(Rii'1)-C(0)CHRii'1-N(Rii'1)2, -C(0)-(0)m-(Ci-2o alkylene)-O-C(O)CHRii l-N(Rii l)-C(0)CHRii l-N(Rii l)2, or -C(0)-(0)m-(Ci.2o alkylene)-N(Rii'1)-C(0)CHRii'1-N(Rii'1)-C(0)CHRii'1-N(Rii'1)2wherein: m is 0 or 1; each R11'1independently is H or C1-6alkyl; and each R11’1independently is H, Ci.6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(0)-0H, -C(O)-O-C1 6alkyl, -C(0)-NH2, - S-C1-6 alkyl, -NH-C(=NH)NH2, C6.10 aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;R IS:Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544(i)-O-C(O)-C(Riif)N(Riif)(Riif), -C(Riif)N(Riif’)(Riif), -C(O)N(Riif)-(Ci-i2 alkyl), -N(Riif’)C(O)-(C 1-12 alkyl), or -C(O)OH;(ii) Ce-ioaryl, -0-(Ce-io arylene)-(Ci-i2 alkyl), -(C6-ioarylene)-(Ci-i2 alkyl), -(Ce-io arylene)-C(O)N(Rllf)-(Ci-i2 alkyl), -NH-(Ce-io arylene)- C(O)N(Riif)-(Ci-i2 alkyl), -(C6-io arylene)-N(Riif’)C(O)-(Ci-i2 alkyl); or(iii) -(C3-8 cycloalkylene)-C(O)N(Rllf)-(Ci-i2 alkyl), -(C3-8 cycloalkylene)-(Ci-i2 alkylene)-N(Rllf)-C(O)-(Ci-i2 alkyl); wherein: each Rllfindependently is H or C1-12 alkyl; each Rllfindependently is H or C1-6alkyl; and each C1-6alkyl, C1-12 alkyl, Ce-io aryl, Ce-io arylene, C3-8 cycloalkylene, or C 1-12 alkylene is optionally substituted or unsubstituted.(ii-q) -C(O)-N(RNlb)RN2b, wherein RNlbis H or optionally substituted or unsubstituted Ci-0 alkyl; andRN2bis:(i-b) H or optionally substituted or unsubstituted C1-30 alkyl, -(C1-12 alkylene)- S(O)2-(Ci-i2 alkyl), or -(Ci-i2 alkylene)-S(O)-(Ci-i2 alkyl), wherein each C1-12 alkylene or C1-12 alkyl is optionally substituted or unsubstituted;(ii-b) -(5- to 10-membered heteroarylene)-(Ci-i2 alkylene)-O-C(O)-(Ci-i2 alkylene), wherein each 5- to 10-membered heteroarylene, or C1-12 alkylene is optionally substituted or unsubstituted;(iii-b) -(C1-12 alkylene)-C(O)-NRiiibRiiib, -(C1-12 alkylene)-NRiiibRiiib’-C(O)-(Ci-i2 alkyl), -(C6-ioarylene)-C(0)-NRlllbRlllb, or -(Ci-i2 alkylene)-(C3-8 cycloalkylene)-C(O)- NRiubRiub’, wherein each Ci -12 alkylene, C1-12 alkyl, Ce-io arylene, or C3-8 cycloalkene is optionally substituted or unsubstituted;Riiib is H or optionally substituted or unsubstituted C1-12 alkyl; andRiiib’ is H, optionally substituted or unsubstituted C1-12 alkyl, or -(Ci-nalkylene)- (Ce-io aryl), wherein each C1-12 alkylene or Ce-io aryl is optionally substituted or unsubstituted;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544(iv-b) -(Ci-i2 alkylene)-C(0)-0-(bile acid), -(Ci-i2alkylene)-C(O)-O-(cholesterol), or -(Ci-i2 alkylene)-C(O)-O-(dehydrocholesterol), wherein each C1-12 alkylene is optionally substituted or unsubstituted; or(v-b) -(Ci-i2 alkylene)-C(O)-O-(Ci-i2alkylene)-(3- to 10-membered heterocyclyl), -(C1-12 alkylene)-(C3-8 cycloalkylene)-C(O)-O-(Ci-i2alkylene)-(3- to 10-membered heterocyclyl), or - (C6-ioarylene)-C(0)-0-(Ci-i2alkylene)-(3- to 10-membered heterocyclyl), wherein each C1-12 alkylene, C3-8 cycloalkylene, Ce-io arylene, or 3- to 10-membered heterocyclyl is optionallyO R1O c c o^R2substituted or unsubstituted; (iii) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl; wherein the alkyl or aryl are unsubstituted or optionally substituted;R2is C1-20 alkyl, C3-10 cycloalkyl, Ce-io aryl, -(C1-20 alkylene)-O-(C1-6alkyl), -(Ci- 20 alkylene)-O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), 3- to 10-membered heterocyclyl; 5- to 10-membered heteroaryl, -O-(3- to 10-membered heterocyclyl); -O-(5- to 10-membered heteroaryl), - (Ci-10 alkylene)-C(O)-O-(C1-6alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)-O-(3- to 10-membered heterocyclyl); -(C1-10 alkylene)-C(O)-O-(5- to 10- membered heteroaryl), -(C1-20 alkylene)-(3- to 10-membered heterocyclyl); -(C1-20 alkylene)-(5- to 10-membered heteroaryl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -O-C(O)-(Ci -20 alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl); -(C1-20 alkylene)-NRN-C(O)- O-(5- to 10-membered heteroaryl), -CHRAA-NRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(Ci- 20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)- -CHR^-NR^, -(C1-20 alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)- C(0)-0-(Ci-2o alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)-N+(Ci-6alkyl)3, — (C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, or -(C1-6alkylene)-NRNC(O)-bile acid, -(C1-6alkylene)-NRN-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)-C(O)- cholesterol, or -(C1-6alkylene)- NRNC(O)- cholesterol, -(C1-6alkylene)-NRN- cholesterol, -NRN- cholesterol, -(C1-6Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 alkylene)-NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)- dihydrocholesterol, -(C1-6alkylene)-NRNC(O)-dihydrocholesterol, -(C1-6alkylene)-NRN-dihydrocholesterol, or - NRN-dihydrocholesterol, wherein the alkyl, cycloalkyl, aryl, heterocyclyl, heteroaryl, or alkylene are unsubstituted or optionally substituted; or(n-k) -C(O)-NRiik-(Ci -20 alkylene, C 1-20 alkenylene, or C1-20 alkynylene)- (optionally substituted Ce-io aryl), -C(O)-NRiik’-(Ci -20 alkylene, C 1-20 alkenylene, or Ci -20 alkynylene)-(optionally substituted 5- to 10-membered heteroaryl), - C(O)-NRllk-(optionally substituted Ce-io aryl), -C(O)-NRllk-(optionally substituted 5- to 10-membered heteroaryl), -C(O)-NRllk-(C1-20 alkylene)-O-C(O)- Riik’, -C(O)-N(Riik)2or -C(0)-NRiik’-(Ci-2o alkylene)-C(O)-O-Riik” wherein each Rllkindependently is H or C1-20 alkyl;(11-I) -(C(O))n-(O)m-(Ci-20 alkylene)-O-C(O)CHRii f-N(Rii f)2, -(C(O))n- (O)m-(Ci-20alkylene)-N(Rii'f)-C(O)CHRii'f-N(Rii'f)2, -(C(0))n-(0)m-(Ci-2o alkylene)-O-C(O)CHRii f-N(Rii f)-C(O)CHRii f-N(Rii f)2, or -(C(0))n-(0)m-(Ci-2o alkylene)-N(Rii'f)-C(O)CHRii'f-N(Rii'f)-C(O)CHRii'f-N(Rii'f)2wherein: n is 0 or 1 ; m is 0 or 1; each R11-findependently is H or C1-6alkyl; and each R11-findependently is H, Ci-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)-NH2, - S-C1-6 alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl.(11-n) -(C(O))n-(C1-6alkylene)-N(Rii'n)-Rii-n, wherein:R"'11is cholesterol, dihydrocholesterol, or a bile acid; andR"'11is H or C1-6alkyl;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544independently R2T*anCJ R3T* each independently are H, C1-20 alkyl optionally substituted by one or more Ce-io aryl, Ce-io aryl optionally substituted with one or more -O-C1-6alkyl, 5- to 10-membered heterocyclyl, C3-8 cycloalkyl, or -C(O)-4- to 10-membered heterocycle, or (i) R2T* and R3T* or (ii) R2T** and R3T** combine to form oxo, or (i) R2T* and R3T* or (ii) R2T** and R '1**, together with the atom to which they are attached, combine to form a C3-8 cycloalkyl; andalkyl, Ce-io aryl, 3- to 10-membered heterocyclyl, or 5- to 10- membered heteroaryl; wherein the alkyl, aryl, heterocyclyl, and heteroaryl are each unsubstituted or are optionally substituted;wherein: each R2Tand R3Tindependently are as defined for Formula (2);R4Tis Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the Ce-io aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;RNis H, Ci-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted; andRNis H, Ce-io aryl, C1-24 alkyl, -C1-24 haloalkyl, -C2-30 alkenyl, or -C2-24 alkynyl, wherein the aryl, alkyl, alkenyl, or alkynyl is unsubstituted or is optionally substituted;wherein:L1is -C(R2T)(R3T)- or -P(O)(OH)-;R2Tand R3Teach independently are H, C1-6alkyl, or Ce-io aryl, or R2Tand R3Tcombine to form oxo;L2is a bond, -(Ci-8alkylene)-C(O)-*, -O-C(O)-(Ci-8alkylene)-C(O)-*, -C(O)-(Ci-8alkylene)-C(O)-*, -O-C(O)-*, -O-(Ci-8alkylene)-O-C(O)-(Ci-8alkylene)-C(O)-*, -O-P(O)(OH)- *, wherein -* indicates attachment to M and the C1-8 alkylene is unsubstituted or optionally substituted;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544M is -0-R4, -NR’-(CI-20 alkylene)-R4, -0-(Ci-2o alkylene)-R4, -0-(Ci-2o alkylene)-OR4, - (Ci-20 alkylene)-OR4, -(C1-20 alkylene)-C(O)-O-R4or -(C1-20 alkylene)-R4, wherein the C1-20 alkylene is optionally substituted with hydroxyl;R’ is H or C1-6alkyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.(vii), whereinY1, and Y4each independently are CH2, NRN, or O;Y2, and Y3each independently are a bond, NRN, or O; each RNindependently is H or C1-6alkyl;R2Tand R3Tare each independently hydrogen, deuterium, C1-24 alkyl, -C1-24 haloalkyl, C2- 30 alkenyl, -O-C(O)-Ci-C24alkyl, -0-C(0)-C2-C3o alkenyl, -C(O)-Ci-C24alkyl, -C(O)-Ci- 24 haloalkyl, -C(O)-C2-C30 alkenyl, -C(O)-C2-24 alkynyl, -(C1-24 alkylene)-Si(Ruj)2-Ci-24 alkyl, -Si(Rllj)2-Ci-24 alkyl, -(C2-30 alkenylene)-Si(Ruj)2-Ci-24 alkyl, -(C2-24 alkenylene)- Si(R“j)2-C2-24 alkenyl, -Si(Rllj)2-C2-24 alkenyl, -(C1-C24 alkylene)-Si(Ruj)2-C2-24 alkenyl, - S(O)2-O-Ci-6alkyl, S(O)2-O-Ci-6haloalkyl, -S(0)2-0-C6-io aryl, -(C1-24 alkylene)-S(O)- C1-24 alkyl, — (Ci-24 alkylene)-S(O)2-Ci-24 alkyl, -(C1-24 alkylene)-S(O)-Ci-24 alkylene, - (Ci-24 alkylene)-S(O)2-Ci-24 alkylene, -(Ci.24alkylene)-(O-CH2CH2)i.50-O-Riv, -C(O)-(Ci- 24alkylene)-(O-CH2CH2)i-50-O-Rlv, Ce-io aryl, 5- to 10-membered heteroaryl, 4- to 10- membered heterocyclyl, C3-8 cycloalkyl, -C1-6alkylene-(C6-io aryl), C1-6alkylene-(5- to 10-membered heteroaryl), -C1-6alkylene-(C3-s cycloalkyl), -C1-6alkylene-(4- to 10- membered heterocyclyl), -C(0)-(Ce-io aryl), -C(O)-(5- to 10-membered heteroaryl), - C(O)-(C3-8 cycloalkyl), or -C(O)-(4- to 10-membered heterocyclyl), wherein the alkyl, alkenyl, alkylene, cycloalkyl, heterocyclyl, heteroaryl, or aryl is unsubstituted or is optionally substituted, orDate of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544R2Tand R3Tcombine to form oxo, C3-8 cycloalkyl, or 3- to 10-membered heterocyclyl, wherein the heterocyclyl, or cycloalkyl is unsubstituted or is optionally substituted; each R1Vis independently H, deuterium, C1-24 alkyl or C1-24 alkenyl; each R“j independently is C1-6alkyl or two Rllj, together with the atom to which they are attached combine to form a 3-8-membered ring;L is a bond, Ci.24alkylene, C2-24 alkenylene, or C2-24 alkynylene; andR4Tis H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-10 alkylene)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -O-C(O)-(Ci-20 alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-(cholesterol), -(C1-10 alkylene)-(dihydrocholesterol), -(C1-10 alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)- C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)- NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)-NRNC(O)- dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-C(O)-O-(Ci-6alkyl), -(C1-20 alky lene)-O-C(O)-O-(C 1-6 alkyl), -(C1-20 alky lene)-O-(C 1-6 alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)0-C(0)-(Ci-2o alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(0)-0-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkylene)-C(O)-O-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544(Ci-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - (Ci-6alkylene)-C(O)NRN-(C1-6alkylene)-C(O)-OH, -(C1-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, or alkyl is unsubstituted or is optionally substituted;R is H, -C(O)-NRN-CHRAA2-C(O)-OH; CI-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-C1 6alkyl, -C(O)-NH2, -S-C1 6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;R2is H, C1-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci-6alkyl, -NH-C(=NH)NH2, or Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, - CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Rlld)3, wherein the alkyl, alkenyl, and alkylene are unsubstituted or optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl;(viii), wherein Y4is CH2, NRN, or O;Y2and Y3each independently are a bond, NRN, or O;L is a bond, C1-24 alkylene, C2-24 alkenylene, or C2-24 alkynylene, wherein the alkylene, alkenylene, or alkynylene is unsubstituted or optionally substituted; each RNindependently is H or C1-6alkyl;R4Tis H, 3- to 10-membered heterocyclyl, 5- to 10-membered heteroaryl, cholesterol, dihydrocholesterol, bile acid, -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), -(C1-10 alkylene)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-(5- to 10-membered heteroaryl), -(C1-10 alkylene)-O-C(O)-O-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-C(O)- O-(5- to 10-membered heteroaryl), -O-(5- to 10-membered heteroaryl), -O-C(O)-(Ci-20 alkylene)-(5- to 10-membered heteroaryl), -(C1-20 alkylene)-NRN-C(0)-0-(5- to 10-memberedDate of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 heteroaryl), -(Ci-io alkylene)-(cholesterol), -(Ci-io alkylene)-(dihydrocholesterol), -(Ci-io alkylene)-(bile acid), -(C1-6alkylene)-NRN-bile acid, -(C1-6alkylene)-C(O)-bile acid, -(C1-6alkylene)-NRNC(O)-bile acid, -NRN-bile acid, -(C1-6alkylene)-NRN-cholesterol, -(C1-6alkylene)- C(O)-cholesterol, -(C1-6alkylene)-NRNC(O)-cholesterol, -NRN-cholesterol, -(C1-6alkylene)- NRN-dihydrocholesterol, -(C1-6alkylene)-C(O)-dihydrocholesterol, -(C1-6alkylene)-NRNC(O)- dihydrocholesterol, -NRN-dihydrocholesterol, amino, monoalkylamine, dialkylamine, trialkylammonium, -(C1-6alkylene)-(O-CH2CH2)n-OCH3, -(C1-6alkylene)-(O-CH2CH2)n-CH3, - C(O)-(Ci-22 alkylene)-(O-CH2CH2)n-OH, -(C1-20 alkylene)-NRN2, -(C1-20 alkylene)-O-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)-O-C(O)-O-(C1-6alkyl), -(C1-20 alkylene)- O-C(O)-(Ci-6alkyl), -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-O- CHR^-NR^, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -(C1-20 alkylene)-N+(Ci-6alkyl)3, -(C1-20 alkylene)-C(O)-O-(Ci-20 alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)O-C(O)-(Ci-20 alkylene)- N+(CI-6 alkyl)3, -(C1-20 alkylene)0-C(0)-0-(Ci-2o alkylene)-N+(C1-6alkyl)3, -(C1-20 alkylene)-O- C(O)-(3- to 10-membered heterocyclyl), -0-C(0)-(Ci-2o alkylene)-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-NRN-C(O)-O-(3- to 10-membered heterocyclyl), -O-(3- to 10- membered heterocyclyl), -(C1-20 alkylene)-C(O)-O-(3- to 10-membered heterocyclyl), -(C1-20 alkylene)-O-C(O)-(C1-6alkylene)-(3- to 10-membered heterocyclyl), -CHR^-NR^, -(C1-20 alkylene)-RAANRN2, -(C1-20 alkylene)-CHRAA-NRN2, -(C1-20 alkylene)-C(O)-O-CHRAA-NRN2, - (C1-20 alkylene)-O-C(O)-O-CHRAA-NRN2, -(C1-20 alkylene)-O-C(O)-CHRAA-NRN2, -OCHRiid2, - (Ci-6alkylene)-C(O)NRN-(C1-6alkylene)-C(O)-OH, -(C1-6alkylene)-C(O)-OH, -C(O)-(Ci-22alkyl), -C(O)-(C3-i5 cycloalkyl), -C(O)-O-(C3-i5 cycloalkyl), -C(O)-(3- to 10-membered heterocyclyl), -C(O)-O-(3- to 10-membered heterocyclyl), -C(O)-(C2-6 alkenylene)-(5- to 10- membered heteroaryl), -C(O)-O-(C2-6 alkenylene)-(5- to 10-membered heteroaryl), or C1-24 alkyl, wherein the heterocyclyl, heteroaryl, cholesterol, dihydrocholesterol, bile acid, alkenylene, alkylene, monoalkylamine, dialkylamine, trialkylammonium, cycloalkyl, alkenyl, or alkyl is unsubstituted or is optionally substituted;R is H, -C(O)-NRN-CHRAA2-C(O)-OH, or Ci-6alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, -C(O)-O-Ci6alkyl, -C(O)-NH2, -S-Ci-6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544R2is H or Ci-6 alkyl optionally substituted by one or more -OH, -SH, -NH2, -C(O)-OH, - C(O)-O-Ci-6alkyl, -C(O)-NH2, -S-Ci-6alkyl, -NH-C(=NH)NH2, Ce-io aryl optionally substituted by -OH, or 5- to 10-membered heteroaryl;RNis H or optionally substituted C1-6alkyl; each Rlldindependently is -CH2-O-C(O)-CI-24 alkyl, -CH2-O-C(O)-C2-24 alkenyl, or - CH2-O-P(O)2-O-(CI-6 alkylene)-N+(Rlld)s, wherein the alkyl, alkenyl, and alkylene are unsubstituted or optionally substituted; and each Rlldindependently is optionally substituted C1-6alkyl.

3. A combination comprising a compound of Formula (1’) and a Compound of Formula(2’).

4. A compound of Table 1.

5. A compound of Table 2.

6. A combination comprising a compound of Table 1 and a compound of Table 2.

7. A combination of any one of the preceding claims, wherein the combination comprises WTB 464 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-25448. The combination of any one of the preceding claims, wherein the combination comprises WTB 464 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

9. The combination of any one of the preceding claims, wherein the combination comprisesWTB 464 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

10. The combination of any one of the preceding claims, wherein the combination comprises WTB 464 in combination with any compound of Formula (2-ii-b-v’):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

11. The combination of any one of the preceding claims, wherein the combination comprisesWTB 464 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

12. The combination of any one of the preceding claims, wherein the combination comprisesWTB 464 in combination with any compound of Formula (2-iii-a):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

13. The combination of any one of the preceding claims, wherein the combination comprises WTB 464 in combination with any compound of Table 2.

14. The combination of any one of the preceding claims, wherein the combination comprises WTB AY-0200 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-254415. The combination of any one of the preceding claims, wherein the combination comprises WTB AY-0200 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

16. The combination of any one of the preceding claims, wherein the combination comprises WTB AY-0200 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

17. The combination of any one of the preceding claims, wherein the combination comprises WTB AY-0200 in combination with any compound of Formula (2-ii-b-v’):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

18. The combination of any one of the preceding claims, wherein the combination comprisesWTB AY-0200 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

19. The combination of any one of the preceding claims, wherein the combination comprises WTB AY-0200 in combination with any compound of Formula (2-iii-a):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

20. The combination of any one of the preceding claims, wherein the combination comprisesWTB AY-0200 in combination with any compound of Table 2.

21. The combination of any one of the preceding claims, wherein the combination comprises WTB AY 0035 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-254422. The combination of any one of the preceding claims, wherein the combination comprises WTB AY 0035 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

23. The combination of any one of the preceding claims, wherein the combination comprises WTB AY 0035 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

24. The combination of any one of the preceding claims, wherein the combination comprises WTB AY 0035 in combination with any compound of Formula (2-ii-b-v’):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

25. The combination of any one of the preceding claims, wherein the combination comprisesWTB AY 0035 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

26. The combination of any one of the preceding claims, wherein the combination comprises WTB AY 0035 in combination with any compound of Formula (2-iii-a):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

27. The combination of any one of the preceding claims, wherein the combination comprisesWTB AY 0035 in combination with any compound of Table 2.

28. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 0209 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-254429. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 0209 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

30. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 0209 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

31. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 0209 in combination with any compound of Formula (2-ii-b-v’):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

32. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 0209 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

33. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 0209 in combination with any compound of Formula (2-iii-a):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

34. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 0209 in combination with any compound of Table 2.

35. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1729 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-254436. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1729 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

37. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1729 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

38. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1729 in combination with any compound of Formula (2-ii-b-v’):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

39. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1729 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

40. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1729 in combination with any compound of Formula (2-iii-a):Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-2544 wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

41. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1729 in combination with any compound of Table 2.

42. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1690 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.Date of Deposit: October 23, 2024 Attorney Docket No.: STBI-087 / 001WO 331775-254443. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1690 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

44. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1690 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

45. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1690 in combination with any compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

46. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1690 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

47. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1690 in combination with any compound of Formula (2-iii-a):wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

48. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1690 in combination with any compound of Table 2.

49. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1504 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.

50. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1504 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

51. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1504 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

52. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1504 in combination with any compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

53. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1504 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

54. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1504 in combination with any compound of Formula (2-iii-a):wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

55. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1504 in combination with any compound of Table 2.

56. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1688 in combination with any compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.

57. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1688 in combination with any compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

58. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1688 in combination with any compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

59. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1688 in combination with any compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

60. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1688 in combination with any compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

61. The combination of any one of the preceding claims, wherein the combination comprisesWTB NX 1688 in combination with any compound of Formula (2-iii-a):wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

62. The combination of any one of the preceding claims, wherein the combination comprises WTB NX 1688 in combination with any compound of Table 2.

63. The combination of any one of the preceding claims, wherein the combination comprises WTB 418 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or Ci-i5 alkylene.

64. The combination of any one of the preceding claims, wherein the combination comprises WTB 418 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

65. The combination of any one of the preceding claims, wherein the combination comprises WTB 418 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

66. The combination of any one of the preceding claims, wherein the combination comprises WTB 418 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

67. The combination of any one of the preceding claims, wherein the combination comprises WTB 418 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

68. The combination of any one of the preceding claims, wherein the combination comprises WTB 418 in combination with any compound of Table 1.

69. The combination of any one of the preceding claims, wherein the combination comprises WTB 416 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

70. The combination of any one of the preceding claims, wherein the combination comprises WTB 416 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

71. The combination of any one of the preceding claims, wherein the combination comprises WTB 416 in combination with any compound of Formula (1-ii-a-iv’)wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.'ll. The combination of any one of the preceding claims, wherein the combination comprises WTB 416 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -O-(Ci-20 alkylene)-R4or -O-(Ci-20 alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; andeach X' independently is a pharmaceutically acceptable anion.

73. The combination of any one of the preceding claims, wherein the combination comprises WTB 416 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

74. The combination of any one of the preceding claims, wherein the combination comprises WTB 416 in combination with any compound of Table 1.

75. The combination of any one of the preceding claims, wherein the combination comprises WTB 285 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

76. The combination of any one of the preceding claims, wherein the combination comprises WTB 285 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

77. The combination of any one of the preceding claims, wherein the combination comprises WTB 285 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

78. The combination of any one of the preceding claims, wherein the combination comprises WTB 285 in combination with any compound of Formula (1-iii-a)wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(0)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

79. The combination of any one of the preceding claims, wherein the combination comprises WTB 285 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

80. The combination of any one of the preceding claims, wherein the combination comprises WTB 285 in combination with any compound of Table 1.

81. The combination of any one of the preceding claims, wherein the combination comprises WTB 731 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

82. The combination of any one of the preceding claims, wherein the combination comprises WTB 731 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

83. The combination of any one of the preceding claims, wherein the combination comprises WTB 731 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

84. The combination of any one of the preceding claims, wherein the combination comprises WTB 731 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X" independently is a pharmaceutically acceptable anion.

85. The combination of any one of the preceding claims, wherein the combination comprisesWTB 731 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X" is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

86. The combination of any one of the preceding claims, wherein the combination comprises WTB 731 in combination with any compound of Table 1.

87. The combination of any one of the preceding claims, wherein the combination comprises WTB 728 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

88. The combination of any one of the preceding claims, wherein the combination comprises WTB 728 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

89. The combination of any one of the preceding claims, wherein the combination comprises WTB 728 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

90. The combination of any one of the preceding claims, wherein the combination comprises WTB 728 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

91. The combination of any one of the preceding claims, wherein the combination comprises WTB 728 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

92. The combination of any one of the preceding claims, wherein the combination comprises WTB 728 in combination with any compound of Table 1.

93. The combination of any one of the preceding claims, wherein the combination comprises WTB 289 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

94. The combination of any one of the preceding claims, wherein the combination comprises WTB 289 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

95. The combination of any one of the preceding claims, wherein the combination comprises WTB 289 in combination with any compound of Formula (1-ii-a-iv’)wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

96. The combination of any one of the preceding claims, wherein the combination comprises WTB 289 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -O-(Ci-20 alkylene)-R4or -O-(Ci-20 alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; andeach X' independently is a pharmaceutically acceptable anion.

97. The combination of any one of the preceding claims, wherein the combination comprises WTB 289 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

98. The combination of any one of the preceding claims, wherein the combination comprises WTB 289 in combination with any compound of Table 1.

99. The combination of any one of the preceding claims, wherein the combination comprises WTB 1815 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

100. The combination of any one of the preceding claims, wherein the combination comprises WTB 1815 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

101. The combination of any one of the preceding claims, wherein the combination comprises WTB 1815 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

102. The combination of any one of the preceding claims, wherein the combination comprises WTB 1815 in combination with any compound of Formula (1-iii-a)wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

103. The combination of any one of the preceding claims, wherein the combination comprises WTB 1815 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

104. The combination of any one of the preceding claims, wherein the combination comprises WTB 1815 in combination with any compound of Table 1.

105. The combination of any one of the preceding claims, wherein the combination comprises WTB 750 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

106. The combination of any one of the preceding claims, wherein the combination comprises WTB 750 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

107. The combination of any one of the preceding claims, wherein the combination comprises WTB 750 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

108. The combination of any one of the preceding claims, wherein the combination comprises WTB 750 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X" independently is a pharmaceutically acceptable anion.

109. The combination of any one of the preceding claims, wherein the combination comprisesWTB 750 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X" is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

110. The combination of any one of the preceding claims, wherein the combination comprises WTB 750 in combination with any compound of Table 1.

111. The combination of any one of the preceding claims, wherein the combination comprises WTB 1419 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

112. The combination of any one of the preceding claims, wherein the combination comprises WTB 1419 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

113. The combination of any one of the preceding claims, wherein the combination comprises WTB 1419 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

114. The combination of any one of the preceding claims, wherein the combination comprises WTB 1419 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

115. The combination of any one of the preceding claims, wherein the combination comprises WTB 1419 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

116. The combination of any one of the preceding claims, wherein the combination comprises WTB 1419 in combination with any compound of Table 1.

117. The combination of any one of the preceding claims, wherein the combination comprises WTB 1214 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

118. The combination of any one of the preceding claims, wherein the combination comprises WTB 1214 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

119. The combination of any one of the preceding claims, wherein the combination comprises WTB 1214 in combination with any compound of Formula (1-ii-a-iv’)wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

120. The combination of any one of the preceding claims, wherein the combination comprises WTB 1214 in combination with any compound of Formula (1-iii-a)wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -O-(Ci-20 alkylene)-R4or -O-(Ci-20 alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; andeach X' independently is a pharmaceutically acceptable anion.

121. The combination of any one of the preceding claims, wherein the combination comprises WTB 1214 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

122. The combination of any one of the preceding claims, wherein the combination comprises WTB 1214 in combination with any compound of Table 1.

123. The combination of any one of the preceding claims, wherein the combination comprises WTB 1618 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

124. The combination of any one of the preceding claims, wherein the combination comprises WTB 1618 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

125. The combination of any one of the preceding claims, wherein the combination comprises WTB 1618 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X" is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

126. The combination of any one of the preceding claims, wherein the combination comprises WTB 1618 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

127. The combination of any one of the preceding claims, wherein the combination comprises WTB 1618 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

128. The combination of any one of the preceding claims, wherein the combination comprises WTB 1618 in combination with any compound of Table 1.

129. The combination of any one of the preceding claims, wherein the combination comprises WTB 1602 in combination with any compound of Formula (1-ii-a-i).Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

130. The combination of any one of the preceding claims, wherein the combination comprises WTB 1602 in combination with any compound of Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene.

131. The combination of any one of the preceding claims, wherein the combination comprises WTB 1602 in combination with any compound of Formula (1-ii-a-iv’)Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl.

132. The combination of any one of the preceding claims, wherein the combination comprises WTB 1602 in combination with any compound of Formula (1-iii-a)Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X" independently is a pharmaceutically acceptable anion.

133. The combination of any one of the preceding claims, wherein the combination comprisesWTB 1602 in combination with any compound of Formula (1 -ii-a-iii’)Formula (1 -ii-a-iii’) wherein:X" is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

134. The combination of any one of the preceding claims, wherein the combination comprises WTB 1602 in combination with any compound of Table 1.

135. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-a-i):Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; andX' is a pharmaceutically acceptable anion.

136. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-a-i):Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; andRing A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

137. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-a-i):Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-a-v):Formula (2-ii-a-v) whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

138. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-a-i):Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

139. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-a-i):Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

140. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-a-i):Formula (1-ii-a-i) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (I)Formula (2-iii-a) wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(C1-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

141. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.

142. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

143. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-a-v):whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

144. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

145. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

146. The combination of any one of the preceding claims, wherein the combination comprises a compound Formula (1-ii-b-i),Formula (1-ii-b-i) wherein:X' is absent or is an anion;R2is CH3;R3is C6;R5and R6independently are H, Ce-io aryl, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl; each R4is H or CH3; andL is a bond or C1-15 alkylene; in combination with a compound of Formula (2-iii-a)Formula (2-iii-a) wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(C1-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

147. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-a-iv’):Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl; in combination with a compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.

148. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-a-iv’):Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl; in combination with a compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; andRing A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

149. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-a-iv’):Formula (1-ii-a-iv’) wherein:X" is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl; in combination with a compound of Formula (2-ii-a-v):whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

150. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-a-iv’):Formula (1-ii-a-iv’) wherein:X' is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl; in combination with a compound of Formula (2-ii-b-v’):whereinX" is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

151. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-a-iv’):Formula (1-ii-a-iv’) wherein:X" is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl; in combination with a compound of Formula (2-ii-a-viii):whereinX" is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

152. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-a-iv’):Formula (1-ii-a-iv’) wherein:X" is absent or is an anion;Y1is O;Y2is O;Y3is a bond;Y4is a bond;R2is CH3;R3is Ce alkyl;R5and R6independently are hydrogen, C3-10 cycloalkyl, Ce-io aryl, or C1-24 alkyl;L is Ci-24 alkylene; andR4is H, C1-6alkyl; or -(C1-20 alkylene)-(3- to 10-membered heterocyclyl), wherein the heterocyclyl is optionally substituted with oxo or C1-6alkyl; in combination with a compound of Formula (2-iii-a)Formula (2-iii-a) wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

153. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-iii-a):wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion; in combination with a compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; and X' is a pharmaceutically acceptable anion.

154. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-iii-a):wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion; in combination with a compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

155. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-iii-a):wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion; in combination with a compound of Formula (2-ii-a-v):whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

156. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-iii-a):wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion; in combination with a compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

157. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-iii-a):Formula (1-iii-a) wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -0-(Ci-2o alkylene)-R4or -0-(Ci-2o alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion; in combination with a compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

158. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-iii-a):wherein:R5and R6are each independently H or C1-6alkyl;L2is a -C(O)-*;M is -O-(Ci-20 alkylene)-R4or -O-(Ci-20 alkylene)-OR4;m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion; in combination with a compound of Formula (2-iii-a)Formula (2-iii-a) wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

159. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1 -ii-a-iii’):Formula (1 -ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl; in combination with a compound of Formula (2-iii-d):Formula (2-iii-d) wherein:R1is hydrogen, C1-20 alkyl, or Ce-io aryl;R2is C1-20 alkyl, C3-10 cycloalkyl, or Ce-io aryl; andX' is a pharmaceutically acceptable anion.

160. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1 -ii-a-iii’):Formula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl; in combination with a compound of Formula (2-ii-a-iii’):Formula (2-ii-a-iii’) whereinL is a bond, or C1-24 alkylene; wherein -* indicates attachment to Ring A; and; and Ring A is:(i) Ce-14 aryl;(ii) 3- to 10-membered heterocycle;(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl.

161. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-aFormula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl; in combination with a compound of Formula (2-ii-a-v):whereinX' is absent or is an anion;R2Tand R3Tindependently are H, Ce-io aryl, or C1-24 alkyl;L is a bond or C1-24 alkylene; and each R4Tis independently H or CH3.

162. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-aFormula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl; in combination with a compound of Formula (2-ii-b-v’):Formula (2-ii-b-v’) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a bond, or C1-24 alkylene; and each R4Tis independently H or CH3.

163. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-aFormula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl; in combination with a compound of Formula (2-ii-a-viii):Formula (2-ii-a-viii) whereinX' is absent or is an anion;R2Tand R3Tindependently are H or C1-24 alkyl;L is a Ci-24 alkylene; andR4Tis H or C1-6alkyl.

164. The combination of any one of the preceding claims, wherein the combination comprises a compound of Formula (1-ii-aFormula (1-ii-a-iii’) wherein:X' is absent or is an anion;R2is CH3;R3is Ce alkyl;R5and R6independently are, C1-6alkyl optionally substituted with Ce-io aryl, or C3-10 cycloalkyl;L is a bond or C1-24 alkylene; andRing A is:(i) Ce-14 aryl,(ii) 3- to 10-membered heterocycle,(iii) C3-15 cycloalkyl; or(iv) 5- to 10-membered heteroaryl; in combination with a compound of Formula (2-iii-a)Formula (2-iii-a) wherein:L1is -C(R2T)(R3T)-;R2Tand R3Teach independently are H, or C1-6alkyl;L2is -O-C(O)-*, wherein -* indicates attachment to M;M is -(Ci-20 alkylene)-R4or -(Ci -20 alkylene)-C(O)-O-R4, wherein the alkylene is optionally substituted with hydroxyl;wherein m is 1 or 2; each Rcindependently is C1-6alkyl or two Rccombine to form a 3- to 10- membered heterocyclyl; and each X' independently is a pharmaceutically acceptable anion.

165. A combination therapeutic comprising the combinations specified in the following table:

166. A method for treating a neuropsychiatric disease in a subject in need thereof comprising administering to the subject a combination of any one of the previous claims.

167. A method for treating a neuropsychiatric disease in a subject in need thereof comprising administering to the subject a combination of any one of the previous claims, wherein the neuropsychiatric disease is migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or addiction (e.g., substance use disorder).

168. A method of treating schizophrenia in a subject in need thereof comprising administering to the subject a combination of any one of the previous claims.

169. The method of any one of the preceding claims, wherein the xanomeline analog and the trospium analog are administered in separate pharmaceutical compositions.

170. The combination of any one of the preceding claims, wherein the combination comprises a combination of any one of the previous claims for use in treating a neuropsychiatric disease in a subject in need thereof.

171. The combination of any one of the preceding claims, wherein the combination comprises a combination of any one of the previous claims for use in treating a neuropsychiatric disease in a subject in need thereof, wherein the neuropsychiatric disease is migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychological disorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or addiction (e.g., substance use disorder).

172. The combination of any one of the preceding claims, wherein the combination comprises a combination of any one of the previous claims for use in treating schizophrenia.

173. The combination of any one of the preceding claims, wherein the combination comprises a combination for use according to any one of the previous claims, wherein the xanomeline analog and the trospium analog are in separate pharmaceutical compositions.

174. The combination of any one of the preceding claims, wherein the combination comprises the use of any one of the combinations of the previous claims in the treatment of a neuropsychiatric disease in a subject in need thereof.

175. The combination of any one of the preceding claims, wherein the combination comprises the use of a combination of any one of the previous claims in the preparation of a medicament for the treatment of a neuropsychiatric disease in a subject in need thereof.

176. The combination of any one of the preceding claims, wherein the combination comprises the use according to any one of the previous claims, wherein the neuropsychiatric disease is migraine, headaches (e.g., cluster headache), post-traumatic stress disorder (PTSD), anxiety, depression, neurodegenerative disorder, Alzheimer’s disease, Parkinson’s disease, psychologicaldisorder, treatment resistant depression, suicidal ideation, major depressive disorder, bipolar disorder, schizophrenia, stroke, traumatic brain injury, or addiction (e.g., substance use disorder).

177. The combination of any one of the preceding claims, wherein the combination comprises the use according to any one of the previous claims, wherein the neuropsychiatric disease is schizophrenia.

178. The combination of any one of the preceding claims, wherein the combination comprises the use according to any one of the previous claims, wherein the xanomeline analog and the trospium analog are in separate pharmaceutical compositions.